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ABSTRACT
In the last decade, a number of high profile medical device recalls have drawn attention to the
regulatory approval process, particularly the streamlined process for devices considered “lower
risk” known as the 510(k). Approval of medical devices through the 510(k) Process is not based
on clinical data, but rather on “substantial equivalence” to predicate devices approved pre-1976
or legally marketed thereafter. A predicate device is one that shares the same intended use as the
new device and technological characteristics which are either the same or different without
introducing new safety hazards. Many scholars believe that the premise of approving medical
devices based on similarity to existing devices is inherently flawed. In particular, there is worry
that presence of technology creep between predicate devices can lead to the approval of medical
devices which ultimately do not resemble the original device for which clinical evidence exists,
even as that evidence is used to validate device safety.

Given these concerns about the safety of the established regulatory process, this thesis explored
the impact of predicate creep within the 510(k) Process through a case study of a Robotic
Assisted Surgery (RAS) devices, with particular focus on the Intuitive Surgical Da Vinci
Surgical System. Through the development of new methodologies using publicly available data
to measure predicate creep, this research traces the predicate ancestry of several RAS devices to
assess the current impact and implications of predicate creep on the current regulatory process.
The study concludes that there is significant evidence of predicate creep within the approval
process and recommend new guidelines for classifying device risk and subsequent evidentiary
requirements within the 510(k) Process, to reduce the number of devices with high levels of
potential risk to public safety released onto the market.
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GLOSSARY/ABBREVIATIONS
Cryosurgery - Surgical procedure utilizing extreme cold to destroy abnormal or diseased tissue
Direct Predicate – The predicate device to which a subject device claims first generation
equivalence; the predicate device listed on a 510(k) approval application
Endoscope - an instrument that can be introduced into the body to give a view of its internal
parts
Endoscopic and Laparoscopic Instruments - Surgical instruments specifically designed for use
in laparoscopic or endoscopic surgical procedures. Typically featuring elongated shafts and
cable-controlled mechanisms to allow the surgeon a range of motion inside the body through a
small incision.
Laparoscope - A small fiberoptic instrument inserted through the abdominal wall to view the
interior of the abdominal cavity
Laparoscopic Surgery - A surgical procedure performed using small incisions in the body,
usually with the aid of a camera. Also known as minimally invasive surgery (MIS)
Originating/Ultimate Predicate - The oldest device to which substantial equivalence can be
traced in a branch line
Predicate - A device upon which a determination of substantial equivalence is made
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Predicate Creep – The introduction of technology creep over time in medical devices cleared
via the 510(k) Process. Typically refers to instances where new technological characteristics are
introduces without significant scientific evidence to support claims of safety and efficacy
Subject - The device receiving approval based on a given predicate
Trocar - A pen-shaped medical device used in laparoscopic surgery to provide an access port for
endoscopic instruments into the abdomen. The device consists of three components, an obturator
(the pointed tip), a cannula (a hollow tube), and a seal.
Technology Creep – The development of new technological advancements over time through a
cumulative series of incremental changes from preceding technologies

Table 1: Definitions of commonly used abbreviations

Abbreviation
510(k)
CDRH
FDA
MDA

NSE
PMA
SE

Term
510(k) Process

Definition
The process used to clear Class I and II
medical devices for market
Center for Devices and Radiological
The Office of the FDA specifically in
Health
charge of medical devices
United States Food and Drug
The government agency responsible for
Administration
medical device regulation
Medical Device Amendments of 1976 The law which created the current
regulatory structure and classification
system for medical devices
Not Substantially Equivalent
A declaration that a device is not cleared
via the 510(k) Process
Pre-market Approval Process
The process used for approval of Class III
medical devices
Substantially Equivalent
A declaration that a device meets the
requirements for clearance via 510(k)
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1 INTRODUCTION
The current FDA regulatory guidelines for medical devices were created by the 1976 Medical
Device Regulation Act (MDRA), which was passed by Congress in response to concerns about
the safety of approved medical devices. The purpose was to create a standardized regulatory
approval framework that would ensure safety, efficacy, and proper labeling of medical devices.
The MDRA established a classification system for medical devices based on their intended use
and level of potential risk to patients. Class I contains low risk devices, such as dental floss or
tongue depressors. Class II contains moderate to high risk devices that are not considered life
sustaining or supporting, ranging from acupuncture needles to robotic assisted surgical
platforms. Class III contains the highest risk devices, those which are life sustaining or
supporting, such as pacemakers and most medical implants.

Devices which fall into Classes I and II may use a streamlined approval process, known as the
510(k) Process. The process is based on “substantial equivalence” to devices approved pre-1976
or legally marketed thereafter, known as predicate devices. The FDA determines the amount of
testing performed based on the level of substantial equivalence to the identified predicate
device(s) for both function and technological characteristics and any existing standards
applicable to the device. Devices in Class III are required to go through a more stringent and
individualized approval process, known as the Pre-Market Approval (PMA) process; this
includes clinical trials and more extensive testing requirements.

8

In the last decade, several high profile device recalls have drawn attention to the regulatory
approval process. After studies found that 71% of high risk recalls (those issued due to serious
health risks or deaths) involved devices approved through the 510(k) Process, researchers began
to raise questions about the validity of the 510(k) Process as a broad approval mechanism
(Zuckerman, Brown & Nissen, 2011).

One of the issues raised as a potential flaw is the use of “predicates” to streamline the approval
process. A predicate is any existing legally marketed device which possesses the same intended
use as the new device and either the same or, if specific criteria are met, different technological
characteristics. The additional criteria for validation of a predicate possessing different
technological characteristics is sufficient evidence to determine that the new device does not
raise additional questions of safety or efficacy past those addressed in the predicate, and that it is
at least as safe and effective as the established predicate (FDA, 2014).

The use of a predicate device to establish safety and efficacy for a new device, when there are no
substantial differences between the form or function of the two devices, is straightforward and
logical. However, this same approval mechanism is also used under a clause in the definition of
substantial equivalence permitting “different technical characteristics” for many Class II devices
which possess significant differences in form or function, both physically and technologically,
compared to the predicate device. Although the FDA does require some evidence of safety and
efficacy in these cases, many scholars believe that the existing measures are insufficient to
ensure the safety of the public (CDRH, 2010; Heneghan & Thompson, 2012; Hines, Lurie, Yu,
& Wolfe, 2010). In a 2011 report conducted at the request of the FDA to evaluate the 510(k)
9

Process, the Institute of Medicine (IOM) concluded that the premise of approving medical
devices based on similarity to existing devices was inherently flawed, and recommended that the
510(k) Process should be replaced in its entirety (Institute of Medicine [IOM], 2011).

In addition to concerns about the validity of the 510(k) Process as a whole, many scholars have
expressed concerns that new devices approved based on another device previously approved via
510(k) and so on, may create a cycle whereby devices are continually approved without
introducing any new clinical evidence to support claims of device safety (Hines, Lurie, Yu, &
Wolfe, 2010; Zuckerman, Brown, & Das, 2014). If these devices were all identical to each other,
the risk of repeated, cumulative approvals via substantial equivalence would be mitigated by the
evidence provided through the successful function of the predicate device on the market.
However, the FDA permits manufacturers to use this same process for approval of devices with
different technological characteristics than the identified predicate, thereby introducing
technology creep into the approval process. This cycle of technology creep through repeated
approval of devices based on predicates with slightly different technical characteristics is known
as predicate creep. Researchers worry that the combination of predicate creep and minimal
evidentiary requirements for the 510(k) Process will allow devices to be approved which are
completely different from the original predicate device, even as they rely on the scientific
evidence provided by that original predicate to prove safety claims (Hines, Lurie, Yu, & Wolfe,
2010).

Given the increasing number of technologically complex medical devices entering the market,
lack of scientific research into mechanisms of the approval process, and growing concern about
10

the safety of the established regulatory process, this thesis aims to explore the 510(k) Process
through a case study of a Robotic Assisted Surgery (RAS) device, the Intuitive Surgical Da Vinci
Surgical System. In particular, this thesis aims to:

1. Explore what information exists in publicly available FDA regarding device approval
history via predicate relationships.
2. Develop a methodology for the identification and analysis of predicate relationships via
publicly available data.
3. Assess whether predicate creep has occurred between predicates and identify any other
patterns in the device approval history.
4. Identify implications of finding for the current approval process and other related medical
device policies

11

2 BACKGROUND: THE FDA AND THE
REGULATORY PATHWAY
The FDA was originally created after the passage of the Pure Food and Drug Act of 1906 in
response to growing concerns about the safety of products marketed for human consumption. In
1938, the passage of the Food, Drug, and Cosmetic Act (FFDCA) gave the FDA jurisdiction over
medical devices. However, that jurisdiction extended only to device which were considered
“adulterated” or “misbranded”. The FDA was not given premarket approval power over devices
until Congress passed the Medical Device Amendments of 1976 (MDA), which established the
current definition of a medical device and the risk-based device classification framework and
approval process in use today.

The intention of the MDA was that the FDA would classify all existing devices into one of three
risk categories, and that the level of regulatory rigor would be based on the category a device
was placed in (90 Stat. 539). Any new device entering the market was automatically required to
go through a strict pre-market approval process (PMA) intended for the highest risk devices,
unless the device was shown to be substantially equivalent to an existing device with a low level
of risk or was reclassified by the FDA into a lower-risk category. Lower risk categories did not
have to meet the strict PMA requirements, but instead had to meet device based performance
standards created by the FDA. New device manufacturers were required to give the FDA at least
90-days’ notice of a new product to be brought to market, regardless of risk classification, to
allow for the device to pass through FDA approval processes.
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The 510(k) Process was developed from the MDA to reduce the amount of resources required for
the FDA to meet the growing demand for device approvals. Rather than put each new device
through the PMA process, the FDA developed a process based on the 90-day notification clause.
The new process classified new devices as low(er) risk based on substantial equivalence to
existing devices. However, even with the creation of the 510(k) Process, the FDA lacked
sufficient resources to complete the tasks assigned in the MDA (IOM, 2011). As a result, the
Safe Medical Devices Act (SMDA) of 1990 was passed to clarify and modify the guidelines set
in the MDA in order to streamline the FDA’s work.

The SMDA modified the definition of a Class II device to differentiate Class II devices from
lower risk Class I devices. It also removed the previous requirement that all Class II devices have
defined performance standards, replacing the mandatory standards with special controls for
specific devices developed at the discretion of regulators. The SMDA formalized the 510(k)
Process by creating a legal definition of substantial equivalence, although the only specifications
provided for a “predicate device” was that it had to be legally approved for market. Additionally,
the Act created a series of rules for post-market surveillance and adverse event reporting.

The Food and Drug Administration Modernization Act (FDAMA) of 1997 was passed to further
simplify the approval process in response to concerns that regulations were creating backlogs at
the FDA (Merrill, 1999). The FDAMA eliminated 510(k) notification requirements for most
Class I and some Class II devices. It also created the De Novo approval process for new Class I
or II devices that had no legally marketed predicate and would therefore had previously been
required to undergo PMA as a Class III device by default. This process allows manufacturers to
13

seek approval for Class I or II medical devices using scientific evidence and existing regulatory
guidelines without going through the full PMA process. Moreover, the FDAMA requires the
FDA to take the “least burdensome approach” to demonstrating equivalence, which resulted in
the creation of the Special and Abbreviated 510(k) Processes. The Act eliminated the FDA
burden of creating performance standards for Class II devices by allowing for recognition of
established standards created by a nationally or internationally recognized organization.

The current definitions of each device class originally established by the MDA of 1976 and
subsequently modified, and the general approval process followed by devices in each class, are
detailed below.

2.1 CLASS I DEVICES
Class I devices are low risk and not life sustaining, and therefore subject only to general
regulatory controls (US Food and Drug Administration [FDA], 2006). Examples of Class I
devices include dental floss, elastic bandages, and tongue depressors. Many Class I devices are
considered exempt from premarket notification requirements, meaning they do not need FDA
approval to enter the market. If a device is not classified as exempt, the manufacturer must
submit a 510(k) identifying a predicate device and providing evidence that the new device is
substantially equivalent.

14

2.2 CLASS II DEVICES
Class II medical devices pose a higher risk than those in Class I, but not life sustaining or
supporting. The level of technical complexity of Class II devices varies widely, with examples
ranging from plastic surgical drapes to infusion pumps. While the complexity of less technical
Class II devices and Class I devices is often similar, the distinction between the two
classifications is typically drawn based on the potential severity of device failure. Failure of
dental floss, such as fraying or breakage, is merely an annoyance that poses little risk to the
patient. However, failure of a plastic surgical drape, which is used to ensure equipment sterility
in operating rooms, could potentially result in bacterial contamination of equipment that might
cause life threatening infections in a patient. Class III devices that are considered to possess wellunderstood technical characteristics may be placed under Class II by exemption to expedite the
approval process. Class II devices are subject to both general controls and more specialized
performance controls based on the functionality and potential risk of the individual device (US
Food and Drug Administration [FDA], 2006).

The approval pathway for a Class II device varies based on the intended use and level of
potential risk inherent in the particular device design. Like many Class I devices, some low risk
Class II devices have been exempted entirely from the premarket notification process. Other
lower risk Class II devices are subject only to general controls and special controls well defined
by official guidance documents or recognized standards, which allows manufacturers to file for
approval using the Abbreviated 510(k) Process. If the manufacturer of a Class II device can
utilize an existing device they marketed as a predicate for substantial equivalence, then the new
device can be approved using a streamlined alternative process known as the Special 510(k).
15

This approach is typically only accepted by the FDA for generational product improvements, as
it allows the manufacturer to declare conformity to design control requirements without
providing data to support their claims.

If a Class II device does not meet any of the requirements for exemption or streamlined 510(k)
approval, it must go through the traditional 510(k) Process. This process relies on the
performance of similar devices currently on the market, known as predicates, to provide proof of
safety for the new device, rather than independently evaluating the device through lengthy
clinical trials. The process begins with the manufacturer submitting an application detailing the
device description, intended use, intentions for use, identified predicate devices, and
performance data supporting the claim of substantial equivalence. The FDA then has 90 calendar
days to declare the device either substantially equivalent (SE) or not substantially equivalent
(NSE) to the predicate (s) based on the material presented in the 510(k) application. If a device is
declared SE by the FDA, the manufacturer receives clearance to place the device on the market
after registering and officially listing the device (Center for Devices and Radiological Health,
2017b).

If the FDA finds a device NSE, it will automatically be reclassified as a Class III device unless
the manufacturer submits a De Novo approval application. The De Novo process evaluates the
scientific evidence presented by the manufacturer and allows the FDA to grant approval without
a predicate device if the evidence provides sufficient proof of safety, effectivity, and minimal
risk (Center for Devices and Radiological Health, n.d.).
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2.3 CLASS III DEVICES
Class III medical devices are life sustaining or supporting, or present unreasonable potential risk
to the user. These include most implantable devices, such as pacemakers, stents, and orthopedic
prosthetics, as well as life supporting devices such as external defibrillators. The FDA has
determined that general or special controls are insufficient to assess the safety and efficacy of
these devices. Instead, the vast majority of Class III devices are approved via Premarket
Approval (PMA) process, a rigorous scientific and regulatory review which requires device
specific non-clinical and clinical testing to prove safety and effectiveness (US Food and Drug
Administration [FDA], 2006). A limited number of Class III medical devices receive PMA
exemptions, allowing them to be approved via the 510(k) Process instead.

17

3 A REVIEW OF THE LITERATURE ON THE 510(K)
PROCESS
Existing research has identified a variety of potential gaps in the 510(k) Process, including
concerns about the validity of “substantial equivalence” as an approval mechanism, lack of
scientific evidence to support claims, predicate creep, Class III device exemptions, and
insufficient post market surveillance among others. Some major studies also presented
suggestions for improvements to the process, which resulted new guidance documentation issued
by the FDA beginning in 2012.

3.1 GAPS IN THE 510(K) PROCESS
3.1.1 VALIDITY OF SUBSTANTIAL EQUIVALENCE
One major criticism of the 510(k) Approval Process commonly identified is the use of
“substantial equivalence” as an approval mechanism for ensuring safety and efficacy of new
devices. According to the current FDA definition a device is substantially equivalent if, in
comparison to a predicate it:
1. has the same intended use as the predicate; and
2. has the same technological characteristics as the predicate;
Or
1. has the same intended use as the predicate; and
2. has different technological characteristics and does not raise different questions of
safety and effectiveness; and
3. the information submitted to FDA demonstrates that the device is at least as safe and
effective as the legally marketed device.
(Center for Devices and Radiological Health [CDRH], 2017b)
18

Although this definition was intended to clarify when the use of substantial equivalence was
appropriate for medical device approval, some scholars have expressed concerns about the
vagueness of the definition. A 2010 CDRH working group report identified confusion
surrounding the definition of “intended use” for substantial equivalence determinations
compared to the term “indications for use”. The report defines “intended use”, a requirement for
substantial equivalence, as based on the objective intent expressed by the manufacturer.
“Indications for use,” a more general term often used in 510(k) applications but not required to
be the same for substantial equivalence, describes the general disease or condition the device is
designed to treat. However, among industry officials and in many official FDA documents the
two terms are used interchangeably, creating a lack of clarity about the actual requirements of
substantial equivalence (CDRH, 2010).

Another issue identified is that, due to the lack of a clear official definition for the key term
“intended use”, the FDA has allowed permissive interpretation of “intended use” by applicants.
Since intended use is defined by the manufacturer rather than regulators, manufacturers are able
to modify the wording of the stated intended use to make changes in device function appear
minimal. Over time, this has resulted in the approval of significantly altered devices, or even
novel devices, as substantially equivalent to established predicates (CDRH, 2010; Heneghan &
Thompson, 2012; Hines et al., 2010).

One example of this provided by the CDRH Working Group (2010) was the gradual approval of
cryosurgical devices as a treatment for prostate cancer, rather than a tool for removal of
19

unwanted tissue these devices were initially designated for. A new cryosurgical device that could
more readily be used to access the prostate area was approved in 1990 with an indicated use for
“tissue destruction.” Manufacturers aggressively pushed to have the indicated use expanded to
include “treatment of prostate cancer,” but were refused on the grounds that a clinical application
carried different risks and implications than the general use. Instead, manufacturers went around
the FDA by gradually changing the intended use, first to “tissue destruction in urology,” then
including “removal of prostate tissue” and “prostate tumor – palliative.” At this point in time,
with an intended use specifically indicated for prostate tumors, a growing number of researchers
began experimenting with the tool as a treatment for prostate cancer, despite the lack of official
approval for this express purpose. Caving to pressure from manufacturers and the increasing
prevalence of the device as a treatment in clinical settings, in 1997 the CDRH allowed
cryosurgical devices to be cleared for an indicated use of “treatment of prostate cancer” without
ever identifying a new “intended use” or requiring clinical data to support device approval.
Ultimately, many problems arose following the widespread adoption of cryosurgery as a
treatment for prostate cancer, an application of the device that the CDRH never specifically
evaluated for safety or effectiveness (CDRH, 2010). Many issues may have been prevented had
the device undergone a full review prior to being placed on the market for this application.

The example of cryosurgical devices as a treatment for prostate cancer shows the potential risk
of permissive interpretation even in the case of a device which has already been on the market
and proved safe for other applications. However, the potential risk of permissive interpretation
increases drastically when combined with the provision within the definition of substantial
equivalence that allows for approval of devices with different technological characteristics. This
20

provision expands the selection of predicates to include devices with different materials or
mechanisms of action, if the new device has a similar safety profile to the predicate, which
creates additional uncertainty about how a device will perform when placed on the market.

3.1.2 OUTDATED PREDICATES
One major concern identified by researchers is that the 510(k) Process makes the implicit
assumptions that substantial equivalence means that a device is safe and effective, and that the
predicates on which substantial equivalence determinations are based are safe. In his concurring
opinion for the 1996 case of Medtronic v. Lohr, Supreme Court Justice O’Connor explained the
court’s interpretation that a finding of substantial equivalence proves only that the device
introduces no new safety hazards and functions at least as effectively as the predicate device
(Medtronic vs. Lohr, 1996, pg. 513). However, if the predicate device poses risk or is ineffective,
then the new device may perpetuate these flaws. Thus, there are concerns that the 510(k) Process
can create a cyclical approval pattern of unsafe devices. There is disagreement, however, as to
whether the process is invalid entirely or only for specific types of high risk or technologically
complex devices (Ardaugh, Graves, & Redburg, 2013; Lennox, 2014; Zuckerman, Brown, &
Das, 2014).

3.1.3 PREDICATE CREEP
Some literature pointed to the risks of using of multiple predicate devices for a single substantial
equivalence determination. The CDRH working group report identified three types of 510(k)
predicate submissions: single, multiple, and split (CDRH, 2010). While most academics agree
21

that single predicate submissions, which directly compare a new device to a single device on the
market, provide significant assurance of safety and efficacy in most cases, many have raised
questions about whether multiple and split predicates can provide the same level of assurance
(Ardaugh, Graves, & Redburg, 2013; Zuckerman, Brown, & Das, 2014). For example, Ardaugh
et. al examined the approval history of the DePuy ASR XL Acetabular Cup System, a metal-onmetal hip implant that caused life altering injuries to hundreds of patients due to metal particle
shedding within the body. The ASR XL was approved using three different devices as predicates,
each with a unique technological characteristic which was incorporated into the XL. Since all
three devices were deemed safe based on market performance, and the XL simply combined
parts of the devices, it was placed on the market without undergoing clinical testing. However,
after the discovery of particle shedding, it was determined that the cause of the failure was the
unique combination of the material (from one predicate) and geometry (from a different
predicate) of the ASR XL (Ardaugh, Graves, & Redburg, 2013). Regulators had reasoned that if
these characteristics were safe independently, then they should be safe when put together.
However, without any evidence from previous devices with this combination of material and
geometry or actual testing of the device over time, that reasoning was mere assumption, which in
this case proved disastrous.

Another growing concern expressed in the literature is that, in many cases, the predicates on
which evaluations of safety and efficacy are based were also approved via 510(k) (Hines et al.,
2010). Substantial equivalence allows a device to “piggyback” on the reasonable assurance of
safety from existing predicate devices without undergoing independent testing. (CDRH, 2010;
Lennox, 2014). However, when the predicate was also approved via substantial equivalence, as
22

was its predicate and so on, a cycle is created in which there may be a significant gap between
the current device and the most recent device for which scientific evidence of safety was
provided (Fargen et al., 2012). This creates an iterative process through which, over multiple
cycles of small device modifications and subsequent substantial equivalence findings, a new
device may be approved which is significantly dissimilar to the original predicate for which
scientific evidence exists (Hines et al., 2010). This process is known as predicate creep (Hines et
al., 2010; Zuckerman, Brown, & Das, 2014). While the exact impact of predicate creep is
difficult to identify, a few researchers have attempted to construct ancestral equivalence trees
utilizing the 510(k) database maintained by the FDA, with mixed results (Ardaugh, Graves, &
Redburg, 2013; Waetjen et al., 2015; Zuckerman, Brown, & Das, 2014).

Although there is very little evidence provided within the literature to prove the existence of
predicate creep, two papers were found that used a technique constructing ancestral equivalence
tree to identify information present in the predicate history of a specific device. Ardaugh et. al
(2013) used documents obtained through the FDA 510(f) Database and Freedom of Information
Act filings to trace the predicate history of the DePuy ASR XL Acetabular Cup System, a metalon-metal hip implant, over five decades with the purpose of identifying the cause of safety flaws
present in the design. Zuckerman et. al (2014) used the FDA 510(k) Database to trace the
predicate history as far back as available for a random sample of 50 newly cleared devices, with
the stated purpose of identifying the most recent predicate to present definitive scientific
evidence of safety and effectiveness to support a claim of substantial equivalence. Neither
article specified the exact methodology used to trace predicates. Examination of the database,
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however, shows that in many cases the predicate device(s) is readily identified in the available
paperwork.

The research performed by Zuckerman et al. (2014) focuses on identifying the most recent point
in the predicate history when scientific evidence was presented to support a claim of substantial
equivalence, as part of a larger argument the researchers present about a lack of publicly
available scientific evidence to support the safety and effectiveness of implantable medical
devices. This group’s research focuses on whether evidence was provided to support claims of
equivalence, and the type of evidence provided, rather than examining the technological
relationship between the devices on which the claim was based. One notable finding presented in
this research was the identification through an ancestral trace of predicate devices that have been
recalled from the market due to safety concerns, which raises red flags about the safety of
subsequent devices.

Ardaugh et al. (2013) studied the predicate history of the ASR XL with the express purpose of
discovering how a device with major design flaws was able to enter the market through the
510(k) Approval Process. The researchers examined the technological relationship between
predicates with the specific purpose of identifying when features which became “flaws” in the
final device were introduced in predicates. However, the characterization of predicate
relationships in this research was performed with the specific intention of locating technological
characteristics present in the final device, rather than to understand and characterize predicate
relationships in general.
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3.1.4 SCIENTIFIC BURDEN OF PROOF
Another flaw commonly identified in the literature is insufficient scientific evidence of safety
and efficacy. The 510(k) Process requires only sufficient scientific evidence to prove substantial
equivalence to a predicate and, in the case of new technological characteristics, mitigate any new
concerns of safety and efficacy. This evidence is typically presented in the form of non-clinical
data, which may range from descriptive device data, essentially physical characteristics, to more
involved performance testing (Flaherty, 2008; Waetjen et al., 2015). While in some cases this
evidence is clearly enough to demonstrate substantial equivalence and assure device safety,
many worry that it is insufficient to ensure the safety of devices which are inherently higher risk,
or which are declared equivalent to devices of questionable safety (Ardaugh, Graves, & Redburg,
2013; Heneghan & Thompson, 2012; Janetos, Ghobadi, Xu & Walter, 2017; Waetjen et al.,
2015; Zuckerman, Brown, & Nissen, 2011). The lack of available scientific evidence supporting
substantial equivalence claims may be partially due to inconsistently defined testing
requirements dictated by the FDA. While the regulatory definition of a Class II device identifies
“general and specialized performance controls” (FDA, 2006) as requirements for approval, what
specifically defines those controls is not necessarily scientifically based and often unclear
(Zuckerman, Brown, & Das, 2014).

3.1.5 CLASS III DEVICE EXEMPTIONS
Along with a lack of required clinical testing, another flaw identified with the 510(k) Process in
the literature is the approval of devices identified as Class III (high-risk) through the less
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stringent 510(k) Process. While Congress mandated in the 1990 Safe Medical Devices Act that
the FDA either reclassify these devices or establish a schedule for requiring PMAs (Hines et al.,
2010), as of 2008, 20 of these device types could still be cleared via 510(k) (GAO, 2010). In fact,
a GAO report found that between 2003 and 2007 more Class III devices were cleared for market
via the 510(k) Process than the original PMA process (GAO, 2010). Many high profile failures
of Class III devices approved via 510(k), including the DePuy ASR XL Acetabular Cup System
and Poly Implant Prosthese (PIP) breast implants, have had increased calls for the removal of the
Class III device exemption (Garber, 2010; Heneghan & Thompson, 2012; Kramer, Xu, &
Kesselheim, 2012; Sorenson & Drummond, 2014).

3.1.6 INSUFFICIENT POST MARKET SURVEILLANCE

A comprehensive post market surveillance system is a necessary complement to premarket
approval processes to mitigate potential patient exposure to harmful medical devices. The FDA
maintains the Manufacturer and User Facility Device Experience (MAUDE) database, a
centralized database for reporting data on device safety and efficacy (Dhruva & Redburg, 2012).
Current post market surveillance rules require mandatory manufacturer reporting of serious
adverse events or deaths associated with a device, although the decision of whether an event is
associated with the device is left to the manufacturer (Sorenson & Drummond, 2014). Voluntary
reporting by healthcare providers, fear of litigation, lack of causal association with a particular
device, and several additional factors lead to severe underreporting of adverse events (Sorenson
& Drummond, 2014). Druhva & Redburg (2012) found that only 5 -10% of all adverse events
are reported to the FDA.
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In addition to a lack of reporting, insufficient device traceability and a lack of formal review
mechanisms make it difficult for the FDA to identify patterns in adverse events reports that may
suggest serious safety risks (Dhruva & Redburg, 2012; Garber, 2010). This limited availability of
data makes identification of hazardous devices difficult, and has led to calls for an improved post
market surveillance system with more comprehensive data and traceability (Heneghan &
Thompson, 2012; Hines et al., 2010; Janetos, Ghobadi, Xu & Walter, 2017).

3.2 PROPOSED 510(K) PROCESS MODIFICATIONS

3.2.1 CDRH WORKING GROUP REPORT (2010) RECOMMENDATIONS

The lack of consistent testing requirements and potential for high risk devices to enter the market
without clinical data supporting safety claims led the CDRH working group to propose a
modification to the existing device classification system in their 2010 report. To prevent a
complete overhaul of the existing regulatory structure while still improving regulatory
predictability and safety outcomes, the group suggested the creation of Class II subclasses, Class
IIa and IIb. Class IIa would contain the majority of devices for which guidance documentation
exists or safety and efficacy is well established by existing predicates. Class IIb would contain
those devices which, due to new technological characteristics, technical complexity, or inherent
risk to patients, require higher levels of device specific testing and evidentiary support to prove
safety and efficacy. This may include devices such as implantables, in vitro diagnostic devices,
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or reclassified Class III exemption devices which typically pose more risk. Devices in Class IIb
would be typically require significant scientific data, including animal testing and clinical data,
for approval (CDRH, 2010).

3.2.2 INSTITUTE OF MEDICINE REPORT: THE 510(K) PROCESS AT 35
YEARS (2011)
Following the publication of the 2010 Working Group Report identifying potential flaws within
the 510(k) Process, and recognizing growing concerns within the industry, the Department of
Health and Human Services tasked the Institute of Medicine with conducting a thorough review
of the 510(k) Process (IOM, 2011). The report, published on October 25th, 2011, presented a
comprehensive review of the 510(k) Process and considered a multitude of sources both internal
and external to the regulatory process, including some found in this literature review (CDRH,
2010; Hines et al., 2010; Zuckerman, Brown, & Nissen, 2011).

The report ultimately concluded that the existing 510(k) Process was insufficient to adequately
determining the safety and efficacy of new devices, and the committee recommended that the
FDA design a new regulatory framework to replace the process entirely. However, the report
specifically addressed the implications of that recommendation by stating that “The committee is
not suggesting that all, many, or even any medical devices cleared through the 510(k) clearance
process and currently on the market are unsafe or ineffective. Rather, the committee found that
the available information is insufficient to support highly confident conclusions about the safety
and effectiveness of 510(k)-cleared medical devices in clinical use” (IOM, 2011, pg. 193).
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3.2.3 FDA RESPONSE
Although the FDA declined to implement either of the major recommendations from (name the
two) for a restructuring of the classification and approval process made in these reports, the FDA
has responded to the concerns identified. Based on the findings of these two major reports, the
FDA began implementing a series of reforms and new regulations in early 2012 to improve the
510(k) Process. In 2014, the FDA issued new guidance documentation for evaluating substantial
equivalence in 510(k) applications which addresses many of the concerns identified in the
literature. The new documentation provides specific definitions for “intended use” and
“intentions for use”, clarifications on the use of multiple predicates, and more detailed guidelines
for the use of scientific evidence in supporting substantial equivalence claims (United States
Food and Drug Administration [FDA], 2014).

Additionally, in 2012 the FDA issued a strategy document detailing its approach to creating a
comprehensive post market surveillance system. A key element of this strategy is the creation of
a system of standardized Unique Device Identifiers (UDI) that can be incorporated into
electronic health databases to increase device traceability and streamline the response to adverse
events reports (Gross & Crowley, 2012).

29

3.3 SUMMARY OF LITERATURE REVIEW FINDINGS
The review of current literature on the 510(k) Process conducted above identified two primary
areas of concern regarding the effectiveness of the current process. First, many critics expressed
concerns about vague definitions, lack of clear guidance or requirements for evidentiary support
of equivalence claims, and subjective equivalence determinations by FDA officials which affect
the consistency and predictability of the regulatory process. Second, scholars and regulators
determined that the use of predicate devices as an approval mechanism may have adverse
impacts on the safety of new devices due to the use of inappropriate predicates or the presence of
predicate creep over time. The implication of the various concerns identified within the literature
is that the current approval process has gaps which may allow the approval of devices for market
without ensuring they are safe for use.

Although the FDA has recently implemented changes the approval process to address some of
the concerns identified within the literature, it has declined to implement any major changes to
the overall approval process. Various reasons, including resource restrictions and approval time
constraints, may have contributed to the approach the FDA chose to address the
recommendations it received. However, another important factor the agency is obligated to
consider is the balance of regulation versus innovation. While it is necessary to ensure that
devices are safe and effective prior to placing them on the market, increasing regulatory
requirements for new devices automatically makes it more difficult to bring innovative devices
to market. Many device manufacturers already feel that the application process and approval
times under current regulatory guidelines create barriers to innovation (California Healthcare
Institute [CHI], 2011). Many medical device companies have begun launching initial product
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offerings overseas where regulations are perceived as less stringent and more conducive to
innovation, or relocating operations entirely (CHI,2011). As a result, any modifications made to
the regulatory process within the United States must be carefully structured to allow for
innovation without negatively impacting the safety of devices.

3.4 RESEARCH GOALS
The 510(k) Process was originally envisioned as a means to streamline the approval process and
reduce the impact of regulatory requirements on devices which present minimal risk to patients.
While scholars call into question whether the process effectively serves its intended purpose,
there is a distinct lack of evidence to support the actual impact of many of the gaps identified by
experts within the literature. Most of the articles included in this review simply discussed
potential flaws in the existing process, providing only one or two anecdotal examples of highly
publicized failures to support claims. The internal review conducted by the CDRH Working
Group is the only study identified which compiled data from a large number of approval
applications to identify trends and potential regulatory flaws (CDRH, 2010). The review
conducted by the IOM Committee used a combination of public workshops, literature reviews,
expert opinions, internal CDRH reports, and information contained in public FDA databases to
draw conclusions about the regulatory process. However, the IOM Committee expressly stated
that it was unable to fully assess the quality of 510(k) submissions, including the types of data
submitted to support equivalence claims, due to FDA statutory requirements that prevented the
committee from reviewing applications to protect proprietary information. (IOM, 2011, pg. 20)
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The limited availability of data due to intellectual property protections, as encountered by the
IOM during its review, is a major restriction for determining the impact of predicate creep within
the approval process. Still, it is possible to trace portions of the predicate history of current
medical devices using data available through FDA databases or via Freedom of Information Act
(FOIA) requests. Despite this, only two articles identified within this literature review made any
attempt to trace the predicate relationships of devices in order to determine whether a lack of
scientific evidence or predicate creep occur within the 510(k) Process.

Given the overall lack of data presented within the literature to support concerns surrounding the
510(k) Process, especially regarding the use of predicates as an approval mechanism, the aim of
this thesis is to develop a methodology for identifying predicate relationships of devices
approved via the 510(k) Process and evaluating the potential impact of predicate creep and other
trends observed within this data. In order to concentrate on the development of an effective
analysis method, this research will be structured as a case study of the Da Vinci Surgical System,
a robotic surgical platform. The following section discusses in depth the methods used to select
this case study, gather data, and identify instances of predicate creep. The Data Analysis section
illustrates the data gathering process and relationship comparisons. Findings discusses the
conclusions drawn from the relationships identified within the Analysis section, and the
Conclusions section discusses the implications of those findings for policy and future research.
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4 METHOD
4.1 CASE STUDY SELECTION: THE INTUITIVE SURGICAL DA VINCI
SURGICAL SYSTEM
The method I have chosen to analyze the effectiveness of the current regulatory structure for
developing biomedical technologies, particularly in robotics, is a case study of the Intuitive
Surgical Da Vinci robotic surgical system. I will conduct a comprehensive review of the
approval process by tracing the predicate history of the Da Vinci. This methodology for
analyzing the regulatory approval process of the Intuitive Da Vinci was selected based on the
availability of data through public databases.

One of the first and only examples of a robotic medical device approved for market is the
Intuitive Da Vinci Surgical Platform, a Robotic Assisted Surgery (RAS) device initially
approved by the FDA in 2000 for laparoscopic surgery. While Intuitive has subsequently brought
multiple iterations of the Da Vinci to market, 16 years later it remains the only full RAS platform
on the market as competitors struggle to develop a viable competitor around Intuitive’s strong
patent foothold. While the Da Vinci served as a predicate device for subsequent models, as well
as for RAS devices produced by competitors and potentially for other robotics technologies, the
Da Vinci itself was initially approved under a 510(k) application. This approval was granted
based on a complex web of component-level substantial equivalence, most likely supplemented
by additional testing.
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The Da Vinci Surgical System is a robotic-based laparoscopic surgical tool which replaces a
surgeon’s hands with robotic arms for more precise control and motion. It is comprised of three
physical components. A “cart” onto which three robotic arms are mounted, a “tower” which
houses the computer systems, and a “console” where the surgeon sits to control the arms and
view the procedure. The system also includes a software component which allows the surgeon to
control the arms and a 3D vision system, so the surgeon can view inside the patient during
surgery. Typically, the device is configured so that two robotic arms are mounted with surgical
tools, and the third arm acts as an endoscope (Intuitive Surgical, 2017). Use of a Da Vinci
System requires extensive training, and the estimated cost of installation in $2 million.

The Da Vinci is an interesting case study for assessing the FDA approval process for several
reasons. As stated, the Da Vinci is one of the only examples of robotics surgical devices on the
market, and since it has been approved for over 15 years, its function is well documented. In fact,
over 10,000 peer-reviewed articles have been published about the Da Vinci. Additionally, the Da
Vinci is well documented legally, with over 800 patents registered to Intuitive Surgical and 3000
product liability claims filed. The uniqueness of the device as an emerging technology with no
direct competitor on the market makes it representative of many of the challenges the FDA will
face with other developing medical technologies currently in development. Many of these
upcoming medical technologies, such as personalized 3D printed prosthetics, nanotechnologies,
and other devices with high levels of software integration, possess unique functions and
challenges which do not necessarily fit within the existing regulatory structure. The Da Vinci
was one of the first major medical technologies to pose similar challenges regarding software
integration, in addition to the technical complexity of the device, so it serves as a good case
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study to use as a basis for identifying the general regulatory approach to these types of complex
devices. The methodology described here for evaluating the Intuitive Da Vinci seeks to give a
more complete view of how the FDA adapts the existing regulatory process for innovative
medical devices with high levels of technical complexity and no clear predicate.

4.2 DATA GATHERING AND ANALYSIS
The main objective of this research is to identify publicly available data pertaining to approval of
medical devices via the 510(k) Process, with a focus on RAS devices, and examine that data to
draw conclusions about how that process has been implemented. Therefore, the first step to
conducting my research was to develop a methodology for identifying and compiling pertinent
publicly available data in FDA databases.

4.2.1 DATABASE EXPLORATION
The FDA maintains a number of different databases related to various aspects of medical device
regulation, including post-market surveillance, incident reporting, device recalls, and device
approvals. As illustrated in Figure 1, there are a variety of different methods and databases which
can be used to identify information relevant to this research. As this research is focused on Class
II medical devices, the database containing the most directly applicable data is the 510(k)
approval database. This database was created in the early 1990’s during the implementation of
the Safe Medical Devices Act, which officially developed the 510(k) Process as a separate
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approval process, to serve as a centralized location for all information pertaining to 510(k)
approvals.

Figure 1: Overview of database structure and locations of useable information for three FDA database searches;
the 510(k) Database, the Product Code Database, and the Full FDA Website

The existing search mechanisms allows for searches based on keywords, applicant, device name,
decision date, approving panel, and 510(k) Number. The 510(k) Number (K#) is a unique
identification number used to track approval applications. A K# corresponds to an approval
application, which may be for a new device, a new functionality of an existing device, or a
modification of an existing device. Inputting a search term into the database results in a list of
relevant results, including the device name, applicant, K#, and decision date, which can be sorted
alphanumerically based on a selected parameter. Clicking on either the device name or K# within
the search results brings you to a standardized device-summary page containing information that
pertains to that 510(k) application. This includes all the searchable parameters present on the
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main search page, as well as additional information specific to the application filing, such as
initial application date and applicant contact information, relevant regulations, the review
information, and in some cases an attached PDF summarizing the information contained in the
actual application. It is within the attached application summary, if one exists, that information
required for determination of substantial equivalence, such as predicate devices, intended use,
indications for use, and scientific evidence may be presented.

In addition to the application summary, another useful piece of information contained on the
device summary page is the device product classification code. This product code identifies a
more device-specific classification based on the technological characteristics and intended use of
a device. (Stuart, J., n.d.) This can be used to identify potential predicate devices based on the
substantial equivalence parameters for a new device. For this research, it may also be useful to
identify devices which are predicated on a particular device, information which cannot be easily
found in the 510(k) database due to the nature of the application summary formatting.

The FDA product classification database functions similarly to the 510(k) database, with a main
page allowing for searches via parameters including device name, review panel, product code,
and regulation number. As product classification codes are applied to all medical devices, not
just Class II devices, the database also allows for specification of parameters based on medical
device class.

A search via product code results in a code summary window identifying the device to which the
code pertains, a regulatory description, and details about the regulatory process for devices under
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this classification. The code summary also includes a link to the Total Product Life Cycle
(TPLC) Report which summarizes all regulatory activity associated with the code, including
information about all devices with approval applications filed under this code. This can be used
to directly identify devices with related predicate histories.

If information about a Class II device cannot be found via the 510(k) or Product Code databases,
a final option for investigating available public information is the “brute force” method. Rather
than a targeted search through specialized databases, this method involves entering search terms
in the general search bar on the FDA web page. This returns results from all FDA publications,
including database information, conference presentations, regulations, and internal memos.
Although this method returns significantly more results, the search function offers limited
filtering options and requires manual sorting to determine whether results are relevant.

4.2.2 DATA COMPILATION
Although data on Class II medical device approvals does exist, multiple databases and layers of
search results presented in different formats within the databases prevents direct analysis of
device information and predicate relationships. Instead, manual construction of a separate
database containing general device information and available approval details was required
before meaningful data analysis could be performed. Identification of devices for inclusion in a
manual database was guided by a database construction parameters. The two major construction
parameters considered for this research were product code classification and predicate
relationship, meaning a device was either a predicate of or predicated on the device, such as the
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Da Vinci, around which the database was constructed. Each newly constructed database included
the K#, device name, manufacturer, approval date, product code, and any predicate or intended
use information available for all devices relevant to the database construction parameter.

4.2.2.1 Da Vinci Initial Search
The initial focus of my research was tracing the approval history of the Intuitive Da Vinci
Surgical System. Using the previously described methodology, I searched the 510(k) database
for applications filed by Intuitive Surgical and identified an application for the Da Vinci Si
Surgical system, the second iteration of the device family offered by Intuitive. Examination of
the regulatory summary revealed that this device is classified under the product code NAY,
which refers to devices classified with the keywords “System, Surgical, Computer Controlled
Instrument” under a regulatory description of endoscope and accessories (FDA, Product
Classification- System, Surgical).

As the Da Vinci was the first device of its kind, devices identified under the product
classification code NAY are exclusively iterations of the Da Vinci itself, devices which serve as
direct predicates, or devices that are directly predicated on the Da Vinci. Therefore, I was able to
use the information contained in the Total Product Life Cycle report to construct a database of
information about every 510(k) application Intuitive Surgical has ever filed directly related to the
Da Vinci System. This new database includes the device name, 510(k) number, applicant,
approval date, predicates identified, and the substantial equivalence determination (See
Appendix 1).
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4.2.3 EXPANSION TO RELATED DEVICES
After observing the wide variety of technological characteristics present across a given predicate
generation in the Da Vinci trace, I looked at how the technological characteristics of the Da
Vinci compare to other devices in its own generation. While tracing backwards through
equivalence identifies predicates with different characteristics ultimately present in a subject
device, tracing forward from a given predicate to subsequent subject devices should reveal a
group of devices which share the common characteristics of the initial predicate. Based on the
definition of substantial equivalence, these devices should share a common intended use and
similar technological characteristics. However, each device may incorporate different
technological aspects of the identified predicate device(s) along with new technology to develop
a device with unique benefits for users. As a result, it is possible that significant deviations in
technological characteristics exist between two subject devices with the same predicate, even if
the stated intended use is the same. When multiple predicate devices are identified in an approval
application, the new device design may be composed of a combination of the technological
characteristics of the predicates, including functions present only in one predicate device,
potentially creating even more significant deviations in overall device function compared to the
predicate.

I chose to start my investigation by searching for subject devices predicated on Computer Motion
Inc.’s Automated Endoscopic System for Optimal Positioning (AESOP) System, rather than any
devices within the first generation of the Da Vinci trace, for three reasons. The first reason was
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that the devices contained within the first generation were all identified as components of the
previous Da Vinci model ISI 1000, which makes it unlikely that any subsequent subject device
would be predicated on a component rather than the system as a whole. Secondly, the AESOP is
the first recorded device in the NAY product classification family to which the Da Vinci belongs.
Although I was already aware through the TPLC Report that no additional devices within this
product code family were predicated on AESOP, I felt that using this device as the starting point
would return subject devices with functionality closest to that of the Da Vinci. Finally, AESOP is
one of the oldest and most well-known devices to appear in the tree, so I felt it was the most
likely of the devices in the trace to have multiple subject devices predicated on it.

Due to the construction of the 510(k) database, it is essentially impossible to search for a subject
device, rather than a predicate, without knowing the product code of the device you are searching
for. As I already knew no eligible devices were present in the NAY classification family, I was
required to use the brute force approach to identify devices predicated on AESOP. This was done
by searching the keywords “AESOP” and “Computer Motion” in the overall FDA search bar and
manually sorting through the results to identify relevant devices.
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4.2.4 PREDICATE TREE CONSTRUCTION
Using the data gathered in these newly created databases, I constructed predicate trees, structured
similarly to an ancestry tree, to help identify instances of predicate creep and any patterns present
in the regulatory history of the device(s). Creation of an equivalence tree is a technique that has
been used by two other research groups working in the space of FDA regulations to identify
information present in the predicate history of a specific device. Ardaugh et al (2013) used
documents obtained through the FDA 510(f) Database and Freedom of Information Act filings to
trace the predicate history of the DePuy ASR XL Acetabular Cup System, a metal-on-metal hip
implant, over five decades with the purpose of identifying the cause of safety flaws present in
this design. Zuckerman et. al (2014) used the FDA 510(k) Database to trace the predicate history
as far back as available for a random sample of 50 newly cleared devices, with the stated purpose
of identifying the most recent predicate to present definitive scientific evidence of safety and
effectiveness to support a claim of substantial equivalence. Neither article specified the exact
methodology used to trace predicates, however examination of the database shows that in many
cases the predicate device(s) is readily identified in the publicly available paperwork.

Following a similar method as Ardaugh et al. (2013) and Zuckerman et al. (2014), I constructed
an ancestral equivalence tree using the information gathered from the FDA databases as
described in the previous section. An example structure for a resulting equivalence tree is shown
in Figure 2 below.
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Figure 2: Sample predicate tree tracing the history of the “subject” device and illustrating major structural
elements including a predicate generation (blue) and a predicate branch line (red).

As illustrated in the sample predicate tree above, the subject device is the device from which the
predicate trace originates. A question mark in the trace indicates that the device was approved
via the 510(k) Process, indicating that a predicate device does exist, but there is insufficient
information available in the databases to identify that predicate. For this research, a predicate
generation is identified as a group of predicates that are the same number of steps removed from
the subject device. The generation number is the total number of steps between the predicate and
main subject device. For example, the generation identified in blue in Figure 2 is the 2nd
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generation and contains a total of 3 different devices, C, D, and E. A branch is defined as a group
of devices whose relation can be traced directly through single-step substantial equivalence
determinations. In this example devices E, H, I, and J all belong to the device B branch. A
branch line is a more specific group of devices which belong to a single branch, with each device
belonging to a different generation as shown in red in Figure 2. Ultimate or originating
predicates are defined as the oldest devices to which a branch line(s) can be traced, such as
Predicates J for the sample branch line shown above. For purposes of clarity when discussing
findings, a device within an ancestral trace will be defined based on the presence of a unique Knumber, even in cases where multiple K-numbers have been identified as part of a single device.

For devices where overlapping or increased numbers of predicates appear make traditional tree
diagrams unwieldy, an alternate diagram structure known as a network map was used to display
predicate relationships within the approval ancestry. A network map represents each unique
device with a dot corresponding in size to the number of predicate relationships associated with
that device. The dots are arranged from left to right in reverse chronological order beginning
from the subject device, in a similar manner to that shown in Figure 2. Each predicate
relationship is represented by an arrow between two dots, with the arrowhead pointing from the
subject device towards the predicate. Unlike the traditional ancestry tree structure illustrated in
Figure 2, predicate arrows within a network map can overlap, create a significantly more
compact diagram.
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4.3 IDENTIFICATION OF PREDICATE CREEP
Predicate creep is the introduction of technology creep into the 510(k) Process via the substantial
equivalence relationship between devices. Researchers have theorized that accumulation of
predicate creep may ultimately result in the approval of devices which possesses significantly
different technological characteristics than earlier predicates with little assurance of safety, due
to the minimal evidentiary requirements of the 510(k) Process. However, due to the nature of
information contained within the public 510(k) databases, it is impossible to determine exactly
what level of scientific evidence was provided to support each substantial equivalence claim.
Therefore, this research focuses on identification of gradual changes in the technological
characteristics of devices over multiple predicate generations based on small changes made
within each predicate relationship.

For this research, predicate creep is identified using three primary methods: direct comparison of
technological characteristics, comparison via regulatory structures, and presence of multiple
predicate devices. Direct comparison of technological characteristics is the traditional method for
identifying technology creep involving identification of the technological characteristics of two
or more related devices and observation of changes in technical characteristics between them.
For this research, devices will be compared along branch lines, using the identified predicate
relationship as a basis for comparison, and within a predicate generation. This method can be
used to identify specific instances of predicate creep and illustrate potential impacts it may have
on device functionality and safety.
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In addition to direct comparison of technological characteristics, a second method for identifying
predicate creep is through the use of existing mechanisms or structures which identify
characteristics of the technology from a regulatory perspective. FDA product codes are
particularly useful for this purpose, as they are designed to identify groups of devices with the
same intended use and technological characteristics. As possessing the same intended use is a
requirement for approval via substantial equivalence, it follows that any device approved via
510(k) with a different product code that the predicate must either possess different technological
characteristics, or be in violation of the requirements for substantial equivalence. Therefore, the
introduction of new product codes in the predicate ancestry tree should be indicative of the
introduction of new technological characteristics.

Another indicator of technological creep within the approval tree is the presence of multiple
predicate devices. Although it is perfectly permissible to have multiple predicated with the same
intended use and extremely similar technological characteristics present on a 510(k) application,
the inclusion of both devices is redundant if the subject device also possesses the same
characteristics. Instead, an application including multiple predicate devices is often used when a
new device contains a unique combination of the different technological characteristics present
in the predicate devices. Although the technological characteristics of the subject device did exist
individually before, they are present in this device in a unique combination that did not exist
previously, which is a form of predicate creep.
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4.4 PATTERNS IN THE REGULATORY HISTORY
Patterns in the regulatory history will be identified using a combination of qualitative and
quantitative observation to draw conclusions about how the general guidelines of the 510(k)
Process have been implemented in practice by regulators and process users. As predicate creep,
these patterns will be identified using the manually constructed databases and predicate approval
trees developed from publicly available FDA data. Observations made during this portion of the
analysis will include whether there is a common methodology used during the 510(k) application
process for selection of predicate devices, the level of overlap between different predicate traces,
comparison of the number of predicates identified in different traces, and other general
observations.

In addition to general observations, data collected from the FDA Medical Device Recall
Database will be used to identify devices with documented safety concerns. Although it is
difficult to identify the scientific evidence presented to support claims of safety between
predicates, a correlation between the presence of predicate creep and issued recalls would be
indicative that concerns expressed by researchers surrounding the effects of predicate creep are
founded.
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5 DATA ANALYSIS
5.1 INITIAL PREDICATE TRACE DEVELOPMENT
Using the information in the newly constructed NAY Product Code database, I was able to
identify the earliest iteration of the Da Vinci System known as the Da Vinci Surgical System
Model ISI 1000, which was first approved on May 30th, 2001. However, the 510(k) database
contained no application summary or information regarding the direct predicates used in the
approval process. Further investigation via additional FDA databases and Intuitive Surgical’s
website revealed no additional information regarding the approval process for this model. In fact,
Intuitive does not list or reference this model anywhere on its website (Intuitive Surgical, 2018).

Although this the lack of information on the first Da Vinci System poses a problem for this
investigation, information is available for the next iteration of the device approved in June 2002,
the Da Vinci Surgical System Model IS1200. Using the information obtained from the TPLC
Report, I was able to obtain the 510(k) application number for this device, K021036, which in
turn allowed me to obtain the application summary.

From the application summary I was able to identify the predicate of the Da Vinci Model IS1200
as the Da Vinci Surgical System Model ISI 1000. This application referenced four K-numbers
associated with the predicate device, including K011002, the number previously identified and
investigated without success. Using the information found in the 510(k) database for the
remaining three K-numbers and subsequently identified predicates, I was able to construct an
ancestral equivalence tree going back four generations on the longest branch.
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Figure 3: Intuitive Da Vinci Model IS1200 predicate ancestry tree, with predicates identified by K# (see Table 2 for
device descriptions) and substantial equivalence relationships numerically identified in grey circles (see Table 3 for
device characteristic comparisons).
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There are a total 14 predicate devices listed in this tree, with four devices in the first generation,
eight in the second, and two in the third. The tree contains 11 unique branch lines, but only two
primary multi-generational branches. Unfortunately, the size of this trace is limited by the
availability of information in the database, with the oldest identified predicate device receiving
approval only ten years before the subject device, in May 1992. Additionally, one identified
predicate device, K975001, was listed by K#, name, and manufacturer on the application
summary for the Intuitive Surgical Reposable Endoscopic Instruments and Accessories, but no
record of that K# or device exists in the 510(k) database. Further examination revealed that the
identified device possessed the same name, Intuitive Surgical Endoscopic Instrument Control
System and Select Instruments, as is identified by K002489 and within the application summary
of K965001, which suggests that this may be an earlier model of the Intuitive Endoscopic
Control System. However, the non-existence of the device within the 510(k) database and the
extreme similarity between its identified K# K975001and the K# K965001, which was identified
by the same name, leads me to believe that this may have been an error on the part of the
summary writer, and that the correct predicate device may in fact be K965001. However, for
purposes of this analysis I used the information as found in the database, regardless of suspected
errors. Table 2 below contains a summary of the devices identified in this trace, including the
stated intended use (if available), product code, and a brief device description.

50

Table 2: Summary of information for device contained within the Da Vinci IS1200 predicate history, including the
intended use (if indicated) and a brief description of the technical characteristics of each device,
K-Number

K021036

K965001

K002489

Device Name

Da Vinci Surgical System,
Model Is1200

Monarch Laparoscopic
Manipulator **

Da Vinci Endoscopic
Control System

Manufacturer

Intuitive Surgical,
Inc.

Intuitive Surgical,
Inc.

Intuitive Surgical,
Inc.

K011002

Da Vinci Surgical System,
Model ISI 1000

Intuitive Surgical,
Inc.

K990144

Intuitive Surgical Reposable
Endoscopic Instruments
and Accessories

Intuitive Surgical,
Inc.

K931783

AESOP (Automated
Endoscopic System for
Optimal Positioning

Computer Motion,
Inc

K936308

K914190

K933169

Endex Endoscopic
Positioning System

Andronic Devices,
Ltd.

Auto Suture(R) Endoscopic
Fan Retractor

United States
Surgical, A Division
of Tyco Healthcare

Endoscopic Blunt Dissector

Inman Medical
Corp.

Approval Product
Intended Use*
Date
Code

6/26/2002

7/31/1997

3/2/2001

5/30/2001

7/11/2000

11/22/1993

3/31/1994

5/6/1992

4/19/1994

Device Description

NAY

Three manipulator arms (8 DOF
Assist in accurate
each) with attached endoscope and
control of endoscopic
endoscopic instruments, controlled
instruments during
by a surgeon from a console with a
laparoscopic surgical
3D vision system, used to perform
procedures
laparoscopic surgical procedures

GCJ

Precise and accurate Multiple manipulator arms (8 DOF
control of instruments each) with attached endoscope and
during thoracoscopic endoscopic instruments controlled
and laparoscopic
from a surgeon console to view and
surgical procedures
perform surgical procedures

NAY

Multiple manipulator arms (8 DOF
each) with attached endoscope and
endoscopic instruments controlled
from a surgeon console to view and
perform surgical procedures

NAY

Two manipulator arms (8 DOF
Assist in accurate
each) with attached endoscope and
control of endoscopic
endoscopic instruments, controlled
instruments during
by a surgeon from a console with a
laparoscopic surgical
3D vision system, used to perform
procedures
laparoscopic surgical procedures

NAY

Assist in accurate
control of endoscopic
instruments during
laparoscopic surgical
procedures

Various endoscopic instruments
with control interfaces designed for
use with the Intuitive Endoscopic
Control System

GCJ

An endoscopic telemanipulator
consisting of a motorized arm with 6
degrees of freedom, controlled by a
foot pedal to manipulate and
stabilize an endoscope

FQO

A jointed arm which can be
manually positioned by a surgeon to
position and stabilize an
endoscope. A single motor-driven
linear joint (1 DOF) controlled by a
foot pedal is used to move the
endoscope into and out of the body.

GAD

An endoscopic instrument with
multiple prongs which can be
expanded inside the body using a
cable-driven mechanism into a fanlike shape to keep tissue away from
the operating area.

GCJ

A manually controlled endoscopic
instrument with a rounded tip used
to manipulate tissue during
laparoscopic surgical procedures
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Approval Product
Intended Use*
Date
Code

K-Number

Device Name

Manufacturer

K953059

Kittner Dissector

Medical
Perspectives Corp.

9/14/1995

GDY

A non-absorbable gauze sponge for
use with an endoscopic blunt
(rounded tip) dissector

K931340

Endoscopic Instruments

Baxter Healthcare
Corp.

7/1/1993

GCS

Various manually positioned, motor
driven endoscopic instruments
including grasp forceps, scissors,
dissectors, and a needle holder

K960400

Diamond-Touch And Micro
Diamond-Touch
Instruments/Diamond-Line
Instruments/Diamond-Port
(Access Parts)

Snowden-Pencer

3/12/1996

FBM
GCJ
GEI

K975001***

Intuitive Surgical
Endoscopic Instrument
Control System and Select
Instruments

Intuitive Surgical,
Inc.

N/A

Various endoscopic
instruments for use in
laparoscopic cardiac
surgical procedures

Device Description

Manual endoscopic instruments,
including an access port,
endoscopes, needle holders,
graspers and clamps, scissors,
probes, knife blade handles,
clippers, and other instruments

N/A

Multiple manipulator arms (8 DOF
each) with attached endoscope and
endoscopic instruments controlled
from a surgeon console to view and
perform surgical procedures

K930666

Reusable Laparoscopic
Instruments W/
Electrocautery

Snowden-Pencer

5/19/1994

GEI

Various laparoscopic instruments
with reusable handles which
incorporate wire electrodes to
generate heat, which is used to
burn away unwanted tissue and
seal blood vessels during surgery

K930667

Reusable Laparoscopic
Instruments

Snowden-Pencer

5/16/1994

GCJ

Various laparoscopic instruments
with reusable handles which

*Intended use information only available for devices with approval application summaries present in the public
510(k) database

** The name for this device referenced in the approval application summary is the Intuitive Surgical Endoscopic
Instrument Control System

*** This device is referenced in the approval summary for K990144 by K# and Device Name. However, the K#
listed does not appear in the FDA database, and the name corresponds with K965001
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The Da Vinci IS1200 trace includes devices from eight unique manufacturers, although
Computer Motion later combined with Intuitive Surgical in 2003. Devices belong to eight unique
device product code classifications. It is worth noting that in addition to the four K-Numbers
marketed under the Da Vinci Model ISI 1000 (those in the first predicate generation), KNumbers K930666 and K930667 are both associated with the Snowden-Pencer Reusable
Laparoscopic Instruments. This means that this trace contains only 9 unique devices which were
manufactured and introduced to the market, compared to 14 difference devices when referenced
from a regulatory perspective. Since the successful performance of each predicate device on the
market is part of the body of evidence to support the safety claims of the new device, a smaller
number of unique devices with market performance data effectively reduces the level of
assurance of safety for the subject device, in this case the Da Vinci IS1200.

To identify instances of predicate creep within the trace, I have compiled in Table 3 a list of the
technological differences between each of the subject-predicate pairs present in this trace. The
numbered predicate relationship corresponds to the numbers identified in grey in Figure
3.
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Table 3: Differences in technological characteristics between the two devices in each predicate relationship
(identified by number in Figure 3) within the Da Vinci IS1200 approval history
Predicate
Relationship

Subject Device

Predicate Device

New Technological Characteristics
in Subject Device

1

Da Vinci Surgical System,
Model IS1200

Monarch Laparoscopic
Manipulator

The IS1200 incorporates a 3D vision system
and specialized endoscopic instruments
designed to mimic the motion of a human wrist

2

Da Vinci Surgical System,
Model IS1200

Da Vinci Endoscopic Control
System

The IS1200 incorporates a 3D vision system
and specialized endoscopic instruments
designed to mimic the motion of a human wrist

3

Da Vinci Surgical System,
Model IS1200

Da Vinci Surgical System, Model
ISI 1000

The IS1200 includes updated software and a
3rd manipulator arm

4

Da Vinci Surgical System,
Model IS1200

Intuitive Surgical Reposable
Endoscopic Instruments and
Accessories

The Da Vinci includes a surgeon console, 3D
vision system and manipulator arms for control
and positioning of existing endoscopic
instruments

AESOP (Automated Endoscopic
System for Optimal Positioning

The Monarch includes multiple teleoperated
arms with increased range of motion, is
controlled from a surgeon console, and is used
to perform surgical procedures using
endoscopic instruments in addition to
positioning and stabilization of an endoscope

5

Monarch Laparoscopic
Manipulator

6

Monarch Laparoscopic
Manipulator

Endex Endoscopic Positioning
System

The Monarch includes multiple teleoperated
arms with increased range of motion, is
controlled from a surgeon console, and is used
to perform surgical procedures using
endoscopic instruments in addition to
positioning and stabilization of an endoscope

7

Monarch Laparoscopic
Manipulator

Auto Suture(R) Endoscopic Fan
Retractor

Monarch incorporates articulated instrument
control arms and multiple instruments operated
from a console

8

Monarch Laparoscopic
Manipulator

Endoscopic Blunt Dissector

Monarch incorporates articulated instrument
control arms and multiple instruments operated
from a console

9

Monarch Laparoscopic
Manipulator

Kittner Dissector

Monarch incorporates articulated instrument
control arms and multiple instruments operated
from a console

10

Intuitive Surgical Reposable
Endoscopic Instruments and
Accessories

Baxter Healthcare Endoscopic
Instruments

The Intuitive instruments have a unique control
interface which enables use with the Intuitive
Endoscopic Control System

11

Intuitive Surgical Reposable
Endoscopic Instruments and
Accessories

Diamond-Touch And Micro
Diamond-Touch
Instruments/Diamond-Line
Instruments/Diamond-Port
(Access Parts)

The Intuitive instruments have a unique control
interface which enables use with the Intuitive
Endoscopic Control System

12

Intuitive Surgical Reposable
Endoscopic Instruments and
Accessories

Intuitive Surgical Endoscopic
Instrument Control System and
Select Instruments

No technological changes identified between
instruments

13

Diamond-Touch And Micro
Diamond-Touch
Instruments/Diamond-Line
Instruments/Diamond-Port
(Access Parts)

Reusable Laparoscopic
Instruments W/ Electrocautery

No technological changes identified

14

Diamond-Touch And Micro
Diamond-Touch
Instruments/Diamond-Line
Instruments/Diamond-Port
(Access Parts)

Reusable Laparoscopic
Instruments

No technological changes identified
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An initial overview of the technological differences identified in Table 3 reveals that almost
every device present in the trace demonstrated some level of technological creep. In some cases,
technology creep was limited to the introduction of a new mechanical control interface or the
addition of an extra arm, but in other cases the degree of technological difference is striking. This
is most conspicuous in the comparison of the various endoscopic instruments to the Monarch
Laparoscopic Controller, which incorporates telemanipulator arms and a surgeon console to
move the instruments and perform procedures. However, the Monarch is a system which
incorporates versions of these instruments, so it appears that they are serving as predicates only
for the endoscopic end effectors and are not intended to provide any assurance of safety or
efficacy for the system as a whole. However, the technological gap between the AESOP and
ENDEX Systems and the Monarch is still quite large. The Monarch not only incorporates
additional degrees of freedom into the manipulator arm, but it also consists of multiple arms, is
controlled by a surgeon sitting at a separate viewing console, and is used to perform actual
surgical procedures without the surgeon directly contacting the patient. This is a huge change in
technology within a single predicate relationship.

5.2 EXPANSION TO RELATED DEVICES
Examination of the wide variety of technological characteristics present across a given predicate
generation in the Da Vinci IS1200 trace led me to wonder how the technological characteristics
of the Da Vinci compare to other devices in its own generation. Therefore, I decided to identify
other devices which share a common predicate with the Da Vinci IS1200, in order to identify the
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degree of difference between different devices within the same technological generation and
theoretically also the same device family. The predicate which I chose to base my trace off of
was the AESOP system, both because it is the oldest device within the IS1200 trace which is not
a basic surgical instrument, and because it is the ultimate predicate which is most similar to the
Da Vinci in terms of technological characteristics, complexity, and function.

5.2.1 DEVICE IDENTIFICATION
While tracing backwards through substantial equivalence relationships identifies predicates with
different characteristics ultimately present in a subject device, tracing forward from a given
predicate to subsequent subject devices should reveal a group of devices which share the
common characteristics of the initial predicate. Based on the definition of substantial
equivalence, these devices should share a common intended use and similar technological
characteristics. However, this type of tracing is extremely difficult to do within FDA databases,
as devices approved based on a specific device are not identified anywhere in that device’s
approval information. Therefore, I used the brute-force search methodology to identify a total of
seven additional devices predicated on AESOP, including a newer model of the AESOP system.
The ancestry of each device was then traced to construct a tree connected to the Da Vinci trace as
shown in Figure 4. Rather than identify generations based on predicate distance, the number of
predicates between the two devices, for this tree generations were grouped based on the number
of subject devices between the two devices, known as subject device distance. As a result, while
previous trees were constructed to trace the approval history of a device backwards in time

56

through predicate generations, this tree was used to trace forwards in time and identify
generations of subject devices approved based on the AESOP System.
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Figure 4: Ancestry tree illustrating devices predicated on the AESOP System. Arrows indicate a substantial
equivalence relationship pointing from newer subject device to older predicate device, with “subject generation
zero” including the oldest devices (far right).

The trace above illustrates the substantial equivalence relationships between the devices
predicated on the AESOP system. To identify any safety issues identified while on the market,
each device was run through the FDA recall database. Of the eleven devices included in this
trace, only the Da Vinci model IS1200 had any recalls associated with it. The IS1200 has
undergone a total of 18 Class II recalls, recalls of moderate severity, ranging from user manual
mistakes to incorrect component installation which may cause power loss. Table 4 (below)
provides additional information about the devices in this trace, along with a brief technical
description of each device.
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Table 4: Summary of Devices in Expanded AESOP Trace
510(k)
Number

Device
Name

Manufacturer

K931783

AESOP
Laparoscopic
Positioning and
Control System

Computer Motion

K922626

Endex
Endoscopy
Instrument
Positioning
System / Adept
Instrument
Positioning
System

Andronic Devices

K973249

EndoAssist

Armstrong
Healthcare
Limited

K972699

AESOP 3000

K050027

K965001

K082233

K021036

K023735

K043284

K090340

Device Description

Generation
(Subject)

GCJ

An endoscopic telemanipulator consisting
of a motorized arm with 6 degrees of
freedom, controlled by a foot pedal to
manipulate and stabilize an endoscope

0

GAD

A jointed arm which can be manually
positioned by a surgeon to position and
stabilize an endoscope. A single motordriven linear joint (1 DOF) controlled by a
foot pedal is used to move the endoscope
into and out of the body.

0

11/26/97

GCJ

A freestanding arm mounted on an
extended boom with 2 DOF. It is
controlled by a head-tracking system
which tracks the head motion of the
surgeons and is engaged using a foot
pedal.

1

Computer Motion

12/19/97

GCJ

An endoscopic telemanipulator consisting
of a motorized arm with 6 degrees of
freedom, controlled by a foot pedal to
manipulate and stabilize an endoscope

1

Laparocision
Scope Controller
System

GMP

1/25/05

GCJ

N/A

1

Monarch
Laparoscopic
Manipulator

INTUITIVE
SURGICAL, INC.

GCJ

Multiple manipulator arms (8 DOF each)
with attached endoscope and endoscopic
instruments controlled from a surgeon
console to view and perform surgical
procedures

1

GCJ

An endoscope holder consisting of a
jointed arm with three actuated degrees
of freedom which can be attached directly
to an operating table and a command
from which the surgeon can control
position using a footswitch or verbal
commands

1, 2

NAY

Three manipulator arms (8 DOF each)
with attached endoscope and endoscopic
instruments, controlled by a surgeon from
a console with a 3D vision system, used
to perform laparoscopic surgical
procedures

2

GCJ

An actuation arm composed of two
parallel kinematic joints and one linear
joint to provide 3 DOF, located on a
moveable cart and controlled with a
wireless joystick for use in gynecological
surgery.

2

GCJ

A freestanding arm mounted on an
extended boom with 2 DOF. It is
controlled by a head-tracking system
which tracks the head motion of the
surgeons and is engaged using a foot
pedal.

2, 3

GCJ

A portable arm mounted to the operating
table with 3 DOF. It is controlled by a
head-tracking system which tracks the
head motion of the surgeons and is
engaged using a foot pedal.

2, 4

ViKY

EndoControl

Da Vinci
INTUITIVE
Surgical System,
SURGICAL, INC.
Model IS1200

LapMan
Laparoscopic
Manipulator

Medsys

EndoAssist

Armstrong
Healthcare
Limited/Prosurgics

Freehand

Prosurgics

Approval Product
Date
Code
11/22/93

10-19-92

7/31/1997

12/18/08

6/26/2002

8/7/07

2/25/05

5/22/09
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Including the Da Vinci IS1200, this ancestry tree contains a total of eleven devices spanning four
equivalence generations (plus the originating generation). These devices are classified under
three different product codes; 1 device under code NAY, 1 device under code GAD, and the
remaining 9 under GCJ. The common use of product code GCJ implies that the technological
characteristics of the majority of devices contained in the trace should be extremely similar. The
only devices not classified under product code GCJ, which refers to devices described as
“endoscope and accessories” for laparoscopic and general surgery (FDA, 2018d), are the
originating predicate devices and the Da Vinci itself.

Except for the Da Vinci, all the devices within this trace share two originating predicates, the
Endex Instrument Positioning System and the AESOP system. The Endex System is classified
under code GAD, which refers to a retractor with a regulatory description of “manual surgical
instrument for general use” (FDA, 2018d). Code NAY, under which the Da Vinci is classified,
refers specifically to computer controlled surgical devices with the base function of “endoscope
and accessories” (FDA, 2018c). Code GCJ has a more general device description than code
NAY, similar to code GAD, although devices classified under this code share similar technical
characteristics to devices in code NAY, such as the inclusion of a manipulator arm. However, the
addition of “computer controlled” to the device description for code NAY implies that the level
of technical complexity in the control system of Da Vinci may be higher than in other devices in
this trace classified under code GCJ, despite sharing the same regulatory description of
“endoscope and accessories”. This correlation between changes in product code classifications
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and technical complexity is supported by the comparison of actual device technical
characteristics as described in Table 4.

5.2.2 OBSERVATIONS
Inspection of the predicate relationships within the AESOP subject device trace reveals an
interesting pattern. Although there were six additional subject devices introduced in this tree,
tracing the branch lines of the devices creates a web where the subject device equivalence refers
to earlier existing predicates multiple times. This results in an equivalence tree with only two
ultimate predicates, AESOP and the Andronic Endex Instrument Positioning System. Only the
Da Vinci refers to a different set of ultimate predicate devices. Although this interrelatedness is
not entirely unexpected, as there are a limited number of devices available to serve as predicates
for any given device function, it does make the width and variety of the Da Vinci trace appear
unusual. Considering the technological characteristics of the devices, one possible implication of
the size of the Da Vinci trace, which is primarily caused by the presence of multiple predicated
for each 510(k) application, is that Intuitive Surgical used multiple predicate devices to justify
the relatively large differences in technological characteristics when compared directly to each
individual predicate.

Additionally, the appearance of one predicate device multiple times within the trace in different
generations illustrates that the intermediary predicates serve as stepping stones, introducing
slight changes in technological characteristics but ultimately referring back to a single set of
ultimate predicates. This method introduces new technological characteristics incrementally into
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the ultimate subject device, while keeping the majority of the dependence for evidentiary support
of the safety of new characteristics on the ultimate predicate(s).

5.3 EXPANSION TO DA VINCI SI
Due to the age-based limitations of the 510(k) database, it proved to be impossible to expand the
Da Vinci trace past three predicate generations using publicly available data. As a result, a lack
of scientific evidence reduces the significance of observations made using the trace. However,
one option to create a larger ancestral trace is to begin the trace using newer models of the Da
Vinci. As new technological characteristics, and subsequently new predicate devices, were
introduced into the Da Vinci S and Si models, the size of the traceable ancestry tree expanded.
Patterns identified in this larger trace may be more indicative of the regulatory behavior on the
part of both Intuitive Surgical and the FDA.

5.3.1 PREDICATE ANCESTRY TRACE
The predicate ancestry of the Da Vinci Si Model was traced using the same method described
previously for the Da Vinci IS1200 predicate tree development. Unlike the previous trees, the
number of devices and predicate relationships contained in this trace is too large to be easily
illustrated with a traditional ancestry tree diagram, so an alternative diagram was constructed
using network mapping techniques as shown in Figure 5.
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Within this network mapping diagram each device is represented by a dot, with the dot size
increasing based on the total number of substantial equivalence relationships that device is
involved in. Substantial equivalence relationships (also known as predicate-subject device
relationships) are represented by lines drawn between the two devices involved. Each dot is
labeled with the K# of the device which it corresponds to. The trace begins with the main subject
device (i.e. the Da Vinci) on the left side of the trace, and advances toward the left, with each
line originating at a subject device and terminating at its respective predicate. Therefore, the
oldest devices present in the trace are located on the right side, although vertical alignment does
not correlate exactly to approval date, and the newest devices are to the left of the trace.

Figure 5: Expanded Da Vinci Si predicate trace originating from the Da Vinci Si (far left) with each predicate
device represented by a dot and identified by K# (see Appendix 2). Trace lines indicate substantial equivalent
relationships with the arrowhead pointing towards the predicate device and relative dot size indicating the number
of substantial equivalence relationships associated with each device.
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The expanded equivalence tree, which uses the Da Vinci Si as the subject device, includes 2618
device instances, with a total of 50 unique devices. The unique devices within this trace are
classified under a total of 15 different product codes, with the majority of devices, including the
various Da Vinci models, categorized under code NAY. Additional information about each
device, including the manufacturer, approval date, and any recalls issued, can be found in
Appendix 2.

Recall data from the FDA database, which tracks recalls issued by the manufacturer either due to
an error identified internally or in response to a series of incidents traced directly to a problem
with the device, was used to identify devices in the Da Vinci ancestry with significant safety
issues. The FDA classifies recalls based on the severity of potential impact to the patient. Class
III recalls are minor and not likely to cause any adverse health effects. Class II recalls occur
when exposure may cause temporary or reversable adverse health effects, or where there is a low
probability of serious adverse effects. Class I is the most severe type of recall, in which there is a
reasonable probability that exposure will result in serious adverse effects or death. While a
couple of Class II or III recalls will likely have minimal effect on overall device safety, repeated
Class II recalls or any Class I recall is directly indicative of potential device issues.

Of the 50 devices included in the Da Vinci Si trace, 7 devices, all manufactured by Intuitive
Surgical as part of a DaVinci system, had multiple recalls associated with the device. These
recalls include 18 for the Da Vinci Model IS1200, 43 for the Da Vinci IS2000 (aka Da Vinci S),
and 24 for the Da Vinci Si. All the recalls associated with these devices were Class II, which
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means that although there was no immediate risk of patient death due to the issue, there was still
significant risk of harm to the patient.

Figure 6: Da Vinci Si Trace with devices which have undergone 3 or more recalls highlighted in red.

When the devices with associated recalls are highlighted in the ancestry trace, it becomes clear
that all of these devices are newer, complex devices which were approved relatively recently.
Furthermore, despite the high numbers of recalls associated with early Da Vinci models,
Intuitive continued to release subsequent Da Vinci models whose approval was directly reliant
on the previous models.

Looking at the overall spread of the ancestry trace, certain patterns within the predicate structure
begin to emerge. The initial central portion of the trace includes a number of devices with many
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overlapping substantial equivalence lines. These devices are mostly developed by Intuitive
Surgical, with the majority of identified as either sub-components or iterations of the Da Vinci
Surgical System. However, as the trace expands the inter-related predicates are replaced with
five distinct groups of predicate devices with no overlap between substantial equivalence lines.
Each group appears to contain devices with similar characteristics, where each of the five groups
representing diverse technological characteristics which were later combined together to form
the more complex Da Vinci system.

Figure 7: Da Vinci Si trace with the five distinct predicate branches highlighted.
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5.3.2 GROUPING VIA REGULATORY MECHANISMS
Considering the size of this data set, attempting to identify the exact technological characteristics
of each device contained within to try to identify specific examples of predicate creep would be
extremely difficult and time consuming. However, categorizing the devices in the trace by
product code can help identify patterns within the trace using more general device characteristics
to identify trends over time.

A list of the codes, the device identification key, and the regulatory description for each code is
shown in the table below. The device identification key is a set of functions or characteristics
which distinguish devices in that product classification, while the regulatory description is the
primary function or intended use as identified by the FDA.
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Table 5: Product Codes in Da Vinci Si Trace
Code

# Devices

Device Identification

Regulatory Description

FBM

1 Cannula and Trocar, Suprapubic, Non-Disposable

Suprapubic urological catheter and
accessories

NEY

3 System, Ablation, Microwave and Accessories

Electrosurgical cutting and coagulation device
and accessories

NAY

17 System, Surgical, Computer Controlled Instrument

Endoscope and accessories

HET

1 Laparoscope, Gynecologic (And Accessories)

GEI

5 Electrosurgical, Cutting & Coagulation & Accessories and accessories

LFL

4 Instrument, Ultrasonic Surgical

OCL

5 Ablation of Tissue, Including Cardiac Tissue

Electrosurgical cutting and coagulation device
and accessories

GEH

6 Unit, Cryosurgical, Accessories

Cryosurgical unit and accessories

GCJ

6 Laparoscope, General & Plastic Surgery

Endoscope and accessories

GDY

1 Gauze/Sponge, Internal, X-Ray Detectable

Nonabsorbable gauze for internal use

FQO

1 Table, Operating-Room, Ac-Powered

Operating tables and accessories and
operating chairs and accessories

GCS

1 Endoscope, Battery-Powered and Accessories

Endoscope and accessories

GAD

1 Retractor

Manual surgical instrument for general use

MAV

1 Syringe, Balloon Inflation

Angiographic injector and syringe

HQO

1 Unit, Cautery, Thermal, Ac-Powered

Thermal cautery unit

Gynecologic laparoscope and accessories
Electrosurgical cutting and coagulation device

Surgical Device, For Cutting, Coagulation, And/Or

N/A

A breakdown of the devices present in the trace color-coded by product code is pictured in
Figure 8 below. The most prevalent code is NAY for computer controlled surgical systems, as
mentioned previously. The next two most prevalent codes are GEH for cryosurgical units and
GCJ for general laparoscopic surgery. Color-coding devices by code highlights common device
functions within the trace and allows for easy identification of technical characteristics as they
evolve through predicate generations.
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Figure 8: Da Vinci Si Trace with devices color-coded by product classification code (See Appendix 3 for full list of
product code definitions).

Looking at the tree breakdown by product code in Figure 8, we can see the progressive evolution
of devices from more general laparoscopic surgical tools (to the right) to the more
technologically complex computer-controlled system of the Da Vinci. The five distinct branches
identified earlier emerging from the intertwined trace center are each dominated by one or two
distinct product codes, while the devices within the central web belong almost exclusively to the
same product classification as the Da Vinci. This implies that the technological characteristics
the FDA uses to identify devices belonging to code NAY are a combination of the characteristics
present in each distinct predicate group. This illustrates how larger “jumps” in technological
complexity of devices new devices can occur through the 510(k) Process, by combining the
characteristics of multiple well-understood devices into a new type of device.
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Another perspective to examine the technological evolution within the ancestral trace is based on
the regulatory description rather than the product code. While the product code considers both
the intended use and specific characteristics of a device, the regulatory description is a broader,
more general description based on the function of the device as defined by the FDA. For
example, the specific device description for product code GCJ is “laparoscope, general and
plastic surgery,” which specifies both a particular type of device and use, while the regulatory
description “endoscope and accessories” specifies only a general classification of devices.
Because of these broader descriptions, there is often overlap between the regulatory descriptions
of different product codes. In this trace, devices from 15 product codes can be placed into 11
groups based on regulatory descriptions, resulting in the formation of two larger groups which
contain the majority of devices within the trace.

The regulatory definition breakdown reveals that approximately half of the devices (24) within
the trace are classified from a regulatory perspective as endoscope and accessories. A further
~25% (13 total) are classified as electrosurgical cutting and coagulation devices, devices which
use a high frequency electrical current to perform surgical operations. 6 of the devices are
cryosurgical units, all classified under product code GEH, with the remaining devices
representing a wide variety of functions and characteristics.

70

Figure 9: Da Vinci Si trace sorted by product classification code with the upper predicate branch highlighted for
identification.

Unlike a grouping by product code, which highlights the evolution of specific technical
characteristics over time as new codes are introduced to the trace, viewing the trace based on the
regulatory description highlights groups of predicates based on general device functions. For
example, in the product code trace the upper branch is comprised of four distinct product codes.
However, when color-coded by regulatory description it becomes apparent that the originating
predicate (branch tips) are all cryosurgical units with accessories, which serve as predicates to
the electrosurgical cutting and coagulation devices the make up the middle of the branch, which
in turn serve as predicated for the computer controlled surgical devices present in the web center.
While color-coding by the product code specifically identifies groups of devices which the FDA
considers similar enough to be substantially equivalent, devices with the same intended use and
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technological characteristics, color-coding by regulatory description makes it easier to trace the
general progression of technology over time based on the general function of these devices.

Figure 10: Direct comparison of devices in upper Da Vinci Si predicate branch (See Figure 9) color-coded by
product code (left) and regulatory description (right). The new central group present in the regulatory description
trace combines two product codes to create a more general device grouping.

Figure 11 shows the devices in the entire DaVinci Si Trace color-coded by regulatory
description. The teal nodes and lines represent devices approved as “endoscopic instruments and
control systems” under code NAY.
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Figure 11: Da Vinci Si Trace with devices color-coded by regulatory description.

This style of coding based on regulatory description also draws attention to predicate devices
with unusual functional characteristics that do not fit with the primary function of most devices
within the trace. In some cases, this may be an indication of an unnecessary or ineffective
predicate relationship, while in others it may be indicative of secondary device functions.

For example, in this trace there is a device identified as a non-absorbable gauze/sponge for
internal use. This device, the Medical Perspectives Kittner Dissector, is a sponge used during
surgical procedures to prevent bleeding. It was identified as a predicate of the Monarch
Laparoscopic Manipulator system, which included customized versions of many basic surgical
instruments such as gauze. Although there is a purpose for including this device as a predicate
for a custom surgical tool, this part of the system is secondary to the main function of the Da
Vinci as a computer controlled surgical system.
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In fact, sorting predicates by regulatory description appears to allow for easy identification of
both primary and secondary device functions, based on the prevalence and location of a given
function in the trace. Primary device functions would be those identified directly by the
regulatory description of the given device, while secondary functions would be functions present
in predicate devices but absent in the regulatory description of the subject device. The more
prevalent a function is in the predicate history, the more likely it is to be present in the subject
device in at least a secondary capacity. Additionally, the significance of a particular secondary
function to the overall function of the device appears to correspond to the number of predicates
with that secondary function identified as a primary function. For example, the second most
prevalent regulatory description in the Da Vinci trace is “electrosurgical cutting and coagulation
device and accessories,” which corresponds to the function of an essential component of the Da
Vinci system. Although this is no longer listed as a primary function for the Da Vinci, it is an
important component of the system.

However, this absorption of a primary predicate device function into a secondary system
function draws attention to the increasing complexity of devices over time, where the Da Vinci
represents a particularly large leap in complexity. While the five main predicate branch
groupings each generally contain one or two primary device functions which evolve and become
more complex over time, the Da Vinci suddenly combines all those functions together into a
single device where none of the functions serve as the primary function. The listed primary
function “endoscope and accessories,” is a very generalized term which only identifies the device
as one used for internal imaging, even though it includes all the other secondary functions
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derived from the predicate devices, and is in fact used to directly perform surgeries. This
indicates that the regulatory description for product code NAY, and possibly other product codes
classified under this regulatory description, is much too broad to characterize the actual function
of the devices it describes.

5.3.3 GENERAL TRACE OBSERVATIONS
The overall dimensions of the expanded Da Vinci Si equivalence tree are somewhat unequal,
with the longest branch-line (depth) among over 100 branches (width) encompassing only 8
generations. The reason for these uneven dimensions appears to be due to the choice of
participants in the regulatory process to include inter-related predicates in approval applications.
That is to say, the application for the Da Vinci Si is predicated on both the Da Vinci S V1.1 and
the Da Vinci S, even though the Da Vinci S V1.1 is itself predicated on the Da Vinci S. This
essentially creates a duplicate set of predicates in the ancestral history. This practice of using
inter-related predicates appears often in the predicate history of the Da Vinci, resulting in an
extremely wide tree with an extremely high instance of duplication. This is why, although there
are over 2500 instances of predicates referenced in the trace, less than 2% of those device
instances are unique. Of those unique devices, just over half of them have identifiable predicate
device relationships. The remaining 24 ultimate predicates represent devices for which no further
equivalence information is available, terminating the branch-line trace.

The intention of the current regulatory system is for all devices to be clearly traceable via
substantial equivalence to a device legally marketed Pre-Amendment or post-amendment
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through the PMA process. However, only one branch line was traced to an originating predicate
classified as a Pre-Amendment device. Most ultimate predicates in the Da Vinci trace were
approved via the 510(k) Process and therefore were declared equivalent to another previously
cleared device, but the traceability of approval information for older devices is limited by the
availability of data.

5.4 TRACE COMPARISON
Investigation into the approval history of the Da Vinci Surgical System revealed evidence of
technological creep in predicate devices. However, the limited availability of data on older
predicate devices makes it difficult to trace the origin of many significant technological
characteristics present in the system, including the use of a computer-controlled manipulator
arm. Expansion of the substantial equivalence tree to include subject devices in the same
technological generation as the Da Vinci revealed that, although the devices did share similar
technological characteristics, the functionality of the Da Vinci system was significantly more
complex than other devices classified as endoscopic manipulators.

In an effort to determine whether patterns identified in the Da Vinci trace were unique to this
device or common across the approval process, I made the decision to expand my research to
other Class II devices. To directly compare the new device traces to that of the Da Vinci, I
selected devices which the FDA designates as “robotic surgical devices.” Although these
technologies do not have the exact same intended use as the Da Vinci, they do possess
technological characteristics which are extremely similar to the Da Vinci. This allowed for direct
comparison of predicate device relationships and other trace patterns, which in turn allowed me
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to make broader observations about how the FDA regulates complex surgical technologies
through the 510(k) Process.

The method used to identify robotic-based surgical systems with similar functions and levels of
technological complexity as the Da Vinci, was a search of the 510(k) database using the
keywords “robot” and “surgical system” in the device name category. The search was limited to
the 510(k) database rather than the wider FDA database in order to identify systems approved
through the 510(k) Process with a traceable predicate history. The term “robot” returned 62
results, and the term “surgical system” returned 173 results. Each of these results was then
reviewed in order to identify systems with similar technological characteristics to the Da Vinci.
After eliminating devices which did not meet this criteria, and duplicates of devices with
multiple models on the market, this method resulted in the identification of ten devices for
investigation (See Table 6).
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Table 6: Identified Robotic Surgical Devices
510(k) Number Approval Date

Manufacturer

Device Name

Product Code

K171120

10/13/2017

TransEnterix, Inc.

Senhance Surgical System

NAY, GCJ

K021152

09/24/2002

Computer Motion. Inc.

ZEUS' MicroWrist Surgical System

NAY

K072629

8/6/2008

Integrated Surgical
Systems, Inc.

DigiMatch ROBODOC® Surgical System

OJP, HAW

K143420

10/30/15

IMRIS Inc

SYMBIS Surgical System

HAW

K101791

9/23/10

MedTech S.A.

ROSA Surgical Device

HAW

K172796

01/18/2018

Medrobotics
Corporation

Medrobotics Flex® Robotic System and
Flex® Transabdominal Drive

HET, GCJ

K162330

5/4/17

Medrobotics
Corporation

Flex Robotic System and Flex Colorectal
Drive

FDF

K093425

02/24/2010

MAKO Surgical Corp

(RIO) Robotic Arm Interactive
Orthopedic System -THA

OLO

K003431

10/05/2001

Computer Motion. Inc.

Zeus Robotic Surgical System

GCJ

K003661

10/05/2001

Computer Motion. Inc. Socrates Robotic Telemonitoring System

NEQ

Further investigation of these devices revealed some substantial equivalence relationships, where
one device was predicated on another device identified for investigation, which resulted in the
creation of four device groups which could each be used to construct a separate predicate tree.
The Senhance Surgical System, ZEUS MicroWrist Surgical System, and DigiMatch ROBODOC
were all predicated on an iteration of the Da Vinci System, and could be added to the existing Da
Vinci Si trace. The SYMBIS Surgical System is predicated on the ROSA Surgical device, and
the two Medrobotics systems are related to each other. The Zeus and Socrates systems had no
available predicate information, so they were removed from consideration. Thus, I was able to
identify a total of three additional systems to trace beginning from the SYMBIS Surgical System,
MAKO RIO – THA Surgical System, and Medrobotics Flex Transabdominal System (Flex). The
raw data and an overview of the findings from each trace can be found in Appendices 4, 5, and 6
respectively.
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Using the data contained in the four predicate traces described above, it is possible to make
comparisons between the devices to evaluate the regulatory process. Table 7 contains a summary
of the information derived from each trace.

Table 7: Comparison of Robotic Surgical Device Traces
Predicates Unique
Identified Devices

Number of Ultimate
Companies Predicates

Earliest
Approval
Date

Unique
Codes

Most
Unique
Most Prevalent
Prevalent Regulatory
Regulatory
Code
Descriptions
Description

2618

50

18

24

Pre-1976

15

NAY

9

Endoscope and
accessories

SYMBIS

43

26

13

10

6/2/1981

2

HAW

2

Stereotaxic
instrument

RIO - THA

590

53

17

21

12/15/1986

7

HAW

6

Stereotaxic
instrument

Flex

109

42

10

21

1/3/1985

23

GCJ, EOB

10

Endoscope and
accessories

Da Vinci Si

Comparison of the number of predicate relationships identified in each trace indicates that the Da
Vinci Si trace is the largest by a significant margin. However, the number of unique devices
present in each trace indicates that the Da Vinci trace is fact smaller than the RIO -THA trace.
This discrepancy is due to redundancies in predicate identification, where Intuitive Surgical
identified the same device as a predicate multiple times within the approval history. Although
this redundancy is present to some extent within all of the traces, it is far more visible within the
Da Vinci trace than any of the others.

Comparison of the number of companies present within each trace reveals an interesting pattern
in the methodology used by companies to select predicate devices. Each trace contains a number
of companies that is at most half the number of unique devices within the trace. As a limited
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number of medical device manufacturers exists, and most specialize in a specific type of medical
device, it is not unexpected that a manufacturer might show up multiple times in a predicate
trace. However, the number of recurrences of companies listed within these four traces indicates
this pattern was created by choice rather than coincidence. For example, 38 of the 42 unique
devices identified within the trace of the Flex System were developed by the Olympus
Corporation. The common repetition of this pattern across multiple traces indicates that
manufacturers may be preferentially selecting their own devices to serve as predicates, rather
than other devices on the market.

This theory is further supported by the lack of overlap between the traces constructed, all of
which are classified as robotic surgical systems, and which share similar technological
characteristics. In fact, the only overlap of predicates present in any combination of the four
traces is a small group of 9 devices in the SYMBIS and RIO traces, all of which serve as ultimate
predicates or originate ultimate predicate branches, and therefore lack significant connection to
the core section of the trace. The lack of major overlap between the two traces, even though the
shared dominant product code and regulatory description indicates that devices contained within
the trace should be extremely similar, supports the idea that companies are preferentially
choosing predicate devices with which they are familiar.

The only device identified through this expanded investigation which overlaps more than two
traces is the DigiMatch ROBODOC, which is predicated on three (K043153, K991081, and
K052851) present in the Da Vinci Si, SYMBIS, and RIO - THA traces respectively. In fact, the
ROBODOC is directly predicated on the Da Vinci Model ISI 1000 and the MAKO Voyager
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Linux with Tactical Guidance System, both important predicates in their respective traces. The
ROBODOC system uses diagnostic images to assist in planning and performance of total hip
arthroplasty (THA) procedures under direct control of a surgeon, incorporating additional
technological components from the Voyager Linux guidance system, and the Da Vinci System,
which performs surgeries using a robotic arm guided by a surgeon. Although the ROBODOC
does not serve as a predicate device itself, and therefore cannot be used to make any major
observations about predicate creep past the technological components it shares with predicates,
its existence as a device predicated directly on components of multiple major traces investigated
within this thesis validates the selection of devices for predicate history comparison.

A combined trace of all four RAS systems is shown in Figure 12 below to illustrate the
relationships between the predicate ancestries. Unlike the diagrams for the individual traces, the
combined trace originates from the newest devices located at the center of the trace, with older
devices serving as ultimate predicates located at the outer edges of the combined trace. Each
RAS System trace is color coded, with the overlap devices between the RIO and SYMBIS trace
identified in yellow, and the DigiMatch ROBODOC identified in purple.
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Figure 12: Combined predicate trace of the four robotic surgical systems analyzed, with the newest devices located
closest to the center of the combined trace. The only overlap between the traces is highlighted in yellow between the
RIO-THA and SYMBIS traces.

Although the Da Vinci Si and Flex Transabdominal System share a common regulatory
description, if you exclude the ROBODOC, there is no overlap at all between the traces.
Considering the different intended use and overall technological characteristics of the two
devices, the lack of overlap is understandable, especially since there is also little overlap between
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the product codes present in the trace. However, the amount of variation in intended use and
technological characteristics between devices and traces with a common regulatory description
does indicate that definitions assigned using the current method may be too broad. In fact, these
broad regulatory definitions may be contributing to increased levels of technology creep present
within the 510(k) approval system by allowing approval of devices based on predicates with
significant technological differences due to the broad terms used in approval applications.

5.4.1 RECALLED PREDICATES
In Section 5.3.1, the devices contained within the predicate ancestry of the Da Vinci Si were
analyzed through the FDA’s Recall Database to identify potential safety flaws. The results
included multiple Class II recalls for the Si and many of its immediate predicates, the majority of
which were classified as robotic surgical devices. While a couple of Class II or III recalls will
likely have minimal effect on overall device safety, repeated Class II recalls or any Class I recall
is directly indicative of potential device issues. To determine whether this issue with repeated
recalls was unique to the Da Vinci product line, or a more general issue with complex robotic
devices, the devices contained within the SYMBIS, RIO-THA, and Flex Robotic System
predicate traces were analyzed for comparison. Table 8 below summarizes each instance of
repeated recalls identified within the traces, with a full overview of recall information included
in Appendices 2, 4, 5, and 6.
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Table 8: Summary of predicate devices with more than two registered recalls. Devices are sorted based on which
device trace they belong to.
Trace
Da Vinci Si

SYMBIS

RIO – THA

K Number

Device Name

Manufacturer

Approval Date Recalls

K081137

Intuitive Surgical Da Vinci Si Surgical System:
Model IS3000

INTUITIVE SURGICAL, INC.

2/18/2009

24 – Class II

K063220

Da Vinci S Surgical System-V1.1, Model IS2000 INTUITIVE SURGICAL, INC

12/1/2006

4 – Class II

K050369

Intuitive Surgical Da Vinci Surgical System,
Model IS2000

INTUITIVE SURGICAL, INC.

4/29/2005

43 – Class II

K021036

Intuitive Surgical Da Vinci Surgical System,
Model IS1200

INTUITIVE SURGICAL, INC.

6/26/2002

18 – Class II

K012833

Intuitive Surgical Bipolar Forceps

INTUITIVE SURGICAL, INC

11/16/2001

4 – Class II

K101791

ROSA SURGICAL DEVICE

MEDTECH SAS

9/23/2010

12 – Class II

K092239

ROSA SURGICAL DEVICE, MODEL ROSA 1.1

MEDTECH S.A.

11/17/2009

9 – Class II

K050438

STEALTHSTATION SYSTEM UPDATE

MEDTRONIC SURGICAL
NAVIGATION TECHNOLOGIES

6/2/2005

11 – Class II

K060336

NAVITRACK SYSTEM-OS KNEE UNIVERSAL,
MODEL PRO-05002

ORTHOSOFT, INC.

4/28/2006

2 – Class II
1 – Class III

K022365

STRYKER NAVIGATION SYSTEM - HIP MODULE

STRYKER INSTRUMENTS

1/22/2003

10 – Class II

K001284

STEALTHSTATION SYSTEM GOLDENEYE MICRO- MEDTRONIC SURGICAL
MAGNETIC TRACKING SYSTEM
NAVIGATION TECHNOLOGIES

6/12/2000

27 – Class II
1 – Class III

K993239

STRYKER NAVIGATION SYSTEM - NEURO
MODULE, MODEL 6000-XXX-XXX

STRYKER CORP.

1/18/2000

2 – Class I
4 – Class II

K990214

FLUORONAV MODULE FOR THE
STEALTHSTATION SYSTEM

SURGICAL NAVIGATION
TECHNOLOGIES, INC.

4/22/1999

29 – Class II

Examination of the devices with multiple recalls identified through this research revealed a few
key findings. First, while the Flex system had no instances of repeated recalls within its predicate
ancestry, both the SYMBIS and RIO-THA had multiple instances with comparable levels of
severity to the recalls issues for Da Vinci Si predicates. This indicates that the level of
complexity of robotic surgical technology may be partially responsible for the repeated recalls,
rather than a specific flaw with the Da Vinci System.

Second, two Class I recalls were issued for the Stryker Navigation System – Neuro Model, a
device which serves as a predicate in the RIO – THA trace. These recalls were issued in
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November of 2009, after the approval of multiple subsequent device generations, in response to a
series of software problems which rendered the device unusable and unsafe. Although this is the
only instance of a Class I recall, it does illustrate the potential for devices with serious safety
flaws to be used as predicate devices, if those flaws are not discovered prior to approval of the
subject device seeking approval.
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6 DISCUSSION
6.1 PREDICATE CREEP
It is clear from the data gathered in this research that predicate creep, and technology creep in
general, does indeed exist to some extent within the 510(k) Process. Due to the limited
availability of detailed information on the technical characteristics and testing procedures of new
devices presented in approval application summaries, it can be difficult to determine the amount
of scientific evidence provided to mitigate predicate creep within a device’s approval history.
However, even without knowledge of the evidence provided to support substantial equivalence
claims, correlations can be about the impact of predicate creep on the 510(k) Process.

The 510(k) Process uses a combination of predicate performance data and design validation
testing data to determine if a device is both substantially equivalent to a predicate and safe to be
placed on the market. However, unless the validation testing performed includes clinical trials,
there is no way to ensure for certain that a device will perform as expected when it enters the
market and is used on patients. Therefore, in the absence of clinical trials, the only data used to
support device safety is the performance of predicate devices. As a result, if technology creep
occurs between predicates, even if all the new aspects of a device are tested thoroughly in nonclinical settings, there is no way to 100% guarantee that the new device will perform as
anticipated. However, it is extremely difficult to mitigate this small scale form of predicate creep
without the use of mandatory clinical trials, which would defeat the purpose of the 510(k)
Process entirely. Instead, requirements for non-clinical testing are used to mitigate much of the
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risk associated with small scale predicate creep, which in most cases works effectively.
However, there are two scenarios in which non-clinical evidence may be insufficient to
adequately mitigate the risks associated with small scale predicate creep.

The first case is when the non-clinical evidence provided to support substantial equivalence
claims is insufficient to ensure that new technological characteristics do not introduce new safety
issues within a device design. Given the data available for analysis in this thesis, it was not
possible to determine whether any instances of insufficient evidence were present within the Da
Vinci or other device traces.

The second scenario in which non-clinical evidence is insufficient to support device safety is if
multiple generations of devices approved via substantial equivalence each possess a degree of
technology creep. This is the theory of predicate creep discussed in previous literature, where
technology creep causes subtle changes in device form and function to build up over time, until
eventually a device is introduced to market which bears no resemblance to the original device.
Although each individual device characteristic is supported by some form of non-clinical
evidence, the only clinical evidence supporting the approval of newer devices is based on a
device which they are essentially unrelated to. A simple example of this type of creep is
illustrated using shapes in Figure 13 below, where each change present in a new iteration of the
shape is relatively small and well supported logically.
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Figure 13: An example of the impact of small scale predicate creep over multiple device generations, where a solid
blue triangular shape is transformed step-by-step into a hollow green rectangle which bears no resemblance to the
original shape.

The final device (or shape in the example above) is essentially a totally different device than the
original predicate upon which it is based. However, the original predicate is the only device that
was actually tested pre-market for safety. This means that the cumulative effect of continuous
technology creep over time is large scale predicate creep, where changes in device characteristics
result in the creation of entirely new device types without any clinical evidence of safety and
efficacy. Even if the effects of small scale predicate creep are mitigated by non-clinical testing,
the effects magnified on a larger scale result in the development of entirely new device types
without clinical evidence, essential circumventing the requirements of the PMA process over
time.

This research was able to detect the presence and analyze the effects of large scale predicate
creep (referenced simply as predicate creep) for the data sets using three different methods of
predicate analysis; technological characteristic comparison, regulatory structure comparison, and
predicate relationship analysis.

6.1.1 TECHNOLOGY CHARACTERISTICS
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The first method used to identify technology creep is the traditional method of direct
characteristic comparison described in the methods section. Comparison of the technical
capabilities of devices in a substantial equivalence relationship highlights the exact device
component which represents a new technological innovation, thus making it easy to identify
instances of technology creep. The severity of technology creep varies based on the degree of
change between the technological characteristics of the device, from minor changes of a single
components to major changes in device function.

An examination of the traces constructed in this research finds that, even without detailed
technical descriptions, many instances of technology creep can be identified from the device
descriptions provided in approval application summaries. For example, following one five
generation branch line in the SYMBIS trace connects the SYMBIS system (K143420), which
uses jointed mechanical arm guided from a surgeon console to position stereotactic instruments,
to the Brown-Roberts-Wells Stereotaxic System (K811452), which uses a CT scanner and
physical structure comprised of a series of rods and a curved metal frame to position stereotaxic
instruments for neurosurgery (Apuzzo & Fredricks, 1988). Although both devices have the same
core function, there are significant changes in the technological characteristics between the two
devices. Even the device which the Brown-Roberts-Wells System serves as an immediate
predicate for, the Neuromate Stereotactic System, incorporates significant new technological
components, primarily the use of a jointed mechanical arm for positioning. Another major
example of technology creep from the RIO-THA trace is the progression, within a single
predicate generation, from a handheld flexible endoscope to a system incorporating a robotic arm
for endoscope and tool positioning driven from a separate console as described in Appendix 5.
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Other instances of technology creep include the progression from an intraoperative image
guidance system with a handheld probe (K052213) to a guidance system with a robotic arm
serving an “intelligent” tool holder to provide feedback (K072806) in the Mako RIO trace and
the progression from individual manual surgical instruments to a robotic surgical system within
the Da Vinci Si trace. In fact, even based on the limited information available through approval
summaries, the majority of substantial equivalence relationships examined within this thesis
appear to possess some degree of technology creep. Although it may be expected due to the
nature of the regulatory process, these many examples confirm that technology creep is prevalent
within the 510(k) Process.

The traces within the research where it is easiest to directly identify technological characteristics
are the initial Da Vinci Model IS1200 trace and the AESOP System trace, due to the relatively
small trace size and availability of technical device descriptions. An example of short-term, high
impact technology creep is the branch line between the AESOP and Da Vinci Systems, which
moves from an assistive endoscope positioning system to a system performing robotic surgeries
in only two generations. Starting from AESOP, the line passes to the Monarch (a sub-component
of Da Vinci Model ISI 1000) which incorporates multiple manipulator arms, a console for
controlling the arms, and primary functionality of the arm(s) from scope positioning to actual
surgery, then directly to the Da Vinci IS1200 which incorporates a 3D vision system and
specialized instruments. This significant amount of change within just three generations is
somewhat startling, as it implies that the level of similarity required between technological
characteristics for substantial equivalence is extremely low.
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The high degree of technology creep within the Da Vinci trace becomes even more apparent
when compared to other devices in the AESOP trace, which share the same predicate device.
Although there is also predicate creep present within these branch lines, the degree of
technological change is significantly less. For example, all of the devices in the same generation
as the Da Vinci within this trace share the same basic function as the AESOP system, to position
and hold an endoscope during surgery. The major technological innovations present in these
devices are changes in the number of movable joints in the manipulator arm, and the arm control
interface. Comparatively, the Da Vinci incorporates many additional core device functions, such
as manipulation of surgical tools, cutting and electrocautery, as well as the inclusion of multiple
new manipulator arms and a new control platform. While the other second generation devices
within the Da Vinci trace are examples of low-impact technology creep, where the resulting
predicate creep is small scale and unlikely to introduce major safety concerns, the high-impact
technology creep present in the Da Vinci branch is an example of large scale predicate creep.
Although the stated intended use of these devices is the same, the Da Vinci represents a sudden
“leap” in technology by effectively introducing a new intended use in addition to the prior
intended use of endoscope positioning.
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6.1.2 MULTIPLE PREDICATES
One of the major indicators of technology creep is the use of multiple predicates in an approval
application. If a device is approved based on a single predicate, then technological changes
between the two predicates are easily identifiable and can be directly addressed through nonclinical testing. However, in an approval application with multiple predicate devices the
characteristics of the subject device are typically a combination of characteristics from the
predicate device. This new combination of technological characteristics, which have not
previously been tested, make it more difficult to identify and test for potential device flaws, and
subsequently increase the probability of device failure. This exact problem was responsible for
the failure of the Dupuy ASR XL, which possessed a unique combination of material and
geometry never before tested on patients (Ardaugh et al., 2013). Further, although these devices
often represent significant leaps in technology, they are often approved without additional
clinical testing, as was the case for the ASR XL. In these instances, non-clinical tests alone are
insufficient to assure device safety and mitigate the effects of small scale predicate creep.

Examining the predicate relationships of the Da Vinci Si and other systems, the use of multiple
predicate devices in approval applications appears to have changed over time. Older devices
approved prior to the early 1990’s, when predicates are traceable, typically use only one or two
predicate devices. However, newer devices, especially those approved in the late 1990’s - early
2000’s, often use three or more predicate devices. Although other factors may also contribute, it
appears that this change is mostly due to the increasing pace of technological innovation within
medical device fields. Devices which use more than two predicates typically appear to represent
more significant innovations and changes in technological characteristics compared to devices
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with fewer predicates. For example, in the Da Vinci Si trace 15 of the 20 devices (75%)
associated directly with the Da Vinci System (i.e. the system and components) have three or
more predicate, while only 5 of the remaining 29 predicates (17%) have three or more predicates.
The exception to this rule is when companies use one approval application to approve a group of
devices, for example a line of surgical instruments, rather than a single device.

In addition to larger leaps in technical innovation, the use of multiple predicates as split
predicates also contributes heavily to predicate creep. The FDA defines a split predicate as the
use of one predicate device to validate equivalence of intended use, and different a predicate (or
predicates) to support equivalence of technical characteristics (CDRH, 2010). Using this method,
devices can be approved for new applications without ever undergoing testing to prove that the
device is safe for that application. Further, if the device also combines characteristics of multiple
technical predicates in addition to introducing a new intended use, it is nearly impossible to
ensure that the new device is safe without clinical trials. Previously, companies validated the use
of split predicates by claiming that the term “predicate” in the definition of substantial
equivalence refers to the combination of all prior devices identified in an approval application,
rather than each individual device. However, in the 2010 Working Group report and subsequent
guidance documents issued by the CDRH, the term “predicate” in the definition of substantial
equivalence is clearly interpreted to apply to a single device already on the market. Under this
interpretation of the definition, the use of split predicates as defined by the FDA clearly violates
the terms of substantial equivalence.
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The FDA’s interpretation of the definition of substantial equivalence means that every single
device identified as a predicate is subject to the entirety of the definition of substantial
equivalence, and therefore MUST possess the same intended use as the subject device. However,
there are many instances within the predicate histories investigated in this research where
predicates are identified for the purpose of validating technical characteristics of the subject
device without possessing the same intended use as the subject device. For example, the Intuitive
Monarch Laparoscopic Manipulator/Endoscopic Control System shares the same intended use
and many technological characteristics of the AESOP system, one of its immediate predicate
devices. However, the Monarch also cites three different types of manual surgical tools as direct
predicates, none of which share the same intended use of “control of instruments during surgical
procedures.” By the FDA’s interpretation of substantial equivalence, these surgical tools do not
qualify as valid predicate devices. But without the inclusion of these surgical tools, Intuitive
would not have been able to validate the use of the Monarch System for any surgical tasks other
than endoscope positioning, which was an essential step to the subsequent approval of the Da
Vinci System. These “partial predicates”, which are used to validate technological characteristics
of a device without possessing the same intended use, are often included on approval
applications of “leap” devices, which contain major technological innovations in one or two
predicate generations.

In 2012, to mitigate some of the risk introduced by split predicates while still allowing for larger
technological innovations like those present in the Da Vinci trace, the FDA created a new
regulatory mechanism called Reference Devices. Unlike a predicate device, which is required to
possess the same intended use as the subject device, a reference device can be used to validate
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the safety of technological characteristics without possessing the same intended use as the new
device. However, a reference device can only be used in addition to a valid predicate device and
cannot on its own serve as sufficient validation for device approval. One example of a device
approved using reference devices was found in the Medrobotics Flex Transabdominal System,
described in Appendix 6.

This new regulatory mechanism does address the issue of split predicates as they are defined by
the FDA. However, instances of split predicates are extremely rare, to the point where no
examples can be identified within any of the four traces constructed here. Instead within these
traces there are many instances of partial predicates, which are often associated with the leap
devices that contribute so heavily to technology and predicate creep. Rather than address
potential safety issues with the approval of technology for untested use scenarios, the FDA has
essentially given the green-light to continue using these partial predicates by giving them an
official regulatory definition as Reference Devices. Although it is difficult to determine the
potential impacts to the regulatory process of such a new mechanism, the effects of previous
examples of partial predicates indicate that reference devices will be used to approve devices
with significant new innovations for market without the use of clinical trials.
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6.1.3 PRODUCT CODES AND REGULATORY DESCRIPTIONS
Another interesting pattern is the evolution of product code classifications over time within the
traces. The FDA designates product codes based on the intended use and technical characteristics
of devices, combining those characteristics to identify a device type and basic regulatory
description. If the FDA finds that a device does not fit into an existing product code, they will
designate a new code, even if the device was approved via 510(k). As a result of technological
creep and innovations over time, new product codes are often introduced into the device traces.
For example, in the RIO trace the majority of the devices were classified under code HAW,
while the originating predicates were classified under a variety of different product codes.
Similarly, the devices in the Da Vinci Si trace were classified under a variety of product codes
prior to the designation of code NAY, which subsequently included all of the newer devices in
the trace. Looking at the characteristics of devices under the codes which existed in the trace
prior to the introduction of the dominant code gives clues to the technological characteristics
present in devices classified under the dominant code. Examining the differences between
subject and predicate devices with different codes also gives insight into what level of
technological change triggers the creation of a new product code.
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6.2 OTHER ISSUES
6.2.1 REDUNDANT PREDICATES
As discussed within the Research Expansion section, there is a large discrepancy between the
number of identified predicate relationships and the number of unique devices present within
each trace. This is caused by redundant predicates, where a subject device references a predicate
device multiple times within its ancestral trace. This creates multiple ties to a single predicate
device, which rapidly expands the size of the ancestral equivalence tree. Figure 14 illustrates the
three types of predicate redundancies identified within the ancestral traces, with redundant
predicate relationships highlighted in red.

Figure 14: Sample illustration of the different types of predicate redundancy in both compressed and expanded tree
forms, with the redundant predicates highlighted in red.
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On the left is a basic predicate trace with no redundancy, which consists of the subject device
and 6 predicate devices with a total of 6 substantial equivalence claims, one per unique device. In
the center an example of generational redundancy, where the subject device directly references a
predicate which also appears as a predicate device for another device in the same generation.
This creates a single redundancy, with Predicate C now appearing twice in the trace. The effect
of redundancies is magnified by inter-generational redundancy, where a predicate device present
in the trace references another predicate device within the trace. As seen in the example shown
above, the redundant relationship causes the entire branch originated by Predicate B, circle in
red, to become redundant, which results in a total of 9 equivalence claims for a trace consisting
of only 6 devices. The effects of inter-generational redundancy cause entire branches to be
duplicated, creating a stacking effect that turns the relatively straight expanded trace into a weblike structure when condensed.

There are two major issues with the use of redundant predicate devices in the approval process.
First, although redundancy increases the number of appearances of a particular predicate device
within a trace, this number does not necessarily correlate to the degree of equivalence between
the predicate and subject device. This is because the 510(k) Process makes no differentiation
between predicates used to introduce a single technological characteristic and predicates which
are nearly identical to the subject device. For example, in an expanded version of the Da Vinci Si
trace where all redundant predicate instances are visible, the Baxter Healthcare Endoscopic
Instruments (K931340) appear 170 times, while the AESOP System (K931783) appears only 143
times. Examining the actual technical characteristics of each device, it is apparent that the Baxter
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Instruments are traditional handheld endoscopic surgical instruments used as predicates for the
end effector instruments of the Da Vinci system, while the AESOP system serves as a predicate
for many of the complex technological components of the Da Vinci System such as the
manipulator arms and software control. Based on these technical descriptions, it is apparent that
the AESOP system has a higher degree of technological similarity to the Da Vinci System, and is
therefore more relevant for proving safety and efficacy from a regulatory standpoint. However,
the number of appearances of each predicate device within the trace does not reflect the actual
degree of technical similarity to the Da Vinci.

Because the natural tendency of an observer is to assume that devices which are cited more often
have a higher level of significance within the trace, this lack of discussion on degree of
equivalence may result in an undue amount of importance being placed on redundant predicates.
This is particularly problematic when predicates which appear more often within the trace have
few technical characteristics in common with the subject device, as the level of evidence for
safety assurance provided by these predicates is significantly less than that provided by other,
more technologically similar devices.

The second issue with redundant predicates is the use of repeated device citation to increase the
number of devices on the market that a new device is being compared, and subsequently the
amount of evidence supporting substantial equivalence claims, without increasing the size of the
actual body of evidence present. For example, the Da Vinci Si trace has 2618 different instances
of equivalence claims, where a device is cited as a predicate, but only 50 unique devices actually
present within the trace due to the repeated use of inter-generational redundancy. This
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redundancy is present when Intuitive cites both the previous model of the Da Vinci system and
the devices which served as a predicate for that model. While such duplications may make sense
at first glance, since a greater number of immediate predicates for a new device means more
evidence to support its safety, these duplications are actually indicative of potential flaws within
the previous Da Vinci model.

Since direct predicate device(s) are supposed to provide evidence of safety and efficacy via
performance on the market, the fact that Intuitive felt the need to cite the predicates of the
previous Da Vinci model, in addition to the model itself, indicates that they believe there is
insufficient evidence to support approval of the new model based on the previous model alone.
While this belief may or may not be true, it highlights the potential issues with highly complex
devices introduced to market via the 510(k) Process without a direct predicate device which
shares the same technological characteristics. As a result of the lack of safety evidence provided
by the initial version of such a device, companies like Intuitive are forced to redundantly cite the
predicates of that device in addition to the device itself when filing for approval of subsequent
device models. However, since regulators typically only look at the evidence provided by direct
predicates, and the additional devices already served as predicates to the original model, this
effectively disguises the fact that the only additional evidence provided to support approval of
the new model is the performance of the old model. The initial model of the device therefore
served as a “step” device to incrementally introduce new technological characteristics into the
marketplace before more significant innovations could be introduced in the second model.
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Although incremental development is a common and necessary component of technological
innovation, the use of redundant predicates as a regulatory mechanism to get these innovations to
market can go too far. If a device with innovative components can stand on its own as a predicate
from a safety and efficacy perspective, or with minimal redundancy, then it is valid to use it for
incremental innovation. However, when a company repeatedly cites the same predicate devices
for each incremental innovation of a device, it indicates that either the company habitually cites
prior predicates without purpose, or duplication of earlier predicates is required to prove the
safety of each incremental innovation. Requirement of redundant predicates for device approval
indicates that the amount of innovations present in the new device may be too significant for the
510(k) Process to provide effective assurance of device safety.

6.2.2 SELF-CITATION
The trace maps constructed through this research illustrate the evolution process of technological
characteristics in new medical devices over time. Comparison of four different robotic surgical
device traces reveals an interesting pattern of independent branch line development. While logic
would dictate that devices with similar technological characteristics should share common
predicate devices, these traces reveal instead the development of parallel branch lines, where
technological improvements in one line are made independently of other lines.

Of the four independently traced lines, only the Mako RIO and SYMBIS systems have any
overlap, and that overlap consists of 4 devices contained in a single branch. The only device
identified which truly overlaps multiple traces is the DigiMatch ROBODOC, which is predicated
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on the Da Vinci (K043153), a direct predicate of the Mako RIO called the Mako Voyager Linux
(K052851), and the Frameless Nueromate (K991081) by Integrated Surgical Systems, which
appears in the SYMBIS Trace. Other than these devices, all the devices identified in the approval
traces were unique. However, comparison of the product codes and regulatory descriptions
associated with the traces reveal that many of the predicate devices share similar characteristics.
The methodology for the selection of predicate devices by applicants must therefore be
influenced by factors other than the particular technological characteristic of the device.

One of the most likely factors influencing the selection of predicates is based on the intellectual
property and availability of technical information associated with device. When there are many
similar devices available within the market to serve as predicates, a company will select a device
which they believe they have best access to information about. Most often, this is a device
previously released by the company or a subsidiary for which the company has full access to
both the intellectual property and previous scientific evidence to support equivalence claims.
This practice is evident within all four of the constructed traces, with each trace including a
number of manufacturers less than half the number of unique devices.
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Table 9: Trace Comparison
Unique Devices

Number of Companies

SYMBIS

26

13

Da Vinci

50

18

Flex

42

10

RIO

48

15

This practice of using familiar predicate devices is advantageous to companies, as it reduces the
number of unknown variables present in the approval process. However, it has created a pattern
in which multiple companies often independently develop new technological innovations rather
than piggybacking on existing technologies. This may ultimately slow the overall progress of
technological innovation.

6.2.3 LACK OF INFORMATION ABOUT SOFTWARE CONTROLS
One of the major components of the Da Vinci System and other similar robotic surgical devices
is the software package developed to control the device. In fact, it can be argued that the
software package for the Da Vinci system, capable of interpreting surgeon motions and directly
controlling multiple manipulator arms while providing feedback in real time, was the major
innovation of the device. However, the information available through the FDA databases and
Intuitive Surgical’s website focuses almost exclusively on the physical infrastructure and
capabilities of the device, rather than the software that runs it. In fact, the only information
related to the Da Vinci software infrastructure in the available 510(k) approval summaries was a
statement saying that its exists and has been updated for each new Da Vinci Model.
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At the time of the approval of the original Da Vinci Model ISI 1000 in 2001, the information
regarding device software included in a 510(k) submission was regulated by a guidance
document issued by the FDA in 1998. This document describes how to classify a device based
on the “Level of Concern,” or severity of potential failure implications, and then lays out
requirements for software architecture design, traceability, and verification as well as
international consensus standards which the software should meet (U.S. FDA, 1998). The
document was subsequently updated in 2005 and again in 2016 to clarify when software changes
necessitate resubmission of a 510(k) application.

Creation of standards for validation and testing of software-based device components is
particularly essential given the growing level of software complexity present in newer medical
devices. For a more traditional hardware-based device potential failures of major components
such as motors or switches can be easily predicted and tested using physical methods. However,
the structure of software programs, with thousands of lines of code requiring extremely
specialized knowledge to create and interpret, makes potential software failures much more
difficult to identify or predict. This is especially true of small glitches or “bugs” within the
program, which don’t affect the overall device functionality and appear only under a very
specific set of conditions. Detection of these bugs requires a wide variety of rigorous testing
procedures to ensure that nothing with the potential to harm patients slips through the cracks.
However, although the FDA does require information about software testing to ensure device
safety, specific requirements for testing procedures are covered only by general industry
standards which may or may not be applicable to the medical device being tested.
104

Given the existing FDA regulations at the time, and the lack of major recalls or reports regarding
problems with the Da Vinci software, it was presumably evaluated using various standards to
ensure device safety. However, the lack of evidence surrounding this software testing and that of
subsequent software iterations is somewhat concerning. Since the complexity of the Da Vinci
software is relatively high compared to other devices on the market at the time of its approval,
there is subsequently a higher likelihood of an existing flaw causing major safety issues.
Although there have been no severe recalls on the Da Vinci system due to software malfunctions,
another device in the predicate history of the RIO - THA, the Stryker Navigation System –
Neuro Model, was the subject of two separate Class I Recalls in 2009 due to software flaws
which had the potential to cause fatal injuries to patients.

While the Stryker system illustrates the potential for severe risk posed by software-based
medical devices, the structure of the Da Vinci system, where software directly controls the
motion of the device performing surgery, magnifies the potential risk posed by software
malfunctions. In most other surgical devices at the time of the Da Vinci’s approval, and even in
many of the newer devices examined within this research, the surgeon is still in direct physical
control of the motion of the tool manipulator. This means that, while a software flaw could
potentially freeze the tool in place or provide inaccurate information, the surgeon is still
ultimately in control of the tool motion. However, with the Da Vinci platform the software
directly controls the tools performing surgery, which means a small software glitch could have
catastrophic consequences. For example, if a small software bug causes the manipulator arm
motor to reverse direction or move more than directed during surgery at the wrong time, it could
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potentially sever a blood vessel and cause internal bleeding or worse before the surgeon has a
change to notice or stop it. Although Intuitive has obviously performed software tests to prevent
such occurrences from happening, the lack of information about the testing conducted makes it
difficult to determine whether their success in prevention of such issues is due to intensive
testing or luck.

6.2.4 RECALLED PREDICATES
One of the notable findings identified in the previously reviewed study conducted by Zuckerman
et al. was the presence of devices which had undergone major recalls within the predicate history
of newly approved medical devices (Zuckerman et al., 2014). Similar instances of devices
continuing to serve as predicates after undergoing major recalls or even being removed from the
market were also identified as one of the issues which led to the failure of the DuPuy ASR XL
(Ardaugh et al., 2013). A predicate which has undergone major recalls can be indicative of
inherent safety issues with the technological basis of subsequent devices if they share major
technological characteristics with that predicate. Even if a predicate has not undergone any major
recalls, patterns of multiple minor recalls for similar recurring issues may still be indicative of an
issue with the device design. Alternatively, patterns of multiple minor recalls may indicate that
the associated technology was insufficiently developed or rushed to market without a strong
technical foundation to support the functions it provides. To determine whether there was any
impact from recalled predicates on the devices studied in this thesis, each of the predicates
identified within the four major traces were run through the FDA Recall Database.
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Based on the results of the Recall Database analysis discussed in section 5.3.1 and 5.4.1, there is
a definitive pattern of related device technologies present among the devices with multiple Class
II recalls. All the devices with multiple recalls present in the Da Vinci trace were either iterations
or components of the Da Vinci system itself. Although none of the recalls were due to
catastrophic failures, the repeated pattern of recalls for different, moderately severe issues
indicates that the technology entered the market before it was perfected. This is reinforced by the
fact that issues continued to arise even with subsequent models of the device. Additionally, the
variety of issues which triggered recalls, ranging from overheating batteries to user manual
updates and incompliant factory testing, is likely indicative of the complexity of the system both
as a device to operate and a device to manufacture. It is notable that all the recalls within the Da
Vinci trace were issued for devices manufactured by Intuitive Surgical, which may also point
towards a level of inexperience with this type of device manufacturing as a relatively new
company (it was founded in 1995 and exclusively manufactures the Da Vinci and accessories) in
addition to issues created by the technical complexity of the Da Vinci. Like the Da Vinci system,
the three iterations of the Stealthstation system present across the RIO – THA and SYMBIS
traces have a combined 68 recalls between them. Yet despite the high number of recalls, the
device continues to serve as not only a predicate, but also an active component of the SYMBIS
Surgical System.

However, whether inexperience on the part of Intuitive Surgical contributes to the high number
of recalls or not, the Da Vinci is not the only complex surgical system which experienced high
rates of recalls. Both iterations of the ROSA surgical system, the direct predicate to the SYMBIS
System, experienced a large number of Class II recalls within a relatively short period of time
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during 2017. Similar to the Da Vinci, the reasons for these recalls varied, but the majority were
directly associated with potentially faulty components used during the manufacturing process.
This brings up one of the major issues with highly complex medical devices, which is that they
often rely on third-party vendors for most of the component sourcing and manufacturing. As a
result, even if the design is sound, the sheer number of components and manufacturers involved
in the creation of such a device makes the probability of device failure significantly higher than
less complex devices.

Finally, although not necessarily as prevalent within these traces as in previous research, there
have been significant recalls on devices which continue to serve as predicates for new products.
For example, in the case of the Stryker Navigation – Neuro Model the RIO-Total Hip
Arthroplasty (THA) was approved based on devices predicated on the Neuro Model after the
recall was issued without additional investigation of the intermediary device safety. Nowhere in
any of the documentation presented for approval requests was reference made to any existing
product recalls, and no subsequent evidence to reinforce device safety despite recalls was
provided. Additionally, there was no record anywhere within the publicly available data of the
FDA returning to previously cleared devices to reevaluate safety in light of a new product recall
on a predicate device. This leads to the conclusion that the FDA currently does not possess a
mechanism for evaluating the potential impact of device recalls on devices cleared through the
510(k) Process.
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6.3 AVAILABILITY OF DATA
In the 510(k) database, information required for determination of substantial equivalence, such as
predicate devices, intended use, indications for use, and scientific evidence, is located within the
application summary attached to the main device summary page. However, the level of
information contained within these summaries varies widely, and in many cases these summaries
do not exist at all, due to the gradual evolution of requirements for 510(k) application
submissions. Although the 510(k) Process was officially implemented via the 1990 Safe Medical
Devices Act, official guidelines for the contents of submissions, including the creation of
summaries detailing equivalence claims, were not issued by the FDA until 1994. (Medical
devices; Substantial equivalence, 1994) Further, use of the standardized “Indications for Use”
form was not implemented until 1996, (CDRH, 2010) and specific guidelines for the formatting
of traditional and abbreviated 510(k) applications were not issued until 2005. (CDRH, 2005) As
a result, the level of information available in the 510(k) database varied widely based on the date
of approval. Devices approved prior to 1992 typically only include the basic information
available on the device-summary page, and in some cases are not present in the database at all.
Data available for devices approved between 1992 and 2005 is inconsistent, with some results
containing full PDF summaries of approval applications, including identification of predicate
devices and intended use, and others containing only a statement certifying equivalence claims or
no information at all. Consistent inclusion of application summaries in the database does not
begin until applications filed around 2005-06. Even within applications which include
summaries, the level of information varies as 510(k) application guidelines were modified
multiple times, most notable in 2007 and 2012.
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The lack of consistent data is one of the major challenges to research which seeks to understand
the impacts of the evolution of the 510(k) Process. In cases without an application summary,
such as the device summary shown on the left, it is impossible to identify the predicate device(s)
based on the available public information.

The difficulty of locating relevant data became evident almost immediately during this research
process, as there is no information within wither the FDA database or Intuitive Surgical’s own
website about the approval process utilized with the first model of the Da Vinci Surgical System,
Model IS1000. The lack of publicly available information about the approval process for the
IS1000 model is troubling, as it obscures both the regulatory and technical origins of the device
function. While Intuitive Surgical’s website history section references several medical
innovations created in the early 1990’s with similar technological functions as the Da Vinci,
including the Laparoscopic Assistant Robotic System (LARS) and the Stanford Research
Institute’s Telepresence Surgery System, there is no way to determine whether these devices
served as predicates for the initial model of the Da Vinci.

Theoretically, a map of all of the predicate relationships for every device approved via 510(k)
should resemble a web, where different spurs originating pre-1976 initiate groups of device
based on a primary function which then evolves over time. The density of devices contained
within the map should increase somewhat exponentially reflecting the pace of technological
innovation moving through time away from the web origin. However, if the contents of the entire
510(k) database was mapped today, it would resemble a donut with a large hole in the center due
to lack of information about older devices.
110

The impact of this lack of data varies depending on the intended use of the mapping structure.
From a regulatory perspective, older devices are mostly obsolete, and have been replaced by
newer devices. These new devices would still be visible grouped by device function, due to
mutual originating Pre-Amendments devices, around the central ring. The impact of the lack of
data about older devices is felt only when one attempts to trace technological characteristics to
their origin device. While this type of trace is not performed often, it can be used to identify the
level of scientific evidence supporting claims of device safety and efficacy, which can be useful
when disasters occur.
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7 CONCLUSIONS
7.1 SUMMARY OF FINDINGS
This thesis set out to explore the 510(k) Approval Process as it is applied to complex medical
devices, with particular focus on robotic surgical systems such Intuitive Surgical’s Da Vinci
System. The goal of this research was to develop a methodology to identify predicate
relationships using publicly available data and to determine the validity of concerns expressed by
previous researchers surrounding the potential impact of predicate creep and other issues with
the existing approval process. In this section I will summarize my findings on the impact and
policy implication of predicate creep and other issues within the 510(k) Process.

7.1.1 TECHNOLOGY CREEP
Given the purpose of the 510(k) Process, to bring new medical devices to market, it should be
expected that there is a level of technology creep inherent in the process. If manufacturers are
limited to only submitting identical devices for approval through the 510(k) Process, there can be
no innovation. Even in new versions of existing devices submitted by the same manufacturer,
such as the Da Vinci Models IS1000 and IS1200, there can be somewhat significant
technological changes. Removing all technology creep from the process would only hinder
progress within the medical devices industry.

Inherent predicate creep in limited amounts, where the new device can be guaranteed safe based
on available scientific evidence, appears to actually be beneficial to companies, patients, and
regulators alike. However, there are instances, evidenced both within these traces and in other’s
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research, where technology creep goes too far. Devices are approved via 510(k) which bear little
resemblance to predicates or possess a unique combination of predicate technological
characteristics never before tested on a patient, making it impossible to assure the safety of the
new device through predicate evidence alone.

In the case of devices which bear little resemblance to predicates, it appears from this data that
approval through the 510(k) Process is accomplished by manipulating vague regulatory
definitions using broad device descriptions and general intentions for use to make a device
appear more closely related to a predicate than it actually is. This is especially evident in the case
of the Da Vinci system.

The regulatory description of the Da Vinci as an endoscope, an instrument that is introduced into
the body to view its internal parts, and accessories rather than as a device which directly
performs surgeries offers an important clue into the inner workings of the regulatory process. A
device which is performs a surgical procedure without direct physical control by a surgeon has
significantly more inherent risk than a simple viewing device, and might therefore fall under
Class III regulatory guidelines. Additionally, while endoscopes and accessories are considered to
be well understood devices with clear predicates and a defined intended use, no device has ever
been approved as a “robotic surgical system”. Therefore, any device seeking approval under this
classification would be considered a new device and automatically placed into Class III. By
identifying the Da Vinci as an endoscope with accessories, although the endoscope isn’t the only
major function of the device, it allows the manufacturer and regulators to circumvent the more
stringent and lengthy Class III regulatory requirements.
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Whether devices approved through this method do in fact pose a safety hazard to the public is a
question which cannot be answered without further study. However, it is apparent that the broad
interpretation of regulatory descriptions combined with the discretionary manner in which
special controls to mitigate safety issues are applied, leaves room for unsafe devices to
potentially slip through the cracks and into the market.

7.1.2 MEASURING PREDICATE CREEP
The major contribution of this research to the discussion surrounding the 510(k) Approval
Process for medical devices is the development of two novel methods for identifying predicate
creep: through the use of product classification codes and by identifying instances of multiple
predicates. While many scholars have identified predicate creep as a potential problem within the
510(k) Approval Process, existing literature on the topic is primarily limited to theoretical
discussion. In the few instances where attempts were made to prove the existence of predicate
creep, the methodology used was limited to identification of technological characteristics and
scientific evidence present in each individual predicate within the approval history (Ardaugh et
al., 2013; Zuckerman et al., 2014).

While identifying specific technological characteristics is an effective method for identifying
instances of technology creep, especially for characterizing the nature and extent of the creep to
determine potential impacts, it has many limitations including time, access to data, and
knowledge to interpret data into meaningful results. In particular, this method requires not only
identification of predicates, itself a time consuming process often limited by data availability, but
also identification and understanding of specific technical properties for each predicate. The
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amount of technical data available in FDA databases is extremely limited and often purposefully
vague, most likely to protect proprietary rights, which means that technical details must be
gleaned from other sources such as patent applications or manufacturer publications. However
these publications are not always readily available for devices, such as in the case of the Da
Vinci Model IS1000, and when they are available specialized technical knowledge is often
required to interpret the information provided. As a result, although this method is effective for
identifying predicate creep in specific instances where a particular technical characteristic is
under investigation, it is unnecessarily complicated for identifying general instances of predicate
creep.

Using information readily available in FDA databases, this research developed two methods to
identify instances of predicate creep without requiring additional device information. Like the
method described above, each new method begins by tracing the predicate history of the subject
device. The first method then looks at the developed ancestry tree and identifies instances where
a device has multiple predicates, particularly 3 or more, as predicate creep. This is because to be
substantially equivalent, the subject device must share the same intended use and, most likely,
some technological characteristics as each predicate device. In most of these cases, the subject
device takes specific characteristics from each predicate device and combines them together into
a unique device. This means that the device is not identical to any of the predicate devices, which
is predicate creep. The only way predicate creep would not occur in this instance is if all of the
predicates are essentially identical to each other, which is highly improbable due to intellectual
property laws, especially in the case of more than two devices. Therefore, there must be some
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degree of technological difference between and the subject device and at least one of its
predicates, which is predicate creep.

The second method looks at product classification codes, a regulatory mechanism developed by
the FDA to classify medical devices based on device characteristics. Specifically, a product code
is supposed to identify a group of devices with the same intended use and similar technological
characteristics that can serve as predicates for other similar devices. Since possessing the same
intended use is a requirement for a substantial equivalence finding, it can be assumed that all
devices within the predicate history of a given subject device have essentially the same intended
use. Therefore, any time a device with a different product code than the subject is identified as a
predicate, it must indicate the introduction of new technological characteristics in the subject
which necessitated the new product code, and therefore indicates predicate creep. Although
instances of predicates with different intended uses were identified within this research, which is
a violation of the principle of substantial equivalence, even these instances can be considered a
form of predicate creep, as a new use for a device was introduced without additional evidence to
support safety or efficacy of that use.
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7.2 LIMITATIONS
The depth of this study and significance of conclusions are limited by several factors. First, the
investigations performed in this study were based solely on data available publicly through FDA
databases. Predicate devices are identified within the database only when application summaries
are provided, which was not required for inclusion until the mid 2000’s. This significantly limits
the number of devices with traceable predicate histories, and thus the scope of this investigation.
Additionally, the information available through these databases is from general device
summaries which are written to protect intellectual property rights, including minimal details
about the specific technological characteristics of each device and the evidence provided to
support equivalence claims. Since this information is essential to identifying the level of
technology creep present using traditional comparison techniques, this thesis attempted to
develop alternative methods to identify predicate creep. However, without the information to
correlate findings to actual technological characteristics and the evidence used to support their
existence, it is difficult to evaluate the significance of findings. Further, the lack of insider
information regarding decision making of FDA officials during the review process creates a
knowledge gap, where a given equivalence determination may appear strange on paper, but
regulators may have had good reasons for making that determination.

Another limiting factor for this study was time, as the process for identifying predicate devices is
rather arduous due to the current structure of the database. Application summaries, including
information such as identification of predicates and intended device use upon which substantial
equivalence determinations are based, are attached to device summary page in PDF documents.
This information is not identified anywhere else within the searchable text of the database, and
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these documents lack a standard format and may be typed, scanned, or hand written. This lack of
standardized formatting makes a computer-automated search of summary information nearly
impossible. As a result, tracing the predicate history of each device required manual construction
of a database before any analysis could be performed. This is time consuming and significantly
more prone to human error, requiring additional effort and making the overall process extremely
time consuming.

Another limiting factor which may impact the significance of conclusions is the choice to limit
the scope of this research to robotic surgical devices. Conclusions drawn from this research
about patterns present in the larger regulatory picture may be biased by practices specific to the
regulation of robotic surgical devices. In particular, the technical complexity of robotic surgical
devices may lead to a higher number of predicate devices than would be present in less-complex
devices. The high number of predicates per generation in this investigation was determined to be
partially responsible for the high rate of predicate creep, so other types of devices may not have
such significant predicate creep.
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7.3 IMPLICATIONS OF FINDINGS

7.3.1 IMPLICATIONS FOR FUTURE RESEARCH
7.3.1.1 Non-public Data
Since the information available in the database is incomplete, particularly with respect to devices
approved prior to 1994, I was unable to trace many of the predicate origins to the originating preamendment or Class III device. Further information about substantial equivalence applications of
earlier devices could be obtained with the use of Freedom of Information Act (FOIA) requests.

Another limitation related to the availability of data is the lack of inside information about the
process of substantial equivalence determinations. While the general process is outlined by
regulatory guidelines, many of the decisions used to implement these regulations are made at the
discretion of regulators. Conducting interviews with regulatory officials would provide
additional perspectives not available through examination of predicate data, and may provide
explanations for some of the common regulatory patterns identified by this investigation.

7.3.1.2 Expansion to Other Device Types
The choice to limit this investigation to robotic surgical devices allowed for an in-depth
exploration of the predicate history and technological development of a particular device type.
This investigation proved the presence of technological creep in predicate histories and made
observations about common regulatory patterns and practices, which were then generalized to
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the overall regulatory process. However, the choice to focus this investigation on robotic surgical
systems, a device type known for its technical complexity, may have biased the resulting
conclusions drawn. Exploring the predicate history of additional device types with primary
functions unrelated to the devices observed for this investigation would allow for comparison of
regulatory patterns across device types and validate the conclusions of this investigation.

Long-term, the creation of a map of the full 510(k) database could provide useful information to
regulators and applicants about devices eligible to serve as predicates. A complete map would
reveal common patterns in predicate relationships which could be used as a basis for identifying
viable predicates for new technologies. For example, the Da Vinci trace revealed a strong
equivalence connection between endoscope controllers and robotic surgical systems. The map
might also be used for market research by companies, to identify areas of the medical device
market which are developing or have space for development, or areas which are oversaturated.

Another potential use of this map would include the identification of devices predicated on
recalled devices or devices with known regulatory problems, such as those identified by
Zuckerman et al. (2014). The FDA currently does not have a mechanism for identifying these
devices, which results in the devices remaining on the market and continuing to serve as
predicates for future devices without additional scrutiny to determine whether safety concerns
exist.
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7.3.1.3 Balancing FDA Approval with Patent Requirements
While the 510(k) Process purports to identify predicate devices based on substantial equivalence
in both functionality and technology, the patent process in the US requires proof that an idea is
new and novel to secure a patent. For medical devices, the requirements of substantial
equivalence and novelty appear to be in direct conflict. If a device is substantially equivalent,
how can it then be novel enough to be granted a patent?

In the US, the most comprehensive database to track and identify new technologies is part of the
patent system, which provides legal protection of innovative technologies in return for public
disclosure. In the medical community it is common practice to apply for patent rights and FDA
approval concurrently to ensure a first-to-market advantage. Examination of the patent literature
for devices which appear in the ancestral equivalence tree constructed from the regulatory
history might allow for identification of new technological characteristics introduced in each
device. Theoretically, larger technological “leaps” present in substantial equivalence trees
should correspond to a stronger patent presence for a given device.

For substantial equivalence, applicants are required to provide evidence that the technological
characteristics of the device are similar to existing devices. Conversely, when applying for a
patent companies are required to prove that new technological characteristics do not correspond
to an existing device by referencing all existing devices upon which particular characteristics are
based and defining how the new device is different. Considering the apparent conflict between
the requirements of substantial equivalence and patent rights, it is also likely that some
correlation exists between device relations in the patent and 510(k) databases.
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7.3.2 IMPLICATIONS FOR POLICY
Looking at the regulatory process from an outside perspective, it is clear that predicate creep
exists inherent within the substantial equivalence process. When this technology creep occurs on
a small scale, introducing a new technology feature or application which slightly alters the form
or function of the device while preserving the overall function and technological characteristics
of the predicate, there is little potential impact to the safety of the public. In fact, purposeful
inclusion of small amounts of technology creep is necessary to allow for innovation and
improvement in medical device design. However, the effects of predicate creep over time have
allowed for the development and approval of entirely new devices without undergoing the
stricter PMA approval process. Because this snowballing effect is directly dependent on smallscale predicate creep, it is difficult to address the problem without negatively impacting the
ability of manufacturers to bring innovative devices to market. Therefore, rather than trying to
prevent the snowballing effect in its entirety, my recommendation is for the FDA to develop a
comprehensive, easily accessible database of predicate relationships which can be used to
identify break points, where a new device is significantly different from the closest predicate
with scientific evidence of safety. At these break points the FDA can then require additional
scientific evidence of the overall device function, such as a small clinical trial, to ensure that no
safety flaws have been introduced in the device due to predicate creep. This would allow for the
continued use of small-scale predicate creep for technical innovation, while mitigating the
introduction of untested technical characteristics and potential safety flaws over time.

However, the largest problem identified through this research is not the presence of predicate
creep over time, but rather the sudden introduction of devices with high levels of technical
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complexity into the market through the 510(k) Process. While a combination of various flawed
elements within the approval process make this possible, it appears based on the evidence
presented here that one way companies take advantage of the substantial equivalence process is
by creating “step” devices, which are approved for the specific purpose of serving as a predicate
for technical characteristics, rather than as a marketable medical device. These “step” devices
serve as intermediate predicates to allow more innovative devices with larger technological
“leaps” into the market. Although devices with larger technological leaps are not necessarily
unsafe or ineffective, for example the Da Vinci has remained on the market for over 15 years
without a major recall, they do inherently possess more potential risk due to the fast-paced
introduction of less-understood technologies into the marketplace.

Although the FDA makes efforts to mitigate this risk through existing regulatory mechanisms,
the lack of clearly defined substantial equivalence requirements makes it difficult to determine
whether measures taken for a particular device are sufficient. For example, in their analysis
Ardaugh et. al (2013) found that insufficient measures were taken during the approval process
for the DuPuy ASR XL, which ultimately resulted in approval of a device with serious safety
concerns without any significant new scientific or clinical evidence provided to support safety
claims. The FDA possesses tools to mitigate this risk, including the ability to require clinical
trials or additional scientific evidence for approval, but there are no clear guidelines to determine
when this extra evidence might be required. Like the substantial equivalence determinations
themselves, requirements for evidence are currently left to the discretion of FDA officials. This
results in inconsistent regulatory requirements and creating cracks in the regulatory process
through which potentially unsafe devices, such as the ASR XL, might slip.
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In the future, the FDA should make efforts to identify the “leap” devices and create a more
targeted approval process that addresses new questions raised by these technologies, perhaps
through a hybridized version of the 510(k) and PMA processes that allows for substantial
equivalence evidence while still requiring a level of clinical assurance. Defining clear guidelines
for the amount scientific evidence required based on the significance of new technological
characteristics for device approval would help reduce this inherent systematic risk.

Through the data and subsequent findings gathered in this research, I have identified three
categories of medical devices within Class II based on the technological characteristics and
intended application of the device which can be used to develop guidelines for evidentiary
requirements to support substantial equivalence claims as follows:

1. If the new device is identical to an existing device but being used for a new application,
or introduces a minor technological change, such as replacing one type of motor with
another or using a new material, bench testing adhering to existing standards is sufficient
for defining substantial equivalence.
2. If a device introduces a new technological component which does not exist in a
previously approved device, such as a new software system, or utilizes a novel
combination of technological characteristics from multiple previously approved devices,
additional testing to verify the safety of the novel technological characteristics should be
required.
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3. If a device introduces multiple new technological components at once or possesses a
novel use scenario, such as the Da Vinci System allowing a surgeon to remotely perform
surgical procedures rather than requiring the surgeon to make contact with the patient,
clinical trials should be required to ensure patient safety and identify possible failure
modes within the design.

These guidelines are not intended to create any additional burden for regulators or
manufacturers, and the testing requirements identified are all currently utilized at the discretion
of the CDRH. Rather these guidelines are intended to standardize testing requirements across
510(k) approval applications and close some of the gaps which have allowed the approval of
“leap” devices.

The FDA has recently begun taking steps to address the presence of extreme technology creep,
so-called “leap” devices, in the regulatory process by creating more stringent guidelines for
identification of predicate devices. These new guidelines reject the use of split predicates, where
a device identifies one predicate for intended use and a separate predicate for technological
characteristics. Although rarely utilized, this form of predicate identification is especially
dangerous, as without additional scientific evidence it provides no assurance that a technology is
safe for a particular use scenario. However, most “leap” devices identified in this research were
not approved using split predicates, but rather multiple predicates comprised of “step” devices
specifically designed to advance the desired use case for a particular technology. Although the
FDA discourages the use of multiple predicates when possible, it is still considered a viable
approval mechanism IF the intended use of the predicates and subject device are the same. Based
125

on the high number of multiple predicate relationships identified in the approval history of the
Intuitive Da Vinci and other devices analyzed in this research, I would recommend that the FDA
take steps to create specific guidelines limiting the number of predicates which can be identified
in a single predicate generation.

7.4 CONCLUDING THOUGHTS
Given the number of new medical devices entering the market each year, and the increasing
technical complexity of those devices, it is unsurprising that new regulatory challenges have also
emerged. However, many scholars and experts agree that the regulatory challenges which have
emerged from major device failures in recent years are not due solely to the introduction of new
technologies, but rather are symptomatic of inherent flaws in the foundation of the regulatory
process. In particular, researchers point to the use of substantial equivalence for determining
device safety and efficacy in the 510(k) Approval Process as a mechanism by which many flaws,
such as predicate creep and lack of scientific evidence, are introduced into the regulatory
process.

This research focused specifically on examining the 510(k) Approval Process as it was applied to
various Robotic Assisted Surgical systems, an emerging technology with a high degree of
technical complexity, with specific focus on the Intuitive Da Vinci Surgical System. The
objective of this research was to examine the predicate history of these devices in order to
explore the level of information publicly available about the approval process, assess whether
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significant predicate creep or other issues occurred within the regulatory process, and identify
resulting implications for policy.

The primary method used to address these objectives was the development of multiple predicate
ancestry trees using information available through FDA databases. Although the amount of
available data is significantly limited due to database restrictions, particularly the lack of
approval summaries for older devices, the predicate traces developed contained enough
information to draw conclusions about the approval process. Through analysis of these traces,
including the use of additional regulatory information such as product classification codes, I was
able to conclude that there is indeed predicate creep present within the 510(k) Approval Process.
In fact, upon examination of the relationship between the 510(k) Process and technological
innovation in medical devices, I found that small amounts of technology creep must exist in
predicate relationships for new medical devices to possess any level of innovation or value to the
market. This small-scale predicate creep between one device and the next has minimal impact on
the safety of new medical devices, if the guidelines laid out in the approval process are followed
and adequate precautions are taken to ensure that new device characteristics are safe.
This research has found, however, that although small-scale predicate creep has a place in the
approval process, inadequate measures have been taken to address the impact of large-scale
predicate creep and other regulatory issues, such as multiple predicates, which have allowed for
approval of entirely new devices via the 510(k) Process. Large-scale predicate creep occurs over
time, as repeated small-scale innovations slowly change a device until it no longer resembles the
original predicate. Although this process technically violates the intention of the 510(k) Process
by ultimately approving new devices with minimal scientific evidence, there is some assurance
127

of device safety provided by the market success of existing predicates. If all the preceding
predicate devices are safe, and precautions are taken to mitigate small-scale predicate creep, in
many cases devices exhibiting large-scale predicate creep may still be safe. The potential
problems with large scale predicate-creep arise when the lack of scientific evidence is combined
with unsafe predicates or other regulatory issues.

Although predicate creep was identified by other researchers as one of the primary concerns with
the regulatory process, this research found that the most pressing concern with the 510(k)
Process is the presence of “leap” devices. While large-scale predicate creep occurs through a
series of steps over a long period of time, allowing for some risk mitigation at each step, a “leap”
device is one in which there is a sudden increase or change in the technological complexity and
characteristics of a device. Combinations of vague regulatory definitions, broad device
descriptions, and use of multiple predicates under the current regulatory process have allowed
the approval of these “leap” devices, which display high levels of technology creep in a short
period of time. The regulatory process as it currently exists is unable to consistently ensure the
safety of such devices, as the powers to require additional evidentiary support are applied at the
discretion of FDA officials, and few guidelines exist for when they should be applied. Therefore,
my recommendation is to implement a modified version of the 510(k) Process, which provides
definitive guidelines for the level of scientific evidence required to support safety and effectivity
claims based on the degree of new technological characteristics or functions in a device.
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APPENDIX 1: PRODUCT CODE NAY DATABASE
K Number

Decision Date

Device Name

Company

Application Type

Determination

K965001

Intuitive Surgical Monarch Laparoscopic
7/31/97 Manipulator

Intuitive Surgical

Traditional

SE

K990144

1/15/99 Endoscopic Instrument and Accessories

Intuitive Surgical

Traditional

SE

Intuitive Surgical

Traditional

SE

K002489

3/2/01 DaVinci Endoscopic Control System

K011002

5/30/01 DaVinci Surgical System Model ISI 1000

Intuitive Surgical

Traditional

SE

K011281

7/24/01 Intuitive Surgical Ultrasonic Shears

Intuitive Surgical

Traditional

SE

Intuitive Surgical

Traditional

SE

Intuitive Surgical

Traditional

SE

Computer Motion

Traditional

SE

Traditional

SE

Computer Motion

Traditional

SE

K012833
K021036

11/16/01 Intuitive Surgical Bipolar Forceps
Intuitive DaVinci Surgical System Model
6/26/02 IS1200

K021152

ZEUS Microwrist Surgical System and
09/24/02 Accessories

K022574

Intuitive Surgical da Vinci Endoscopic
Instrument Control System and Endoscopic
11/12/02 Instruments or da Vinci Surgical System
Intuitive Surgical

K030578

Bipolar Grasper and Bipolar Scissors for
6/24/03 the ZUES Microwrist Surgical System

K040948

5/5/04

Intuitive Surgical

Special

SE

K040237

7/7/04

Intuitive Surgical

Traditional

SE

K042855

11/12/04

Intuitive Surgical

Special

SE

K043153

12/15/04

Intuitive Surgical

Special

SE

K050005

1/25/05

Intuitive Surgical

Special

SE

K043288

3/3/05

Intuitive Surgical

Traditional

SE

K050369

4/29/05

Intuitive Surgical

Traditional

SE

K050802

6/29/05

Intuitive Surgical

Traditional

SE

K060391

4/10/06

Intuitive Surgical

Special

SE

K061260

5/18/06

Intuitive Surgical

Special

SE

K063220

12/1/06

Intuitive Surgical

Traditional

SE

K072627

2/7/08

Intuitive Surgical

Traditional

SE

K070947

2/14/08

Intuitive Surgical

Traditional

SE

K080291

3/19/08

Intuitive Surgical

Traditional

SE

K081207

12/19/08

Intuitive Surgical

Traditional

SE

K081137

2/18/09

Intuitive Surgical

Traditional

SE
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K Number

Decision Date

Device Name Company

Application Type

Determination

K082497

5/7/09

Intuitive Surgical

Traditional

SE

K090993

12/16/09

Intuitive Surgical

Traditional

SE

K093217

1/21/10

Intuitive Surgical

Traditional

SE

K101743

2/4/11

Intuitive Surgical

Traditional

SE

K101581

4/8/11

Intuitive Surgical

Traditional

SE

K110451

8/26/11

Intuitive Surgical

Traditional

SE

K112584

9/29/11

Intuitive Surgical

Special

SE

K112263

10/7/11

Intuitive Surgical

Special

SE

K112208

Intuitive Surgical DaVinci Single-site
12/8/11 Instruments and Accessories

Intuitive Surgical

Traditional

SE w/ limits

Intuitive Surgical

Traditional

SE

Intuitive Surgical

Special

SE w/ limits

K110639
K120215

12/28/11
Intuitive Surgical da Vinci Single-Site
4/30/12 Instruments and Accessories

K113706

10/17/12

Intuitive Surgical

Traditional

SE

K121921

10/25/12

Intuitive Surgical

Traditional

SE

K123463

12/3/12

Intuitive Surgical

Special

SE

K123840

2/14/13

Intuitive Surgical

Special

SE

K122532

Intuitive Surgical da Vinci Single-Site
2/21/13 Instruments and Accessories

Intuitive Surgical

Traditional

SE w/ limits

Intuitive Surgical

Special

SE w/ limits

K130726

Da Vinci Single-Site Permanent Cautery
6/7/13 Hook

K130266

8/29/13

Intuitive Surgical

Traditional

SE

K131861

3/28/14

Intuitive Surgical

Traditional

SE

K131861

3/28/14

Intuitive Surgical

Traditional

SE

K131962

Da Vinci Sp Surgical System, Model 5P999,
Endo Wrist Sp Instruments, and
4/17/14 Accessories
Intuitive Surgical

Traditional

SE w/ limits

K140189

6/5/14

Intuitive Surgical

Traditional

SE

K140553

7/25/14

Intuitive Surgical

Traditional

SE

K141077

8/12/14

Intuitive Surgical

Traditional

SE

K123329

Intuitive Surgical da Vinci, da Vinci S and
da Vinci Si Surgical Systems and EndoWrist
9/17/14 Instruments and Accessories
Intuitive Surgical

Traditional

SE w/ limits

K141075

9/26/14 Single-Site Wristed Needle Driver

Intuitive Surgical

Traditional

SE w/ limits

K143217

12/3/14

Intuitive Surgical

Special

SE

K142683

12/10/14

Intuitive Surgical

Traditional

SE
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K Number

Decision Date

Device Name Company

Application Type

Determination

K150837

3/30/15

Intuitive Surgical

Special

SE

K143132

4/2/15

Intuitive Surgical

Traditional

SE

K150284

5/15/15

Intuitive Surgical

Special

SE

K151794

1/15/16

Intuitive Surgical

Traditional

SE

K152421

3/4/16

Intuitive Surgical

Traditional

SE

K152448

3/9/16

Intuitive Surgical

Traditional

SE

K152578

3/30/16

Intuitive Surgical

Traditional

SE

K152892

4/29/16

Intuitive Surgical

Traditional

SE

K161271

7/11/16

Intuitive Surgical

Special

SE

K153276

8/7/16

Intuitive Surgical

Traditional

SE

K162411

9/21/16

Intuitive Surgical

Special

SE

K161178

1/19/17

Intuitive Surgical

Traditional

SE

K162973

2/6/17

Intuitive Surgical

Traditional

SE

K170508

3/10/17

Intuitive Surgical

Traditional

SE

K170865

4/21/17

Intuitive Surgical

Traditional

SE

K171294

5/26/17

Intuitive Surgical

Special

SE

K171388

5/31/17

Intuitive Surgical

Special

SE

K170713

6/13/17

Intuitive Surgical

Traditional

SE

K171426

6/13/17

Intuitive Surgical

Special

SE

K171699

7/28/17

Intuitive Surgical

Traditional

SE

K170644

9/11/17

Intuitive Surgical

Traditional

SE

K170645

9/11/17

Intuitive Surgical

Traditional

SE

K170875

9/12/17

Intuitive Surgical

Traditional

SE

K171632

9/19/17

Intuitive Surgical

Traditional

SE

K170641

9/21/17

Intuitive Surgical

Traditional

SE

K170879

9/21/17

Intuitive Surgical

Traditional

SE
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APPENDIX 2: DA VINCI SI PREDICATES
K Number

Device Name

Manufacturer

K081137

Intuitive Surgical Da Vinci Si Surgical System: Model Is3000 INTUITIVE SURGICAL, INC.

2/18/2009

NAY

24 – Class II

K063220

Da Vinci S Surgical System-V1.1, Model Is2000

INTUITIVE SURGICAL, INC

12/1/2006

NAY

4 – Class II

K050802

Modification To Intuitive Surgical Da Vinci Surgical System
And Endoscopic Instruments

INTUITIVE SURGICAL, INC.

6/29/2005

NAY

0

K050369

Intuitive Surgical Da Vinci Surgical System, Model Is2000

INTUITIVE SURGICAL, INC.

4/29/2005

NAY

43 – Class II

K050404

Intuitive Surgical Da Vinci Surgical System And Endoscopic
Instruments

INTUITIVE SURGICAL, INC.

4/21/2005

HET

0

K043288

Modification To Intuitive Surgical Da Vinci Surgical System
And Endoscopic Instruments

INTUITIVE SURGICAL, INC

3/3/2005

NAY

0

K050005

Intuitive Surgical Monopolar Curved Scissors, Model
400179; Tip Cover Accessory, Model 400180

INTUITIVE SURGICAL, INC.

1/25/2005

NAY

2 – Class II

K043153

Intuitive Surgical Da Vinci Surgical System And Endoscopic
Instruments, Models Is1200 & Is1000

INTUITIVE SURGICAL, INC.

12/15/2004

NAY

0

K042855

Intuitive Surgical Harmonic Curved Shears Instrument

INTUITIVE SURGICAL, INC.

11/12/2004

NAY

0

K041340

Guidant Microwave Ablation System

GUIDANT CORPORATION,
CARDIAC SURGERY

7/28/2004

NEY
OCL

0

K040237

Intuitive Surgical Da Vinci Endoscopic Instrument Control
System And Endoscopic Instruments

INTUITIVE SURGICAL, INC.

7/7/2004

NAY

0

K040948

Intuitive Surgical Endopass Endoscopic Delivery
Instrument, Model P/N 400170

INTUITIVE SURGICAL, INC.

5/5/2004

NAY

0

K022574

Intuitive Surgical Endoscopic Instrument Control System &
Endoscopic Instruments, Model Da Vinci ISI 1000/1200

INTUITIVE SURGICAL, INC.

11/12/2002

NAY

0

K021036

Intuitive Surgical Da Vinci Surgical System, Model IS1200

INTUITIVE SURGICAL, INC.

6/26/2002

NAY

18 – Class II

K013946

Flex 10 Accessory For The Afx Microwave Ablation System

AFX, INC.

2/27/2002

NEY
OCL

0

K013416

Intuitive Surgical Endowrist Endoscopic Instrument Family

INTUITIVE SURGICAL, INC.

1/10/2002

GEI

0

K012833

Intuitive Surgical Bipolar Forceps

INTUITIVE SURGICAL, INC

11/16/2001

NAY

4 – Class II

K011281

Intuitive Surgical Ultrasonic Shears

INTUITIVE SURGICAL, INC.

7/24/2001

NAY
LFL

0

K011002

Intuitive Surgical Da Vinci Surgical System, Model Isi 1000

INTUITIVE SURGICAL, INC.

5/30/2001

NAY

0

K003978

Afx Microwave Generator, Flex Ablation Wand, Lynx
Ablation Wand, Model Series 1000, P/N 102006, P/N
102007

AFX, INC.

5/22/2001

NEY
OCL

0

K002489

Intuitive Surgical Da Vinci Endoscopic Control System

INTUITIVE SURGICAL, INC.

3/2/2001

NAY

0

K990144

Intuitive Surgical Endoscopic Instruments, Intuitive Surgical
INTUITIVE SURGICAL, INC.
Endoscopic Instrument Control System

7/11/2000

NAY

3 – Class II

K993054

Ultracision Harmonic Scalpel Coagulating Shears, Models
Lcs-C5, Lcs-C1, Cs-23c, Cs-231, Cs-14c, Cs-141

12/9/1999

LFL

0

ETHICON ENDO-SURGERY,
INC.

Approval Date Product Code Recalls
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K Number

Device Name

Manufacturer

Approval Date Product Code Recalls

K991859

Dexide Bipolar Forceps Ii ** Device

UNITED STATES SURGICAL, A
DIVISION OF TYCO HEALTHC

6/23/1999

GEI

0

K980099

Ultracision Laparosonic Coagulating Shears (Lcs-5(Lcsk5
And Lcsb5))

ETHICON ENDO-SURGERY,
INC.

4/9/1998

LFL

0

K974320

Cryogen Cardiac Cryosurgical System

CRYOGEN, INC.

2/3/1998

OCL

0

K972662

Cryogen Cryosurgical System

CRYOGEN, INC.

10/1/1997

GEH

0

K972415

Minisite*Bipolar Forceps** Device

UNITED STATES SURGICAL, A
DIVISION OF TYCO HEALTHC

9/19/1997

GEI

0

K965001

Intuitive Surgical Monarch Laparoscopic Manipulator

INTUITIVE SURGICAL, INC.

7/31/1997

GCJ

0

K971861

Ultrasonic Hand Instruments

UNITED STATES SURGICAL, A
DIVISION OF TYCO HEALTHC

7/1/1997

LFL

0

K970496

Heartport Maze System: Cryoprobe Set

HEARTPORT, INC.

5/9/1997

OCL

0

K964971

Cryogen Cryosurgical System

CRYOGEN, INC.

3/28/1997

GEH

0

K960400

Diamond-Touch And Micro Diamond-Touch
Instruments/Diamond-Line Instruments/Diamond-Port
(Access Parts)

SNOWDEN-PENCER

3/12/1996

FBM
GCJ
GEI

0

K953637

CMS Accuprobe 550/530

CRYOMEDICAL SCIENCES, INC. 12/4/1995

GEH

0

K953059

Kittner Dissector

MEDICAL PERSPECTIVES
CORP.

9/14/1995

GDY

0

K930666

Reusable Laparoscopic Instruments W/ Electrocautery

SNOWDEN-PENCER

5/19/1994

GEI

0

K930667

Reusable Laparoscopic Instruments

SNOWDEN-PENCER

5/16/1994

GCJ

0

K933169

Inman Endoscopic Blunt Dissector

INMAN MEDICAL CORP.

4/19/1994

GCJ

0

K936308

Endex Endoscopic Positioning System

ANDRONIC DEVICES, LTD.

3/31/1994

FQO

0

K931783

AESOP (Automated Endoscopic System For Optimal
Positioning)

COMPUTER MOTION, INC

11/22/1993

GCJ

0

K931340

Grasp Forceps/Scissors/Needle Holder/Dissector

BAXTER HEALTHCARE CORP.

7/1/1993

GCS

0

K925699

Harmonic Scalpel Laparosonic Clamp Coagulator Acc.

ULTRACISION, INC.

5/17/1993

GCJ

0

K914190

Auto Suture(R) Endoscopic Fan Retractor

UNITED STATES SURGICAL, A
DIVISION OF TYCO HEALTHC

5/6/1992

GAD

0

K912544

Bipolar Forceps

EVEREST MEDICAL CORP.

6/24/1991

MAV

0

K904421

CMS Oncoprobe

CRYOMEDICAL SCIENCES, INC. 4/8/1991

GEH

0

K882568

130 Cryo Unit & Assoc. Cryoprobes & Spray

SPEMBLY MEDICAL LTD.

9/27/1988

GEH

0

K874367

Various Cardiac Cryoprobes Having Dia. & Cos. Diff

SPEMBLY MEDICAL LTD.

1/4/1988

HQO

0

K811390

Ccs100 Cryosurgical System

FRIGITRONICS OF
CONNECTICUT, INC.

6/16/1981

GEH

0
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APPENDIX 3: PRODUCT CODE DEFINITIONS
Product
Code

Device

Regulation Description

FBM

Cannula And Trocar, Suprapubic, Non-Disposable

Suprapubic urological catheter and accessories

NEY

System, Ablation, Microwave And Accessories

Electrosurgical cutting and coagulation device and
accessories

NAY

System, Surgical, Computer Controlled Instrument

Endoscope and accessories

HET

Laparoscope, Gynecologic (And Accessories)

Gynecologic laparoscope and accessories

GEI

Electrosurgical, Cutting & Coagulation & Accessories

Electrosurgical cutting and coagulation device and
accessories

LFL

Instrument, Ultrasonic Surgical

OCL

Surgical Device, For Cutting, Coagulation, And/Or Ablation Of Tissue,
Including Cardiac Tissue

Electrosurgical cutting and coagulation device and
accessories

GEH

Unit, Cryosurgical, Accessories

Cryosurgical unit and accessories

GCJ

Laparoscope, General & Plastic Surgery

Endoscope and accessories

GDY

Gauze/Sponge, Internal, X-Ray Detectable

Nonabsorbable gauze for internal use

GCS

Endoscope, Battery-Powered And Accessories

Endoscope and accessories

MAV

Syringe, Balloon Inflation

Angiographic injector and syringe

HQO

Unit, Cautery, Thermal, Ac-Powered

Thermal cautery unit

FAJ

Cystoscope And Accessories, Flexible/Rigid

Endoscope and accessories

OWB

Interventional Fluoroscopic X-Ray System

Image-intensified fluoroscopic x-ray system

EOQ

Bronchoscope (Flexible Or Rigid)

Bronchoscope (flexible or rigid) and accessories

DRF

Catheter, Electrode Recording, Or Probe, Electrode Recording

Electrode recording catheter or electrode recording
probe

EOB

Nasopharyngoscope (Flexible Or Rigid)

Nasopharyngoscope (flexible or rigid) and
accessories

NWB

Endoscope, Accessories, Narrow Band Spectrum

Endoscope and accessories

FAM

Sigmoidoscope And Accessories, Flexible/Rigid

Endoscope and accessories

FDF

Colonoscope And Accessories, Flexible/Rigid

Endoscope and accessories

HRX

Arthroscope

Arthroscope

FET

Endoscopic Video Imaging System/Component, Gastroenterology-Urology Endoscope and accessories

FER

Anoscope And Accessories

Endoscope and accessories

FED

Endoscopic Access Overtube, Gastroenterology-Urology

Endoscope and accessories

GCF

Proctoscope

Endoscope and accessories

FCG

Biopsy Needle

Gastroenterology-urology biopsy instrument
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Product
Code

Device

Regulation Description

DXX

System, Catheter Control, Steerable

Steerable catheter control system

DYB

Introducer, Catheter

Catheter introducer

LZA

Polymer Patient Examination Glove

Non-powdered patient examination glove

FDS

Gastroscope And Accessories, Flexible/Rigid

Endoscope and accessories

GWG

Endoscope, Neurological

Neurological endoscope

ERL

Drill, Surgical, Ent (Electric Or Pneumatic) Including Handpiece

Ear, nose, and throat electric or pneumatic surgical
drill

OXO

Image-Intensified Fluoroscopic X-Ray System, Mobile

Image-intensified fluoroscopic x-ray system

FDT

Duodenoscope And Accessories, Flexible/Rigid

Endoscope and accessories

MDA

Elastomer, Silicone, For Scar Management

Silicone sheeting

DZP

Instrument, Diamond, Dental

Dental diamond instrument

FJL

Resectoscope

Endoscope and accessories

FBN

Choledochoscope And Accessories, Flexible/Rigid

Endoscope and accessories

HTZ

Instrument, Cutting, Orthopedic

Manual surgical instrument for general use

CAL

Laryngoscope, Non-Rigid

Flexible laryngoscope

FBO

Cystourethroscope

Endoscope and accessories

HSZ

Instrument, Surgical, Orthopedic, Pneumatic Powered &
Accessory/Attachment

Surgical instrument motors and
accessories/attachments

KIJ

Instrument, Surgical, Orthopedic, Dc-Powered Motor And
Accessory/Attachment

Surgical instrument motors and
accessories/attachments

ODB

Endoscopic Contamination Prevention Sheath

Endoscope and accessories

JAB

System, X-Ray, Fluoroscopic, Non-Image-Intensified

Non-image-intensified fluoroscopic x-ray system

JAA

System, X-Ray, Fluoroscopic, Image-Intensified

Image-intensified fluoroscopic x-ray system

HWE

Instrument, Surgical, Orthopedic, Ac-Powered Motor And
Accessory/Attachment

Surgical instrument motors and
accessories/attachments

GCT

Light Source, Endoscope, Xenon Arc

Endoscope and accessories

FGA

Kit, Nephroscope

Endoscope and accessories

FAL

Panendoscope (Urethroscope)

Endoscope and accessories

EOX

Esophagoscope (Flexible Or Rigid)

Esophagoscope (flexible or rigid) and accessories

DRA

Catheter, Steerable

Steerable catheter

MQB

Solid State X-Ray Imager (Flat Panel/Digital Imager)

Stationary x-ray system

KGE

Forceps, Biopsy, Electric

Endoscopic electrosurgical unit and accessories

GCI

Laryngoscope, Endoscope

Endoscope and accessories

FGB

Ureteroscope And Accessories, Flexible/Rigid

Endoscope and accessories
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Code

Device

Regulation Description

KNS

Unit, Electrosurgical, Endoscopic (With Or Without Accessories)

Endoscopic electrosurgical unit and accessories

HAW

Neurological Stereotaxic Instrument

Stereotaxic instrument.

LLZ

System, Image Processing, Radiological

Picture archiving and communications system

OLO

Orthopedic Stereotaxic Instrument

Stereotaxic instrument.

GAW

Suture, Nonabsorbable, Synthetic, Polypropylene

Nonabsorbable polypropylene surgical suture

EPT

Microscope, Surgical

Surgical microscope and accessories

LNH

System, Nuclear Magnetic Resonance Imaging

Magnetic resonance diagnostic device

IZH

System, X-Ray, Mammographic

Mammographic x-ray system
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APPENDIX 4: ANALYSIS OF SYMBIS SURGICAL
SYSTEM PREDICATES

Figure 15: SYMBIS Surgical System (T., 2015)

The IMRIS (now Deerfield Imaging) SYMBIS Surgical System was designed as a spatial
positioning and orientation guide for instruments in needle based brain biopsies. The system is
comprised of three components, a manipulator arm located on a mobile base, a surgeon
workstation, and a robotic control rack containing electronic equipment. The trajectory of a
stereotactic instrument is guided by the surgeon from the workstation, which includes haptic
feedback and 3D imaging for position control, using a manipulator arm with six degrees of
freedom. The positioning mechanism of the device uses a robotic manipulator controlled from a
separate surgeon control station similar to the method used in the Da Vinci Surgical system.
However in the SYMBIS System the surgeon is required to manually perform portions of the
surgery, including final deployment of the biopsy needle (Pena, 2015). The design of the
SYMBIS Surgical System relies heavily on the incorporation of previously approved third-party
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technologies into the design for key functions, including specifying use of the Medtronic
StealthStation (K133444) for navigation and the Medtronic Biopsy Needle Kit (K971247) for
instrumentation (Pena, 2015).

The traceable predicate history of the SYMBIS Surgical System is comprised of 43 identified
predicate relationships which includes 26 unique devices that can be traced to 10 ultimate
predicate devices. The immediate predicate of the SYMBIS System is the ROSA Surgical
Device (see Table 6), a computer-controlled electromechanical arm intended to aid in the spatial
positioning and orientation of stereotaxic instruments (Eydelman, 2009). The intended use and
technological characteristics of the ROSA System are very similar to those described for the
SYMBIS System, with technological differences primarily associated with the incorporation of
third-party positioning systems in the SYMBIS System (Pena, 2015 ). An overview of the
predicate history for the SYMBIS Surgical System is shown in Figure 16 below.

Figure 16: SYMBIS Surgical System predicate trace (see section A4.1 for additional device information).
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Detailed approval information about the devices which appear in this predicate tree can be found
in the SYMBIS Trace database in Section A4.1.

Additional information about the devices included in the predicate ancestry, particularly
regarding predicate creep, can be gleaned from comparison of the product codes and regulatory
descriptions associated with each device. The product code is an identifier designated by the
FDA to group devices with the same intended use and similar technological characteristics. Each
product code is assigned a regulatory description which describes the function and intended use
based on the device type. The regulatory description is more general than the device description,
which means that two product codes with slightly different device descriptions may possess the
same regulatory description. For example, the SYMBIS was assigned product code HAW, which
describes a neurological stereotaxic instrument with the regulatory description of stereotaxic
instrument. The product code OLO describes orthopedic stereotaxic instruments, however it has
the same regulatory description as code HAW, stereotaxic instrument. A percentage breakdown
of the product codes and regulatory descriptions for the unique devices present in the SYMBIS
trace is shown in Figure 17 below.
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Figure 17: Breakdown of SYMBIS predicate devices by product code and regulatory description. Due to the nature
of the devices in this trace, the two breakdowns are identical.

Unlike the devices in the Da Vinci trace, and the other robotic surgical system traces described
below, the devices in the SYMBIS trace fall under only two product codes, HAW and LLZ.
Code HAW, as described previously, pertains to neurological stereotaxic instruments, while code
LLZ pertains to radiological imaging processing systems under the regulatory description
“picture archiving and communications system”. Because the two codes possess different
regulatory description, the product code and regulatory description breakdowns for the SYMBIS
System are identical. All but two devices contained in the trace fall under code HAW, making it
the dominant device type in this trace. The two devices classified under code LLZ both serve as
ultimate predicates along the branch originating from the Zimmer Knee Ortho Guidance
Instruments (K033011), which incorporates CT scan modeling for surgical instrument guidance.
Thus, these devices appear to be included in the trace to serve as predicates for the introduction
of technological characteristics related to the imaging incorporated in later guidance systems.
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A4.1

ADDITIONAL SYMBIS SYSTEM PREDICATE INFORMATION

K Number

Device Name

Manufacturer

Approval Date

Product Code Recalls

K143420

SYMBIS Surgical System

IMRIS, Inc.

10/30/2015

HAW

0

K101791

ROSA SURGICAL DEVICE

MEDTECH SAS

9/23/2010

HAW

12 – Class II

K092239

ROSA SURGICAL DEVICE, MODEL ROSA 1.1

MEDTECH S.A.

11/17/2009

HAW

9 – Class II

K060556

BRIGIT SURGICAL DEVICE

ZIMMER INC

7/31/2006

HAW

0

K052425

ZIMMER COMPUTER ASSISTED SOLUTIONSELECTROMAGNETIC AND IMAGELESS KNEE ZIMMER, INC.
INSTRUMENTATION

12/28/2005

HAW

0

K050438

STEALTHSTATION SYSTEM UPDATE

MEDTRONIC SURGICAL NAVIGATION
TECHNOLOGIES

6/2/2005

HAW

11 – Class II

K043536

NAVITRACK SYSTEM - S&N IMAGE FREE
KNEE

ORTHOSOFT, INC.

1/14/2005

HAW

0

K033223

ZIMMER ORTHO GUIDANCE SYSTEMS- HIP
INSTRUMENTS

ZIMMER, INC.

2/18/2004

HAW

0

K023651

VECTORVISION CRANIAL/ENT

BRAINLAB AG

2/17/2004

HAW

1 – Class II

K033011

ZIMMER ORTHO GUIDANCE SYSTEMS- KNEE
ZIMMER, INC.
INSTRUMENTS

2/12/2004

HAW

0

K022126

CATHETER INTRODUCER FOR THE
STEALTHSTATION SYSTEM

MEDTRONIC SURGICAL NAVIGATION
TECHNOLOGIES

1/3/2003

HAW

0

K021760

NAVITRACK SYSTEM-OPTICAL TKR CT-LESS,
MODEL 900.120

ORTHOSOFT, INC

8/27/2002

HAW

0

K003589

VECTORVISION CRANIAL, VECTORVISION
SPINAL, VECTORVISION ENT

BRAINLAB AG

5/21/2001

HAW

0

K003347

ORTHOPILOT

KINAMED, INC

2/23/2001

HAW

0

K002053

NAVITRAK SYSTEM-OPTICAL OPTION,
MODEL 900.004

ORTHOSOFT, INC.

8/3/2000

HAW

0

K001801

STEATHSTATION TREATMENT GUIDANCE
PLATFORM

MEDTRONIC SURGICAL NAVIGATION

6/30/2000

HAW

0

K991081

FRAMELESS NEUROMATE

INTEGRATED SURGICAL SYSTEMS, INC.

6/25/1999

HAW

0

K983831

VECTORVISION2

BRAINLAB, AG

5/19/1999

HAW

0

K964801

OPTICAL TRACKING SYSTEM (OTS)

RADIONICS SOFTWARE APPLICATIONS,
INC.

6/2/1997

HAW

0

K963256

NEUROMATE STEREOTACTIC SYSTEM

INTEGRATED SURGICAL SYSTEMS, S. A

5/9/1997

HAW

0

K961844

OPERATING ARM SYSTEM (OAS) [WITH CT
AND MR IMAGES]

RADIONICS SOFTWARE APPLICATIONS,
INC.

10/23/1996

HAW

0
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K Number

Device Name

Manufacturer

Approval Date

Product Code Recalls

K954276

STEALTHSTATION

SURGICAL NAVIGATION
TECHNOLOGIES, INC.

1/24/1996

HAW

1 – Class II

K951262

OPERATING ARM SYSTEM (OAS)

RADIONICS SOFTWARE APPLICATIONS,
INC.

11/13/1995

LLZ

0

K911783

ALLEGRO VIEWING WAND

I.S.G. TECHNOLOGIES, INC.

4/7/1994

LLZ

0

K871046

COMPASS STEREOTACTIC POSITIONING
SYSTEM

STEREOTACTIC MEDICAL SYSTEMS, INC

5/8/1987

HAW

0

K811452

BROWN-ROBERTS-WELLS STEREOTAXIC
SYTEM

TRENT WELLS, INC.

6/2/1981

HAW

0
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APPENDIX 5: ANALYSIS OF MAKO RIO-THA
SYSTEM PREDICATES

Figure 18: MAKO RIO-THA System

The MAKO (now Stryker Medical) Robotic Arm Interactive Surgical Operating System (RIO) is
designed to provide stereotactic guidance during minimally invasive knee (K081867) and hip
(K093425) procedures using patient CT scan data to assist a surgeon in pre-operative planning
and intraoperative navigation. The system consists of three components, a computer station for
inputting CT scan data and identifying markers, a viewing station, and the main RIO platform
mounted on a moveable cart (Stryker, 2018 ). The main platform consists of a multi-jointed arm
which uses sensors to provide real time visual, tactile, and auditory feedback as it is positioned
manually by the surgeon during a procedure (Adventist Health Sonora, n.d.). The RIO arm aids
in positioning and stabilization of tools to identify optimal locations for implant placement
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during procedures to improve results and reduce complications. While the primary purpose of the
Da Vinci system is to serve as a replacement for the surgeon’s hands to increase surgeon
dexterity and reduce error in traditional MIS procedures, the primary purpose of the RIO system
is to assist in optimal positioning of implants for a manually performed surgery.

The traceable predicate history of the MAKO RIO-THA includes 590 predicate relationships
between 53 unique devices, which can be traced to 21 ultimate predicate devices. The RIO
system identified as the subject device for this trace is the RIO-THA, used in total hip
arthroplasty procedures. Another version of the RIO System, used for applications in knee
surgery serves, as a predicate device for the RIO-THA. An overview of the RIO System trace
can be seen in Figure 19, with additional information about each device shown in the trace
located in Section A5.1.

Figure 19: MAKO RIO – THA predicate tree (see section A5.1 for additional device information).

Examination of the RIO trace reveals patterns in the approval application process, including
duplication of predicate devices between generations and within branches. This is evidenced by
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the fact that there are only 53 unique devices identified among 590 substantial equivalence
claims.

The 48 devices present in the RIO trace are grouped into 7 different product codes, with 42 of
the devices under code HAW for stereotaxic instruments. Of the remaining devices, 3 are under
code OLO, also for stereotaxic instruments, 4 are classified under code LLZ for radiological
image processing, and the remaining 4 devices each have a unique product code. Examination of
this breakdown, as seen in Figure 20, reveals that the RIO trace is dominated by stereotaxic
instruments, primarily designated for neurological applications. It is only the two versions of the
MAKO RIO and another associated product in the first predicate generation (closest to RIO)
which are designated for orthopedic use under Code OLO.

Figure 20: Breakdown of RIO-THA predicates by product code and regulatory description, The overall structures of
the breakdowns are similar, with a single classification (HAW and Stereotaxic Instrument) containing most
predicates. However, the largest regulatory description contains devices under product codes HAW and OLO,
making the resulting group slightly larger.
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A5.1

ADDITIONAL RIO-THA PREDICATE INFORMATION

K Number

Device Name

K093425

Manufacturer

Approval Date

Product Code

Recalls

MAKO SURGICAL CORP ROBOTIC ARM INTERACTIVE
MAKO SURGICAL CORP.
ORTHOPEDIC SYSTEM-THA

2/24/2010

OLO

1 – Class II

K091998

ROBOTIC ARM INTERACTIVE ORTHOPEDIC SYSTEMHIP

MAKO SURGICAL CORP.

9/28/2009

OLO

0

K083644

MAKO SURGICAL TACTILE GUIDANCE SYSTEM-HIP

MAKO SURGICAL CORP.

6/19/2009

OLO

0

K081867

MAKO SURGICAL TACTILE GUIDANCE SYSTEM
VERSION 2.0

MAKO SURGICAL CORP.

11/25/2008

HAW

2 – Class II

K072806

MAKO SURGICAL TACTILE GUIDANCE SYSTEM (TGS)

MAKO SURGICAL CORP.

1/24/2008

HAW

1 – Class II

K072716

VECTOR VISION HIP

BRAINLAB AG

10/12/2007

HAW

0

K071714

NAVITRACK SYSTEM - OS UNICONDYLAR KNEE
UNIVERSAL, MODEL# PRO-06003

ORTHOSOFT, INC.

7/20/2007

HAW

2 – Class II

K062146

UNI KNEE SURGETICS NAVIGATION SYSTEM

PRAXIM S. A

8/21/2006

HAW

0

K060336

NAVITRACK SYSTEM-OS KNEE UNIVERSAL, MODEL
PRO-05002

ORTHOSOFT, INC.

4/28/2006

HAW

2 – Class II
1 – Class III

K060282

TOTAL KNEE SURGETICS NAVIGATION SYSTEM

PRAXIM SA

4/10/2006

HAW

0

K052851

VOYAGER LINUX WITH TACTILE GUIDANCE SYSTEM
(TGS)

MAKO SURGICAL CORP.

11/18/2005

HAW

0

K052213

NAVIGATION SW HIP 3.1 ON CI

BRAINLAB AG

11/2/2005

HAW

0

K031196

SURGETICS ORTHO KNEELOGICS NAVIGATION
SYSTEM

PRAXIM

6/7/2005

HAW

0

K050973

MODIFICATION TO: VOYAGER LINUX

MAKO SURGICAL CORP.

5/17/2005

HAW

0

K050615

STRYKER NAVIGATION SYSTEM - CT-BASED HIP
MODULE, MODEL 6007-621-000

STRYKER INSTRUMENTS

4/21/2005

HAW

0

K043536

NAVITRACK SYSTEM - S&N IMAGE FREE KNEE

ORTHOSOFT, INC.

1/14/2005

HAW

0

K040368

VECTORVISION HIP 3.0

BRAINLAB AG

8/23/2004

HAW

0

K031454

ACUMEN SURGICAL NAVIGATION SYSTEM

BIOMET, INC.

7/8/2004

HAW

0

K031337

ACUMEN SURGICAL NAVIGATION SYSTEM

BIOMET, INC.

9/15/2003

HAW

0

K022364

NAVITRACK SYSTEM TOTAL HIP REPLACEMENT,
MODEL 900.200

ORTHOSOFT, INC.

2/4/2003

HAW

0

K022365

STRYKER NAVIGATION SYSTEM - HIP MODULE

STRYKER INSTRUMENTS

1/22/2003

HAW

10 – Class II

K023975

VOYAGER LINUX

Z-KAT, INC.

12/20/2002

HAW

0

K021306

VECTORVISION CT-FREE KNEE

BRAINLAB AG

10/25/2002

HAW

0

K021760

NAVITRACK SYSTEM-OPTICAL TKR CT-LESS, MODEL
900.120

ORTHOSOFT, INC.

8/27/2002

HAW

0
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K014256

KOLIBRI IGS SYSTEMS

BRAINLAB AG

7/19/2002

HAW

0

K013025

MODIFICATION TO FLOUROLAB PLUS

Z-KAT, INC.

10/3/2001

HAW

0

K Number

Device Name

Manufacturer

Approval Date

Product Code

Recalls

K010602

VECTORVISION HIP

BRAINLAB, AG

9/12/2001

HAW

0

K010612

VECTORVISION KNEE

BRAINLAB, AG

9/6/2001

HAW

0

K003589

VECTORVISION CRANIAL, VECTORVISION SPINAL,
VECTORVISION ENT

BRAINLAB AG

5/21/2001

HAW

0

K003347

ORTHOPILOT

KINAMED, INC.

2/23/2001

HAW

0

K002053

NAVITRAK SYSTEM-OPTICAL OPTION, MODEL
900.004

ORTHOSOFT, INC.

8/3/2000

HAW

0

K001284

STEALTHSTATION SYSTEM GOLDENEYE MICROMAGNETIC TRACKING SYSTEM

MEDTRONIC SURGICAL
NAVIGATION
TECHNOLOGIES

6/12/2000

HAW

27 – Class II
1 – Class III

K000310

VOYAGER 6.0 SOFTWARE OPTION

PHILIPS MEDICAL
2/15/2000
SYSTEMS(CLEVELAND), INC.

HAW

0

K993239

STRYKER NAVIGATION SYSTEM - NEURO MODULE,
MODEL 6000-XXX-XXX

STRYKER CORP.

1/18/2000

HAW

2 – Class I
4 – Class II

K984298

Z KAT FLUROTACTIC GUIDANCE SYSTEM MKI

Z-KAT, INC.

6/23/1999

HAW

0

K983831

VECTORVISION2

BRAINLAB, AG

5/19/1999

HAW

0

K990214

FLUORONAV MODULE FOR THE STEALTHSTATION
SYSTEM

SURGICAL NAVIGATION
TECHNOLOGIES, INC.

4/22/1999

HAW

29 – Class II

K964229

REGULUS NAVIGATOR

COMPASS INTL., INC

8/19/1997

HAW

0

K962939

VECTORVISION

BRAINLAB, INC.

5/22/1997

HAW

0

K970604

VIEWPOINT - 3.0 SOFTWARE

PHILIPS MEDICAL
5/19/1997
SYSTEMS(CLEVELAND), INC.

HAW

0

K963221

OPTICAL DIGITIZER OPTION FOR VIEW POINT

PHILIPS MEDICAL
1/10/1997
SYSTEMS(CLEVELAND), INC.

HAW

0

K961844

OPERATING ARM SYSTEM (OAS) [WITH CT AND MR
IMAGES]

RADIONICS SOFTWARE
APPLICATIONS, INC

10/23/1996

HAW

0

K960714

ISG VIEWING WAND

I.S.G. TECHNOLOGIES, INC

5/29/1996

HAW

0

K961168

VIEWPOINT

PHILIPS MEDICAL
5/16/1996
SYSTEMS(CLEVELAND), INC.

GAW

0

K954276

STEALTHSTATION

SURGICAL NAVIGATION
TECHNOLOGIES, INC.

1/24/1996

HAW

1 – Class II

K944612

ACUSTAR I ADVANCED SURGICAL NAVIGATION
SYSTEM

Codman & Shurtleff, Inc.

12/11/1995

LLZ

0

K951262

OPERATING ARM SYSTEM (OAS)

RADIONICS SOFTWARE
APPLICATIONS, INC.

11/13/1995

LLZ

0

K935456

REGULUS MEASUREMENT UNIT

COMPASS INTL., INC.

10/13/1995

HAW

0

K942233

MKM (MULTIPLE COORDINATE MANIPULATOR)
SYSTEM

CARL ZEISS, INC.

7/1/1994

EPT

0

153

K Number

Device Name

Manufacturer

K911783

ALLEGRO VIEWING WAND

K905070

Approval Date

Product Code

Recalls

I.S.G. TECHNOLOGIES, INC. 4/7/1994

LLZ

0

VISTAR

PHILIPS MEDICAL
1/2/1991
SYSTEMS(CLEVELAND), INC.

LNH

0

K901679

RESUBMITTED ISG 3DMV WORKSTATION

I.S.G. TECHNOLOGIES, INC. 5/29/1990

LLZ

0

K861692

FISCHER PPS/MAMMOTEST MAMMOGRAPHY
SYSTEM

FISCHER IMAGING CORP.

IZH

1 – Class II

12/15/1986
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APPENDIX 6: ANALYSIS OF MEDROBOTICS FLEX
ROBOTIC SYSTEM PREDICATES

Figure 21: Medrobotics Flex System

The primary function of the Medrobotics Flex Transabdominal Robotic System, as seen in
Figure 21, is to serve as an assistive laparoscopic device for minimally invasive surgical (MIS)
procedures in areas of the body which may be difficult to reach with traditional rigid scopes. The
system is comprised of two main components, a moveable cart containing the jointed robotic arm
and attached scope, and a surgical control station with an HD imaging display and a joystick for
motion control. The primary innovation in the Flex System is the flexible, multi-jointed
positioning mechanism within the scope and accompanying instruments that allow access to
areas of the body that would traditionally be unreachable with MIS. This mechanism is
structured similarly to a snake, with an external cable steered structure allowing for motion and
an internal skeleton (see Figure 22), which allows the scope to be reliably placed in a stable
position, and then used as a guide for positioning of the handheld Medrobotics Flex Instruments,
which are used to perform the actual surgical procedure (Medrobotics, 2018). Unlike the Da
Vinci System, where the system is controlled remotely to perform surgical procedures, the Flex
System serves solely as an assistive device. Additionally, use of the Flex system is currently
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limited to surgical procedures which can be performed via natural bodily orifices, specifically the
mouth or anus, while the Da Vinci can be used to perform surgery via incisions.

Figure 22: Medrobotics Flex System jointed scope structure (Medrobotics, 2018)

The traceable predicate history of the Medrobotics Flex Transabdominal System includes 109
substantial equivalence relationships between 42 unique devices, which can be traced to 21
ultimate predicates. An overview of the Flex System trace can be seen in Figure 23, with
additional information about each device shown in the trace located in Section A6.1.

Figure 23: Medrobotics Flex System predicate trace (see section A6.2 for additional predicate information).
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The 42 unique devices in the direct predicate trace for the Flex Transabdominal System are
classified into 23 different product codes, with GCJ and EOB the most prevalent. Unlike the
other three traces, which each possessed a clearly dominant product code, the Flex System has 5
codes each containing 7 or 8 predicate devices. However, although the devices described in these
codes possess slightly different intended use cases, the majority share a common regulatory
description as an endoscope with accessories. As a result, there are significant difference
between the structure of the product code breakdown and regulatory description breakdown (see
Figure 24).

Figure 24: Breakdown of Flex System predicates grouped by product code and regulatory description. The product
code classification breakdown shows a large number of product codes with no dominant code(s). However, many of
these product codes share a common regulatory description as evidenced by the appearance of a dominant
regulatory description in that breakdown.

A6.1

REFERENCE DEVICES IN THE TRACE

Unlike the subject devices analyzed in the other three traces, the sole direct predicate of the
Medrobotics Flex Transabdominal System is not identified as a robotic surgical system. Instead
this device, the Olympus EndoEye Flex 3D Deflectable Videoscope and associated system, is a
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flexible video endoscope used for three-dimensional viewing of endoscopic instruments during
surgery within the thoracic and abdominal cavities (Lerner, 2013). This device, shown in Figure
25, utilizes a similar cable-steered mechanism to make the scope flexible, however it does not
include a powered arm for positioning and is controlled manually by the surgeon (Viviano,
2018).

Figure 25: Olympus EndoEye Flex 3D Deflectable Videoscope (Olympus Corp., 2018 )

To mitigate some of the risk introduced with the inclusion of new technological characteristics,
including the robotic arm and software driven positioning system, the 510(k) application for the
Flex System includes two 510(k) applications associated with the Medrobotics Flex Colorectal
System as reference devices. This system is classified under product code FDF as a colonoscopy
and accessories with the regulatory description of endoscope and accessories. Although the
Colorectal System is nearly identical to the Transabdominal System (Viviano, 2018), it was
approved specifically as a device for colorectal surgery and is therefore ineligible to serve as a
predicate for the Flex Transabdominal, which is indicated for a different intended use.
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Inclusion of the reference devices and their subsequent predicates in the substantial equivalence
tree significantly increases the size of the trace. With the reference devices included, there are
147 unique devices present in the trace classified under 48 different product codes (See
Appendix 2). This trace expansion includes devices with a significantly wider array of
technological characteristics, including the introduction of the robotic manipulator technology
which is present in the subject device but missing in all the directly identified predicate devices.
As reference devices are a relatively new regulatory mechanism, there is limited data available
from this research to indicate whether reference devices could potentially impact the regulatory
process. Since these devices are ineligible to serve as predicate devices, and therefore cannot
directly contribute to predicate creep, analysis of the expanded trace was limited to the
identification of reference devices and observation of introduced technological characteristics.
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A6.2

ADDITIONAL FLEX SYSTEM PREDICATE INFORMATION

Note that this table includes devices classified as reference devices and subsequent reference predicates, identified
with red text, in addition to direct predicate devices.
K Number

Device Name

Manufacturer

Approval Date Product Code

Recalls

K011782

Rectosight

SIGHTLINE TECHNOLOGIES LTD.

N/A (no record
in database)

0

K172796

Flex Robotic System And Flex Transabdominal
Drive

MEDROBOTICS CORPORATION

1/18/2018

HET
GCJ

0

K172036

Medrobotics Flex Robotic System

Medrobotics Corporation

8/3/2017

FDF

0

K162330

Flex Robotic System And Flex Colorectal Drive

Medrobotics Corporation

5/4/2017

FDF

0

K150776

Medrobotics Flex System

MEDROBOTICS CORPORATION

7/17/2015

EOB
EOX
GCI

0

K123365

OLYMPUS LTF-190-10-3D, MAJ-Y0154, OLYMPUS
OLYMPUS MEDICAL SYSTEMS CORP.
CV-190

3/1/2013

HET
GCJ
FGB
NWB

0

K111004

HANSEN MEDICAL VASCULAR CATHETER
CONTROL SYSTEM AND CATHETER

5/29/2012

DXX
DRA

2 – Class II

HANSEN MEDICAL, INC.

K111425

OLYMPUS LTF-S190-10, OLUMPUS OTV-S190,
OLYMPUS CLV-S190

OLYMPUS MEDICAL SYSTEMS CORP.

4/20/2012

HET
EOB
FGB
GCJ
NWB
EOQ

K112680

EVIS EXERA III VIDEO SYSTEM

OLYMPUS MEDICAL SYSTEMS
CORPORATION

2/16/2012

FDF

0

K102733

VISION-SCIENCES ENT-5000 VIDEO ENT SCOPE
WITH ENDOSHEATH TECHNOLOGY, VISIONSCIENCES DPU-5000/DPU-5050 VIDEO
PROCESSOR

VISION-SCIENCES, INC.

5/18/2011

EOB
GCJ
HRX

0

K102379

LTF-Y0009; MAJ-YOO41; XOEV-3D1

OLYMPUS MEDICAL SYSTEMS
CORPORATION

1/5/2011

GCJ

0

K102168

SENSEI X ROBOTIC CATHETER SYSTEM

HANSEN MEDICAL, INC.

10/22/2010

DXX

1 – Class II

K100584

EVIS EXERAII 180 SYSTEM

OLYMPUS MEDICAL SYSTEMS
CORPORATION

7/2/2010

NWB
FDF
FDS

0

K093717

C-MOR VISUALIZATION DEVICE

AXIS SURGICAL TECHNOLOGIES, INC

3/2/2010

HRX

0

K091808

SENSEI ROBOTIC CATHETER SYSTEM, MODEL
02057

HANSEN MEDICAL, INC.

9/10/2009

DXX

1 – Class II

K090365

HANSEN MEDICAL ARTISAN S CONTROL
CATHETER

HANSEN MEDICAL, INC.

5/7/2009

DXX
DRA

1 – Class II
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K Number

Device Name

Manufacturer

Approval Date Product Code

Recalls

K080948

HD ENDOEYE LAPARO-THORACO VIDEOSCOPE
OLYMPUS LTF TYPE VH

OLYMPUS MEDICAL SYSTEMS
CORPORATION

9/26/2008

HET
GCJ
NWB

0

K082293

SURGVIEW INTEGRATED VISUALIZATION SYSTEM BIOVISION TECHNOLOGIES, LLC

9/9/2008

HRX
GCJ

0

K081051

SPINEVU ENDOSCOPIC SPINE SYSTEM (SESS),
SPINEVU MINISCOPE

SPINE VIEW, INC.

8/7/2008

HRX
GEI

0

K073225

SENSEI CATHETER CONTROL SYSTEM

HANSEN MEDICAL, INC.

6/30/2008

DXX
DRA

1 – Class II

K080415

DEVICE MODIFICATION TO PINNACLE
DESTINATION PERIPHERAL GUIDING SHEATH

TERUMO MEDICAL CORP.

3/7/2008

DYB

0

K072879

INNERVUE DIAGNOSTIC SCOPE SYSTEM

BIOMET ORTHOPEDICS, INC.

1/14/2008

HRX

2 – Class II

K072073

VISION-SCIENCES ENT-5000 AND ENT-5100
VIDEO ENT SCOPE WITH ENDOSHEATH SYSTEM,
DPU-5000/DPU-5050 VIDEO PROCESSOR

VISION-SCIENCES, INC.

8/29/2007

EOB

0

K070622

NEOGUIDE ENDOSCOPY SYSTEM

NEOGUIDE SYSTEMS, INC.

8/14/2007

FDF

0

K052480

HANSEN MEDICAL CATHETER CONTROL SYSTEM
(CCS) AND ACCESSORIES, HANSEN MEDICAL
HANSEN MEDICAL, INC.
STEERABLE GUIDE CATHETER (SGC) AND SHEATH

5/2/2007

DXX
DRA

2 – Class II

K062049

EVIS EXERA II 180 SYSTEM

OLYMPUS MEDICAL SYSTEMS
CORPORATION

9/22/2006

NWB

0

K061313

EVIS EXERA 180 SYSTEM

OLYMPUS MEDICAL SYSTEMS
CORPORATION

8/31/2006

EOQ
EOB
NWB

0

K061246

ENDOSCOPIC SPINE SYSTEM

ARTHRO KINETICS INC.

8/23/2006

HRX

0

K061345

MODIFICATION TO ENDIUS ATAVI SYSTEM

ENDIUS, INC.

6/6/2006

HRX

1 – Class II

K052241

DISC-FX SYSTEM

ELLMAN INTERNATIONAL, INC.

2/24/2006

HRX
GEI

0

K052930

NAVIGATOR ENDOSCOPY SYSTEM

NEOGUIDE SYSTEMS, INC.

1/31/2006

FDF

0

K053267

ENDIUS ATAVI SYSTEM

ENDIUS, INC.

1/13/2006

HRX

1 – Class II

K051645

EVIS EXERA 160A SYSTEM

OLYMPUS MEDICAL SYSTEMS
CORPORATION

10/13/2005

NWB
FDF
FDS

0

K052452

VISERA RHINO-LARYNGOVIDEOSCOPE OLYMPUS
ENF TYPE VT

OLYMPUS MEDICAL SYSTEMS
CORPORATION

9/21/2005

EOB

0

K051827

JOIMAX ENDOSCOPE/MULTISCOPE, THESSYS
FORAMINOSCOPE/MULTISCOPE, THESSYS
LAMINOSCOPE/MULTISCOPE

JOIMAX GMBH

8/12/2005

HRX

0

K051601

PINNACLE DESTINATION PERIPHERAL GUIDING
SHEATH

TERUMO MEDICAL CORP.

8/4/2005

DYB

0

K050972

VISION-SCIENCES ENT-3000 SCOPE

VISION-SCIENCES, INC.

4/29/2005

EOB

2 – Class II

K043395

SMITH & NEPHEW VIDEOARTHROSCOPE

SMITH & NEPHEW, INC.

1/12/2005

HRX
EOB

0

K040604

INNERVUE DIAGNOSTIC SCOPE SYSTEM

ARTHROTEK, INC.

6/4/2004

GCJ

0
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K Number

Device Name

Manufacturer

Approval Date Product Code

Recalls

K040984

VISION SCIENCES MODEL ENT-2000V FLEXIBLE
NASOPHARYNGO-LARYNGOSCOPE

VISION-SCIENCES, INC

4/27/2004

EOB

0

K033954

SHAPE LOCKING ENDOSCOPIC OVERTUBE

USGI MEDICAL, INC.

3/19/2004

FED
FDF

0

K032688

COLONOSIGHT MODEL 510B

SIGHTLINE TECHNOLOGIES LTD.

3/5/2004

FDF

0

K023902

SHAPE-LOCKABLE ENDOSCOPIC OVERTUBE

USGI MEDICAL, INC.

8/20/2003

FED
FDF

0

K031648

VISERA RHINO-LARYNGOVIDEOSCOPE OLYMPUS
ENF TYPE V

OLYMPUS OPTICAL CO., LTD.

7/24/2003

EOB

0

K031591

POWDER-FREE NITRILE PATIENT EXAMINATION
GLOVE, WHITE (NON-COLORED), BLUE AND
GREEN COLORED

PERUSAHAAN GETAH ASAS SDN BHD

6/26/2003

LZA

0

K030096

VIDEO ARTHROSCOPE, MODELS AR-3050-30, AR3050T-30, AR-3050-70, AR-3051-30, AR-3052-30, ARTHREX, INC.
AR3030AN, AR-3030AS, AR3030AW

3/18/2003

HRX

0

K023984

MODIFICATION TO OLYMPUS BRONCHOSCOPES
THE OLYMPUS OPTICAL CO.
BF-40 SERIES, BF-240 SERIES, AND BF-160 SERIES

1/31/2003

EOQ

0

K021555

STEREOTAXIS NIOBE MAGNETIC NAVIGATION
SYSTEM

STEREOTAXIS, INC.

1/15/2003

DXX

0

K024095

MODIFICATION TO VISION SCIENCES
ENDOSHEATH SYSTEM

VISION-SCIENCES, INC

1/9/2003

EOB

0

K022199

ENDIUS ATAVI SYSTEM

ENDIUS, INC.

10/2/2002

HRX

0

K012543

VISION SCIENCES ENDOSHEATH SYSTEM

VISION-SCIENCES, INC.

7/15/2002

EOB

0

K021748

ENDIUS ATAVI SYSTEM

ENDIUS, INC.

6/26/2002

HRX

0

K021344

B-F200 BRONCHOSCOPE WITH BSS-F21
ENDOSHEATH SYSTEM

VISION-SCIENCES, INC.

5/24/2002

EOQ

0

K021074

VISERA CYSTOVIDEOSCOPE OLYMPUS CYF TYPE
V/VA

OLYMPUS AMERICA, INC.

5/2/2002

FAJ

0

K013484

TELSTAR MAGNETIC NAVIGATION SYSTEMS
[MNS}, TELSTAR BI-PLANE DIGITAL IMAGING
SYSTEM, NIOBE ELECTROPHYSIOLOGY MAPPING
CATH

STEREOTAXIS, INC.

5/2/2002

DRF
DXX
MQB

0

K021073

VISERA RHINLARYNGOVIDEOSCOPE OLYMPUS
ENF TYPE V

OLYMPUS AMERICA, INC.

5/1/2002

EOB

0

K020310

DAVLITE MICROENDOSCOPE & ACCESSORIES

DAVLITE TECHNOLOGIES

3/20/2002

GCJ

0

K013591

XENF-TP RHINO-LARYNGOFIBERSCOPE, ITS
ACESSORIES AND ANCILLARY EQUIPMENT

OLYMPUS OPTICAL CO., LTD.

12/26/2001

EOB

0

K012812

CAROTID GUIDING SHEATH

TERUMO MEDICAL CORP.

11/14/2001

DYB

1 – Class II

K011189

VIADUCT MICROENDOSCOPE AND ACCESSORIES

ACUEITY, INC.

7/16/2001

GCJ

0

K010811

PERC-D SPINEWAND

ARTHROCARE CORP.

5/30/2001

HRX

0

K011151

EVIS EXERA GASTROINTESTINAL VIDEOSCOPE
GIF-Q160Z

THE OLYMPUS OPTICAL CO.

5/15/2001

FDS

0
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K002749

ENDOSCOPE CONTOUR DETECTION DEVICE,
MODEL 3DX45 AND COLONOSCOPE, MODEL XCF- THE OLYMPUS OPTICAL CO.
Q140L/13D

12/4/2000

FDF
JAB

0

K002931

METRX SYSTEM

MEDTRONIC SOFAMOR DANEK, INC.

11/24/2000

HRX

0

K002437

ENDIUS ENDOSCOPIC ACCESS SYSTEM

ENDIUS, INC.

10/2/2000

HRX

0

K001766

OLYMPUS XGIF-N200H GASTROINTESTINAL
VIDEOSCOPE

OLYMPUS OPTICAL CO., LTD.

9/8/2000

FDS

0

K002018

NDO SURGICAL SURGICAL OVERTUBE

SURGICAL, INC.

8/17/2000

FED

0

K994130

RECTOSIGHT RS 300-04

SIGHTLINE TECHNOLOGIES LTD.

6/30/2000

FER
GCF

0

K001241

EVIS EXERA COLONOVIDEOSCOPE CF-Q160 AL/I
AND PCF-160 AL/I

THE OLYMPUS OPTICAL CO.

5/9/2000

FDF

0

K993041

OLYMPUS XCYF-1T3 OES
CYSTOFIBERSCOPE/NEPHROFIBERSCOPE
ACCESSORIES AND ANCILLARY EQUIPMENT

THE OLYMPUS OPTICAL CO.

3/30/2000

FAJ
FGA
KGE
KNS

0

K000046

KNIGHT ENDOSCOPIC SPINE SYSTEM (KESS)

RICHARD WOLF MEDICAL
INSTRUMENTS CORP

3/30/2000

HRX

0

K994425

MODIFICATION TO ENDOSCOPIC SPINAL ACCESS
SYSTEM

ENDIUS, INC.

2/16/2000

HRX

0

K991794

ENDOSCOPIC SPINAL ACCESS SYSTEM

ENDIUS, INC.

8/13/1999

HRX

0

K990354

ENDOSHEATH

VISION-SCIENCES, INC.

3/31/1999

EOB

0

K982819

ENDIUS SPINE ENDOSCOPE

ENDIUS, INC.

1/27/1999

GWG

0

K981543

OLYMPUS LF-TP AND LF-DP TRACHEAL
INTUBATION FIBERSCOPES, ACCESSORIES AND
ANCILLARY EQUIPMENT

THE OLYMPUS OPTICAL CO.

6/8/1998

EOQ

0

K973405

YEUNG ENDOSCOPIC SPINE SYSTEM

RICHARD WOLF MEDICAL
INSTRUMENTS CORP.

3/13/1998

HRX

0

K974355

INTERVENTIONAL MOBILE DIGITAL IMAGING
SYSTEM (HEREIN CALLED IMDIS)

GE DEC MEDICAL SYSTEMS

2/17/1998

OWB
JAA
OXO

1 – Class II

K973500

BARD ENDOSCOPIC OVERTUBE (#000307)

C.R. BARD, INC.

10/16/1997

FED

0

K971253

VARIOUS ARTHROSCOPES, ENDOSCOPIC BLADES,
SMITH & NEPHEW, INC.
MANUAL INSTRUMENTS

6/13/1997

HRX

0

K963795

VISION-SCIENCES MODEL B-F100
BRONCHOSCOPE WITH MODEL BS-F21
DISPOSABLE ENDOSHEATH

VISION-SCIENCES, INC.

12/23/1996

EOQ

0

K961228

KARL STORZ MAGNIFYING ARTHROSOCPES

KARL STORZ ENDOSCOPY-AMERICA,
INC

10/10/1996

HRX

0

K963033

BF 240/P240/IT240 BRONCHOVIDEOSCOPE &
ACCESSORIES

OLYMPUS AMERICA, INC.

9/9/1996

EOQ

0

K950809

VISION-SCIENCES DISPOSABLE ENDOSHEATH FOR
VISION-SCIENCES, INC.
FLEXIBLE NASOPHARYNGO-LARYNGOSCOPES

8/5/1996

EOB

0
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K961591

DISPOSABLE ENDOSHEATH FOR E-F100 FLEXIBLE
NASOPHARYNGOSCOPE

VISION-SCIENCES, INC

7/2/1996

EOB

0

K961570

KEC-3840L/F, VIDEO COLONOSCOPE (*L OR F IN
MODEL NUMBER DENOTES LENGTH)

PENTAX PRECISION INSTRUMENT
CORP.

6/24/1996

FDF

1 – Class II

K961563

EC-384OTL, VIDEO COLONSCOPE

PENTAX PRECISION INSTRUMENT
CORP.

6/19/1996

FDF

0

K954451

EVIS 140 SYSTEM

OLYMPUS AMERICA, INC.

3/29/1996

FET

0

K951579

EC-3800TL, VIDEO COLONOSCOPE

PENTAX PRECISION INSTRUMENT
CORP.

3/21/1996

FDF

1 – Class II

K951574

EC-3800L, VIDEO COLONOSCOPE

PENTAX PRECISION INSTRUMENT
CORP.

3/21/1996

FDF

3 – Class II

K955403

OES LAPARO-THORACO VIDEOSCOPE TYPE V

OLYMPUS AMERICA, INC.

3/11/1996

HET
GCJ

0

K942265

FLEXIBLE NASOPHARYNGO-LARYNGOSCOPE AND
VISION-SCIENCES, INC.
ENDOSHEATH

12/22/1995

EOB

0

K943307

3D SURGICAL ENDOSCOPY SYSTEM FOR GENERAL
OLYMPUS AMERICA, INC.
SURGERY

12/20/1995

GCJ

0

K943304

3D SURGICAL ENDOSCOPY SYSTEM FOR
UROLOGY

OLYMPUS AMERICA, INC.

12/20/1995

FCG
FAL

0

K954989

DYONICS DISPOSABLE ENDOSCOPIC SURGERY
BLADES

SMITH & NEPHEW DYONICS, INC.

11/27/1995

ERL

0

K943305

OLYMPUS 3D SURGICAL ENDOSCOPY SYSTEM

OLYMPUS AMERICA, INC.

11/17/1995

HET

0

K953910

PHILIPS BV 300 SERIES

PHILIPS MEDICAL SYSTEMS NORTH
AMERICA, INC.

10/18/1995

OXO

1 – Class II

K930191

DANEK(TM) SPINAL EPIDURAL ENDOSCOPIC SY

SOFAMOR DANEK MFG., INC.

9/26/1995

HRX

0

K953695

DYONICS DISPOSABLE ARTHROSCOPIC BLADES

SMITH & NEPHEW DYONICS, INC

9/15/1995

HRX

0

K953484

POLLUX OA/POLLUX 30A/POLLUX 70A

POLLUX ENDOSCOPY, INC.

9/1/1995

HRX

0

K945209

PROCTOSCOPEA & ACCESSORIES,
SIGMOIDOSCOPES & ACCESSORIES,
PROCTOLOGY INSTRUMENTS

KARL STORZ ENDOSCOPY-AMERICA,
INC.

3/6/1995

GCF
FAM

0

K950103

LAPAROSCOPE, HAND INSTRUMENTS

OLYMPUS AMERICA, INC.

3/6/1995

GCJ

0

K943895

VISION SYSTEM COLONSCOPE

VISION-SCIENCES, INC.

2/3/1995

FDF

0

K944072

OLYMPUS NASAL AND SINUS ENDOSCOPES

OLYMPUS AMERICA, INC.

1/11/1995

EOB

0

K942338

OLYMPUS PF-8P OES PANCREATO FIBERSCOPE
AND ACCESSORIES

OLYMPUS CORP.

11/30/1994

FDT

0

K942339

SKIN NEUVEAU SCAR TREATMENT

PURITAS HEALTH CARE, INC.

11/28/1994

MDA

0

K941036

CURVED ROTATABLE DISPOSABLE
ARTHROSCOPIC SURGERY BLADES

SMITH & NEPHEW, INC

9/28/1994

HRX

0

K941919

OKTAS ENDOSCOPY VIDEO CAMERA SYSTEM

OKTAS

6/17/1994

FET

0

K942044

BARD ENDOSCOPIC OVERTUBE

C.R. BARD, INC.

6/10/1994

FED

0

K941967

HSW LAPAROSCOPE AND ACCESSORIES

HENKE-SASS WOLF, GMBH.

5/16/1994

GCJ

0
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K932987

BIRTCHER LAPAROSCOPE AND ACCESSORIES

BIRTCHER MEDICAL SYSTEMS, INC

4/25/1994

GCJ

0

K922519

MOD. PERCUTANEOUS ARTHROSCOPIC MICRO
DISCECTOMY

SMITH & NEPHEW, INC.

3/29/1994

HRX

0

K932843

FLEXIBLE VIDEO SIGMOIDOSCOPE SYSTEM
W/DISP. SHEATH

VISION-SCIENCES, INC.

2/14/1994

FAM
FET

0

K934299

DYONICS DISPOSABLE ARTHROSCOPIC SURGERY
BLADES MODIFICATION

SMITH & NEPHEW DYONICS, INC

2/14/1994

HRX
HWE

0

K934918

EPM-3300 VIDEO PROCESSOR

PENTAX PRECISION INSTRUMENT
CORP.

2/7/1994

FET
GCT

0

K934981

DENTAL DRILL

EARE CONSULTING SERVICE

2/3/1994

DZP

0

K934920

VB-1830/VB-1530, VIDEO BRONCHOSCOPE

PENTAX PRECISION INSTRUMENT
CORP.

1/26/1994

EOQ

0

K933247

PROTECTIVE SHEATH FOR FLEXIBLE
NASOPHARY/LARYGNOS

VISION-SCIENCES, INC.

11/22/1993

EOB

0

K931154

EVIS 200 SYSTEM

OLYMPUS CORP.

10/7/1993

EOQ

0

K924125

CRI ELECTRONIC CONTROL SYSTEM

CATHETER RESEARCH C/O BURDITT,
BOWLES & RADZIUS

5/26/1993

DXX

0

K924607

ARROW FISCHELL KINK RESIST PERCUT SHEATH
INTRO SET

ARROW INTL., INC.

4/22/1993

DYB

2 – Class II
1 – Class III

K923982

OLYMPUS OES LAPAROSCOPY SYSTEM

OLYMPUS CORP.

3/15/1993

GCJ

1 – Class II

K926056

9600 FLUOROSCOPIC IMAGING SYSTEM

OEC-DIASONICS, INC.

1/21/1993

OXO

0

K925421

ENDOSHEATH

VISION-SCIENCES, INC.

1/15/1993

EOB

0

K921690

FLEXIBLE FIBEROPTIC SIGMOIDOSCOPE SYSTEM

VISION-SCIENCES, INC.

10/28/1992

FAM
ODB

0

K921244

DISPOSABLE PROTECTIVE SHEATH

VISION-SCIENCES, INC.

10/6/1992

EOB

0

K921707

PENTAX NASO-PHARYNGO-LARYNGOSCOPE FNL- PENTAX PRECISION INSTRUMENT
15P2/15RP2
CORP.

7/1/1992

EOB

1 – Class II

K920800

INTEGRATED ENDOSCOPY SYSTEM 1000

BIOMET, INC.

6/30/1992

HRX

1 – Class II

K914559

SMALL JOINT SYSTEM

SMITH & NEPHEW DYONICS, INC.

2/18/1992

HRX

0

K904940

OLYMPUS INFANT RESECTOSCOPE AND
ACCESSORIES

OLYMPUS CORP.

1/13/1992

FJL

0

K912453

INTELIJET TM FLUID MANAGEMENT SYSTEM

SMITH & NEPHEW DYONICS, INC.

8/26/1991

HRX

0

K912120

URF-P2
URETERORENOFIBERSCOPE/CHOLEDOCHOFIBERS OLYMPUS CORP.
COPE

8/7/1991

FBN

1 – Class II

K910423

BRONCHOSCOPE BF-N20

OLYMPUS CORP.

4/29/1991

EOQ

0

K903842

ST-E1 OVERTUBE

OLYMPUS CORP.

1/23/1991

FED

0

K904284

ARTHROSCOPIC SURGICAL BLADE

SMITH & NEPHEW DYONICS, INC.

12/5/1990

HRX

0

K900765

STEEROCATH(TM)

EP TECHNOLOGIES, INC.

5/7/1990

DRF

0
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K900070

MODIFIED USES OF THE ARTHROSCOPIC
SURGICAL SYSTEM

DYONICS, INC.

2/16/1990

HRX

0

K880518

MOBILE C-ARM OMNI 325

FISCHER IMAGING CORP.

3/9/1988

OXO

0

K853585

OLYMPUS EVS-ENDOSCOPIC VIDEO IMAGE &
DATA SYS

OLYMPUS CORP.

1/21/1986

FET

0

K853678

KAMBIN SPINAL INSTRUMENT SET

PILLING CO.

9/24/1985

HTZ

0

K850978

OLYMPUS LF-1 INTUBATION SCOPE

OLYMPUS CORP.

5/23/1985

CAL

0

K843084

OLYMPUS CHP-P10 NEPHROSCOPE/CYSTOSCOPE OLYMPUS CORP.

1/3/1985

FBO

0

K844131

NUCLEOTOME

MEDICAL INSTRUMENT
DEVELOPMENT LABORATORIES, INC.

11/29/1984

HSZ

0

K833587

DISPOSABLE ARTHROSCOPY BLADE

DYONICS, INC.

11/14/1983

HRX

0

K822846

PENTAX FC-38LA & FC-38SA COLONOFIBER

PENTAX PRECISION INSTRUMENT
CORP.

10/22/1982

FDF

0

K820367

INTRA-ARTICULAR SURGICAL SYSTEM

DYONICS, INC.

5/7/1982

KIJ

0

K771218

INTRA-ARTICULAR SHAVER

DYONICS, INC

2/1/1978

KIJ

0
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